Systematic review of the effectiveness and cost-effectiveness of HealOzone® for the treatment of occlusal pit/fissure caries and root caries

M Brazzelli, L McKenzie, S Fielding, C Fraser,
J Clarkson, M Kilonzo and N Waugh

May 2006

**Health Technology Assessment
NHS R&D HTA Programme**

HTA

How to obtain copies of this and other HTA Programme reports.
An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (http://www.hta.ac.uk). A fully searchable CD-ROM is also available (see below).

Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public **and** private sector purchasers from our Despatch Agents, York Publishing Services.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.

You can order HTA monographs from our Despatch Agents, York Publishing Services by:

– fax (with **credit card** or **official purchase order**)
– post (with **credit card** or **official purchase order** or **cheque**)
– phone during office hours (**credit card** only).

Additionally the HTA website allows you **either** to pay securely by credit card **or** to print out your order and then post or fax it.

Contact details are as follows:
York Publishing Services   Email: ncchta@yps-publishing.co.uk
PO Box 642   Tel: 0870 1616662
YORK YO31 7WX   Fax: 0870 1616663
UK   Fax from outside the UK: +44 1904 430868

NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30–40 titles). The commercial subscription rate is £300 per volume. Please contact York Publishing Services at the address above. Subscriptions can only be purchased for the current or forthcoming volume.

Payment methods

Paying by cheque
If you pay by cheque, the cheque must be in **pounds sterling,** made payable to *York Publishing Distribution* and drawn on a bank with a UK address.

Paying by credit card
The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.

Paying by official purchase order
You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK.

How do I get a copy of *HTA on CD*?

Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact York Publishing Services (see contact details above) by email, post, fax or phone. *HTA on CD* is currently free of charge worldwide.

The website also provides information about the HTA Programme and lists the membership of the various committees.

Systematic review of the effectiveness and cost-effectiveness of HealOzone® for the treatment of occlusal pit/fissure caries and root caries

M Brazzelli,[1]* L McKenzie,[2] S Fielding,[3] C Fraser,[1] J Clarkson,[4] M Kilonzo[2] and N Waugh[3]

[1] Health Services Research Unit, Institute of Applied Health Sciences, University of Aberdeen, UK
[2] Health Economics Research Unit, Institute of Applied Health Sciences, University of Aberdeen, UK
[3] Department of Public Health, Institute of Applied Health Sciences, University of Aberdeen, UK
[4] Dental Health Services Research Unit, MacKenzie Building, Dundee, UK

* Corresponding author. Current affiliation: Department of Clinical Neurosciences, University of Edinburgh, Western General Hospital, UK

Declared competing interests of authors: none

NHS R&D HTA Programme

The research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.

The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.

The HTA Programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public, service-users groups and professional bodies such as Royal Colleges and NHS Trusts.

Research suggestions are carefully considered by panels of independent experts (including service users) whose advice results in a ranked list of recommended research priorities. The HTA Programme then commissions the research team best suited to undertake the work, in the manner most appropriate to find the relevant answers. Some projects may take only months, others need several years to answer the research questions adequately. They may involve synthesising existing evidence or conducting a trial to produce new evidence where none currently exists.

Additionally, through its Technology Assessment Report (TAR) call-off contract, the HTA Programme is able to commission bespoke reports, principally for NICE, but also for other policy customers, such as a National Clinical Director. TARs bring together evidence on key aspects of the use of specific technologies and usually have to be completed within a short time period.

Criteria for inclusion in the HTA monograph series
Reports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this monograph was commissioned and funded by the HTA Programme on behalf of NICE as project number 03/50/01. The protocol was agreed in June 2004. The assessment report began editorial review in June 2005 and was accepted for publication in September 2005. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme, NICE or the Department of Health.

T

Abstract

Systematic review of the effectiveness and cost-effectiveness of HealOzone® for the treatment of occlusal pit/fissure caries and root caries

M Brazzelli,[1][*] L McKenzie,[2] S Fielding,[3] C Fraser,[1] J Clarkson,[4] M Kilonzo[2] and N Waugh[3]

[1] Health Services Research Unit, Institute of Applied Health Sciences, University of Aberdeen, UK

[2] Health Economics Research Unit, Institute of Applied Health Sciences, University of Aberdeen, UK

[3] Department of Public Health, Institute of Applied Health Sciences, University of Aberdeen, UK

[4] Dental Health Services Research Unit, MacKenzie Building, Dundee, UK

* Corresponding author. Current affiliation: Department of Clinical Neurosciences, University of Edinburgh, Western General Hospital, UK

Objectives: To assess the effectiveness and cost-effectiveness of HealOzone® (CurOzone USA Inc., Ontario, Canada) for the management of pit and fissure caries, and root caries. The complete HealOzone procedure involves the direct application of ozone gas to the caries lesion on the tooth surface, the use of a remineralising solution immediately after application of ozone and the supply of a 'patient kit', which consists of toothpaste, oral rinse and oral spray all containing fluoride.

Data sources: Electronic databases up to May 2004 (except Conference Papers Index, which were searched up to May 2002).

Review methods: A systematic review of the effectiveness of HealOzone for the management of tooth decay was carried out. A systematic review of existing economic evaluations of ozone for dental caries was also planned but no suitable studies were identified. The economic evaluation included in the industry submission was critically appraised and summarised. A Markov model was constructed to explore possible cost-effectiveness aspects of HealOzone in addition to current management of dental caries.

Results: Five full-text reports and five studies published as abstracts met the inclusion criteria. The five full-text reports consisted of two randomised controlled trials (RCTs) assessing the use of HealOzone for the management of primary root caries and two doctoral theses of three unpublished randomised trials assessing the use of HealOzone for the management of occlusal caries. Of the abstracts, four assessed the effects of HealOzone for the management of occlusal

caries and one the effects of HealOzone for the management of root caries. Overall, the quality of the studies was modest, with many important methodological aspects not reported (e.g. concealment of allocation, blinding procedures, compliance of patients with home treatment). In particular, there were some concerns about the choice of statistical analyses. In most of the full-text studies analyses were undertaken at lesion level, ignoring the clustering of lesions within patients. The nature of the methodological concerns was sufficient to raise doubts about the validity of the included studies' findings. A quantitative synthesis of results was deemed inappropriate. On the whole, there is not enough evidence from published RCTs on which to judge the effectiveness of ozone for the management of both occlusal and root caries. The perspective adopted for the study was that of the NHS and Personal Social Services. The analysis, carried out over a 5-year period, indicated that treatment using current management plus HealOzone cost more than current management alone for non-cavitated pit and fissure caries (£40.49 versus £24.78), but cost less for non-cavitated root caries (£14.63 versus £21.45). Given the limitations of the calculations these figures should be regarded as illustrative, not definitive. It was not possible to measure health benefits in terms of quality-adjusted life-years, due to uncertainties around the evidence of clinical effectiveness, and to the fact that the adverse events avoided are transient (e.g. pain from injection of local anaesthetic, fear of the drill). One-way sensitivity analysis was applied to the model. However, owing to the limitations of the economic

analysis, this should be regarded as merely speculative. For non-cavitated pit and fissure caries, the HealOzone option was always more expensive than current management when the probability of cure using the HealOzone option was 70% or lower. For non-cavitated root caries the costs of the HealOzone comparator were lower than those of current management only when cure rates from HealOzone were at least 80%. The costs of current management were higher than those of the HealOzone option when the cure rate for current management was 40% or lower. One-way sensitivity analysis was also performed using similar NHS Statement of Dental Remuneration codes to those that are used in the industry submission. This did not alter the results for non-cavitated pit fissure caries as the discounted net present value of current management remained lower than that of the HealOzone comparator (£22.65 versus £33.39).

Conclusions: Any treatment that preserves teeth and avoids fillings is welcome. However, the current evidence base for HealOzone is insufficient to conclude that it is a cost-effective addition to the management and treatment of occlusal and root caries. To make a decision on whether HealOzone is a cost-effective alternative to current preventive methods for the management of dental caries, further research into its clinical effectiveness is required. Independent RCTs of the effectiveness and cost-effectiveness of HealOzone for the management of occlusal caries and root caries need to be properly conducted with adequate design, outcome measures and methods for statistical analyses.

Contents

List of abbreviations

ANOVA	analysis of variance	NICE	National Institute for Health and Clinical Excellence
CDC	Centers for Disease Control and Prevention	NPV	net present value
CI	confidence interval	ns	not significant
DFS	decayed and filled surfaces	NS	not stated
DMFS	decayed, missing and filled surfaces	ORCA	European Organisation for Caries Research
DMFT	decayed, missing and filled teeth	PRCL	primary root carious lesion
ECM	electrical conductance measurement	QALY	quality-adjusted life-years
		QLF	quantitative light-induced fluorescence
FDA	Food and Drug Administration	QOTI/FOTI	quantitative fibre-optic transillumination
GDS	General Dental Services		
IADR	International Association for Dental Research	RCT	randomised controlled trial
ITT	intention-to-treat	SD	standard deviation
NCHS	National Centre for Health Statistics	SDR	NHS Statement of Dental Remuneration
NHANES III	USA National Health and Nutrition Examination Survey	TACT	tuned aperture computed tomography
		UCD	ultrasound caries detector
NHS EED	NHS Economic Evaluation Database	USPHS	US Public Health Service criteria

All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or it has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices in which case the abbreviation is defined in the figure legend or at the end of the table.

Executive summary

Background

Dental caries is a chronic disease caused by the localised and progressive demineralisation of the hard tissues of the coronal and root surfaces of the teeth. Caries location, development and progression depend on a range of environmental, social and genetic factors, and vary greatly among individuals.

Despite the decline in the prevalence of dental caries observed in the high-income countries during the past few decades as a consequence of the increased availability of fluoride products and improved oral hygiene, dental caries is still a common disease experienced by almost 80% of children by the age of 18 years and by almost 90% of adults.

The current management of early non-cavitated occlusal and root caries, and cavitated root caries, which are still accessible to cleaning, is based on non-operative preventive strategies that include information on oral hygiene, dietary advice, use of topically applied fluorides and application of sealants. For cavitated occlusal caries and cavitated root caries that are not easily accessible to cleaning, restorative interventions are adopted (drilling and filling).

HealOzone® (CurOzone USA Inc., Ontario, Canada) has recently been proposed as a novel method for the treatment of dental caries. It is suggested that HealOzone may reverse, arrest or slow the progression of dental caries. The complete HealOzone procedure involves the direct application of ozone gas to the caries lesion on the tooth surface, the use of a remineralising solution immediately after application of ozone and the supply of a 'patient kit', which consists of toothpaste, oral rinse and oral spray all containing fluoride.

Objective

The review aims to assess the effectiveness and cost-effectiveness of HealOzone for the management of pit and fissure caries, and root caries.

Methods

Electronic searches were conducted to identify published and unpublished studies. The following databases were searched: MEDLINE (1966 to May 2004), EMBASE (1980 to May 2004), MEDLINE Extra (17 May 2004), Science Citation Index (1981 to May 2004), BIOSIS (1985 to May 2004), AMED (1985 to May 2004), Cochrane Library (Issue 2, 2004) National Research Register (Issue 2, 2004), Current Controlled Trials (18 May 2004), Clinical Trials (18 May 2004), SCI Proceedings (1991 to May 2004), Conference Papers Index (1982 to May 2002), ZETOC conferences (1993 to May 2004) and IADR meeting abstracts (2002 to 2004). Two reviewers independently assessed the methodological quality of included studies and extracted data. Criteria for assessment of study quality included method and unit of randomisation, concealment of allocation, comparability of groups at baseline, blinding procedures, number of withdrawals/dropouts and completeness of assessment at follow-up.

A systematic review of the effectiveness of HealOzone for the management of tooth decay was carried out. A systematic review of existing economic evaluations of ozone for dental caries was also planned but no suitable studies were identified. The economic evaluation included in the industry submission was critically appraised and summarised.

A Markov model was constructed to explore possible cost-effectiveness aspects of HealOzone in addition to current management of dental caries.

Results

Number and quality of studies, and direction of evidence

Five full-text reports and five studies published as abstracts met the inclusion criteria. Of these, only one was published in a refereed journal, but it lacked some study details. The remaining studies were PhD theses, unpublished reports or conference proceedings. The five full-text reports consisted of two randomised controlled trials

(RCTs) assessing the use of HealOzone for the management of primary root caries and two PhD theses of three unpublished randomised trials assessing the use of HealOzone for the management of occlusal caries. Of the five studies published as abstracts, four assessed the effects of HealOzone for the management of occlusal caries and one the effects of HealOzone for the management of root caries.

Overall, the quality of the studies was modest, with many important methodological aspects not reported (e.g. concealment of allocation, blinding procedures, compliance of patients with home treatment). In particular, there were some concerns about the choice of statistical analyses. In most of the full-text studies analyses were undertaken at lesion level, ignoring the clustering of lesions within patients. The nature of the methodological concerns was sufficient to raise doubts about the validity of the included studies' findings. A quantitative synthesis of results was deemed inappropriate.

Summary of benefits
Root caries
Two studies (one published and one unpublished) assessing the use of HealOzone for the management of primary non-cavitated root caries reported high success rates for ozone-treated lesions and no significant changes in the control lesions, despite application of topical fluoride. This is puzzling, since topical fluoride is known to be effective. Results of cavitated root lesions were poorly defined and reported in one of these two studies. Cavitated lesions did not seem to benefit from ozone application.

One unpublished study showed that fissure sealants preceded by the application of ozone for the preventive treatment of non-cavitated root lesions were more likely to remain intact (61% versus 42%, $p < 0.05$).

Pit and fissure caries
One unpublished study did not show any significant benefits of HealOzone for the management of non-cavitated pit and fissure lesions in the permanent dentition. Similarly, a small unpublished pilot study did not show any significant differences between cavitated occlusal lesions treated with or without ozone, apart from an improvement in the hardness and visual clinical indices. In contrast, findings from conference proceedings (which provide little detail for the assessment of their methodological quality and therefore are of little use in systematic reviews)

reported very high success rates (from 86.6% to 99% of reversal of caries).

Adding ozone to a fissure sealant did not seem to produce better sealant retention in occlusal lesions extending 2–4 mm into dentine.

Data on the use of HealOzone for the treatment of occlusal lesion in the deciduous dentition were available from only one unpublished study. An overall reduction in clinical severity scores was reported for non-cavitated occlusal lesions in primary molars treated with ozone.

On the whole, there is not enough evidence from published RCTs on which to judge the effectiveness of ozone for the management of both occlusal and root caries.

Costs
The perspective adopted for the study was that of the NHS and Personal Social Services. The analysis, carried out over a 5-year period, indicated that treatment using current management plus HealOzone cost more than current management alone for non-cavitated pit and fissure caries (£40.49 versus £24.78), but cost less for non-cavitated root caries (£14.63 versus £21.45). Given the limitations of the calculations these figures should be regarded as illustrative, not definitive.

Cost per quality-adjusted life-year
It was not possible to measure health benefits in terms of quality-adjusted life-years. This was mainly due to uncertainties around the evidence of clinical effectiveness, and to the fact that the adverse events avoided are transient (e.g. pain from injection of local anaesthetic, fear the drill).

Sensitivity analyses
One-way sensitivity analysis was applied to the model. However, owing to the limitations of the economic analysis, this should be regarded as merely speculative. For non-cavitated pit and fissure caries, the HealOzone option was always more expensive than current management when the probability of cure using the HealOzone option was 70% or lower. For non-cavitated root caries the costs of the HealOzone comparator were lower than those of current management only when cure rates from HealOzone were at least 80%. The costs of current management were higher than those of the HealOzone option when the cure rate for current management was 40% or lower.

One-way sensitivity analysis was also performed using similar NHS Statement of Dental

Remuneration codes to those that are used in the industry submission. This did not alter the results for non-cavitated pit fissure caries as the discounted net present value of current management remained lower than that of the HealOzone comparator (£22.65 versus £33.39).

Conclusions

Any treatment that preserves teeth and avoids fillings is welcome. However, the current evidence base for HealOzone is insufficient to conclude that it is a cost-effective addition to the management and treatment of occlusal and root caries.

Limitations of the calculations
The economic analysis was severely constrained by the uncertainty over clinical effectiveness, and it could be argued that such analysis was inappropriate. It was done merely to illustrate the key factors involved in economic modelling. The long-term effects of HealOzone are unknown and the assumption that reversed caries remains inactive may not be reliable.

Recommendations for research

To make a decision on whether HealOzone is a cost-effective alternative to current preventive methods for the management of dental caries, further research into its clinical effectiveness is required. Independent RCTs of the effectiveness and cost-effectiveness of HealOzone for the management of occlusal caries and root caries need to be properly conducted with adequate design, outcome measures and methods for statistical analyses.

Chapter 1

Aim of the review

The review aims to assess the effectiveness and cost-effectiveness of HealOzone® (CurOzone USA Inc., Ontario, Canada) for the management of both pit and fissure caries, and root caries.

1

Chapter 2

Background

Dental caries

Aetiology, pathology and prognosis

Dental caries (tooth decay) is a chronic disease caused by the localised and progressive demineralisation of the hard tissues of the coronal and root surfaces of the teeth. The demineralisation is caused by the interaction of acid-producing oral microorganisms (in particular *Streptococcus mutans*, *Lactobacillus* and *Actinomyces* species) with dietary carbohydrates (sugar).

Caries occurs when the natural dynamic balance between mineralisation and demineralisation of dental tissues is disrupted. The process begins on the surface of the enamel (outer surface of the tooth; see *Figure 1*). In enamel caries, the lesion may reverse or arrest by remineralisation. If remineralisation does not occur, the lesion may penetrate the enamel and consequently result in the formation of a cavity, which may progress through the dentine and the pulp of the tooth. In the absence of treatment, dental caries may ultimately destroy the tooth. Caries location, development and progression are influenced by a range of environmental, social and genetic factors, and vary greatly among individuals. In most individuals dental caries tend to progress slowly over time, with lesions often taking more than 2 years to cavitate, although in some it can take a shorter time. Conversely, some lesions never cavitate.

According to the anatomical location of carious lesions, it is possible to differentiate between coronal lesions, which may affect the pits and fissures or the smooth surfaces of a tooth, and root lesions, which affect the exposed root cementum and dentine. Root caries occurs in the same manner as coronal caries, but demineralisation begins at a higher pH and it is more common in older people. The term primary caries is used to indicate lesions on the unrestored surfaces of teeth, while caries that develops adjacent to a filling is referred to as recurrent or secondary caries. Hidden caries is a term used to identify carious lesions in the dentine that are not detected by visual examination but are large enough to be identified radiographically. According to their activity, carious lesions may be classified as active

or inactive/arrested. A lesion that is considered to be progressive is described as active, whereas a lesion that has stopped further progression is described as arrested. This distinction is clinically important as arrested lesions do not require any further preventive interventions.

The occlusal surfaces (pits and fissures) of teeth are particularly susceptible to dental caries owing to their morphological structure (minute dimensions of pits and fissures) and because microbial plaque is more likely to grow in these areas (plaque stagnation). The teeth are more prone to plaque stagnation during eruption. Occlusal caries is seen more often in molar teeth than in premolar or anterior teeth.

The incidence of root caries begins at about 30–40 years of age and tends to increase thereafter. Root caries is most prevalent in the elderly because when people get older and retain their natural teeth, their gums tend to recede and expose the root surfaces. According to the published NHS Plan for Modernising NHS

FIGURE 1 *Structure of a sound tooth. Reproduced with permission from www.mydr.com.au. Copyright CMPMedica Australia 2005.*

Dentistry, "nearly 90% of people aged over 65 years show some signs of gum disease compared with 14% of 16–24 year olds".[1]

Significance in terms of ill-health
Impact on patient's quality of life
Dental caries may have a significant impact on an individual's life. The most common consequences of untreated lesions are discomfort and pain. Restorative dental treatments can now be provided pain free, apart from the pain of the local anaesthetic injection. However, for some people restorative treatments are associated with fear and anxiety, which, may become barriers to dental attendance. Treatment avoidance can subsequently lead to further progression of caries which, in turn, may cause more distress and long-term complications. Gross decay may lead to disturbances in eating and sleeping patterns because of pain. Psychological distress can arise from the embarrassment and self-consciousness of having missing or decayed teeth, especially in the anterior dentition. Communication problems may ultimately occur as a possible result of tooth loss.

In addition to human cost, dental caries can be costly for the patients receiving treatment. For many patients NHS charges can be expensive, especially for those who earn just enough to disqualify them from exemption or remission of charges. Moreover, where provision of NHS dentistry is patchy, patients may have to depend on private dental care.

Impact on the NHS
Treatments for dental care carry considerable costs for both the NHS and society. NHS General Dental Services (GDS) data reveal that the total number of claims in England and Wales for dental interventions in the financial year 2002/03 was 34 million. Almost half (48%) of claims were for treatments requiring no dental intervention (i.e. examination, simple scaling, X-ray, fissure sealant, topical fluoride). The total number of teeth filled was about 19 million, while the number of teeth with roots filled was just over one million. Overall, the total gross fees authorised was £1634 million. The care and treatment for children accounted for 27% (£461 million) of all gross fees authorised.

Epidemiology
There has been a significant reduction in dental caries since the 1970s in industrialised countries, due to environmental and educational factors such as the increased use of fluoride in public water supplies, dentifrices and dental products; improved oral hygiene and prophylaxis; dietary

counselling; and increased access to dental care. Nevertheless, dental caries is still a common disease, experienced by almost 80% of children by the age of 18 and by almost 90% of adults.[2]

Prevalence in children
Since the significant decline in the 1970s and 1980s, it seems that over the past 20 years caries prevalence rates have become relatively stable.[2] The 2003 Children's Dental Health Survey commissioned by the UK Health Departments provides the most recent estimate of the prevalence of dentine decay in children in England and Wales.[3] The 2003 survey is the fourth in a series of dental health surveys carried out every 10 years since 1973. The criteria used in the survey to assess dental caries were the following:

- filled decay, otherwise sound: teeth with amalgam, or other fillings that had no cavitated dentine caries present
- obvious decay experience: all teeth with cavitated dentine caries, restorations with cavitated dentine caries, teeth with filled decay (otherwise sound) and teeth extracted due to caries. The term relates to the DMFT (decayed, missing, and filled teeth) dental decay index.

The preliminary findings of this survey indicate that:

- there has not been a substantial change in the proportion of 5- and 8-year-olds who presented with obvious decay in the primary (milk) teeth between the 1993 and 2003 dental survey (*Table 1*)
- the proportion of filled primary teeth as well as the proportion of the total obvious decay experience represented by filled primary teeth in 5- and 8-year-olds has declined since 1983, indicating a decline in restorative interventions (*Table 1*)
- the mean number of primary teeth with obvious decay has decreased since 1983 in 5- and 8-year-olds (*Table 2*), but the mean number of primary teeth with obvious decay among children with decay has not changed considerably since 1993, apart from the decline in the number of filled teeth in the 8-year-olds (*Table 3*)
- the proportion of 8-, 12- and 15-year-olds with obvious tooth decay and cavities into dentine in permanent teeth has decreased considerably since 1983 (*Figures 2* and *3*)
- the proportion of filled permanent teeth has declined considerably since 1983 in 12- and 15-year-olds, but not in 8-year-olds (*Figure 4*)

TABLE 1 *Percentage of children with obvious tooth decay in primary teeth by age (Children's Dental Health in the United Kingdom, 2003)*[3]

Tooth condition	Year		
	1983	1993	2003
	Percentage of children:		
Obvious decay experience			
5-year-olds	50	45	43
8-year-olds	70	61	57
Teeth with cavities into dentine			
5-year-olds	41	40	40
8-year-olds	49	50	50
Filled decay (otherwise sound)			
5-year-olds	23	15	12
8-year-olds	47	33	26
Filled teeth as a proportion of total obvious decay experience			
5-year-olds	28	17	15
8-year-olds	50	35	28

TABLE 2 *Mean number of primary teeth with obvious tooth decay by age (Children's Dental Health in the United Kingdom, 2003)*[3]

Tooth condition	Year		
	1983	1993	2003
	Mean number of teeth		
Teeth with cavities into dentine			
5-year-olds	1.3	1.4	1.4
8-year-olds	1.2	1.3	1.3
Filled decay (otherwise sound)			
5-year-olds	0.5	0.3	0.2
8-year-olds	1.2	0.7	0.5
Obvious decay experience			
5-year-olds	1.8	1.7	1.6
8-year-olds	2.3	2.0	1.8

TABLE 3 *Mean number of primary teeth with obvious tooth decay in children with obvious decay experience by age (Children's Dental Health in the United Kingdom, 2003)*[3]

Tooth condition	Year	
	1993	2003
	Mean number of teeth	
Teeth with cavities into dentine		
5-year-olds	3.1	3.2
8-year-olds	2.1	2.3
Filled decay (otherwise sound)		
5-year-olds	0.6	0.6
8-year-olds	1.1	0.9
Obvious decay experience		
5-year-olds	3.7	3.8
8-year-olds	3.2	3.2

TABLE 4 *Proportion of children with obvious tooth decay in permanent teeth by age (Children's Dental Health in the United Kingdom, 2003)*[3]

Tooth condition	Year		
	1983	1993	2003
	Percentage of children:		
Filled teeth as a proportion of total obvious decay experience			
8-year-olds	58	37	52
12-year-olds	70	58	70
15-year-olds	74	68	77

- the proportion of the total obvious decay experience represented by the number of filled permanent teeth in 8-, 12- and 15-year-olds has increased since 1993, indicating an increase in restorative interventions (*Table 4*).

These findings are consistent with those found by the USA Third National Health and Nutrition Examination Survey (NHANES III), Centers for Disease Control and Prevention (CDC), National Centre for Health Statistics (NCHS)[4] and the National Survey of Dental Caries in US School Children 1986–1987, where 52% of children aged 6–8 years and 61% of children aged 15 years

presented with tooth decay in permanent or primary teeth. The proportion of children with untreated caries in permanent or primary teeth was 29% for the 6–8-year-olds and 20% for the 15-year-olds (*Figure 5*).

Dental caries is not evenly distributed across the child population, with about 26% of children (worst cases) presenting with 75% of all carious lesions.[6] This can be interpreted in the light of the fact that dental caries is a disease of lifestyle with strong socio-economic and geographical differences. The use of deprivation categories in the assessment of Scottish schoolchildren aged 5 years is a good example of how measures of socio-economic status may correlate with dental caries experience (*Figure 6*).[5] The link between social status and prevalence of caries is also supported by the data from the National Children's Dental Health Survey carried out in the UK in 1993 (*Figure 7*).[7]

Prevalence in adults
Fewer prevalence data are available for adults.

FIGURE 2 *Proportion of children with obvious decay experience in permanent teeth by age (Children's Dental Health in the United Kingdom, 2003)*[3]

FIGURE 3 *Proportion of children with cavities into dentine in permanent teeth by age (Children's Dental Health in the United Kingdom, 2003)*[3]

**FIGURE 4** *Proportion of children with filled permanent teeth by age (Children's Dental Health in the United Kingdom, 2003)*[3]

FIGURE 5 *Proportion of children with tooth decay and untreated caries by age (NHANES III)*[4]

FIGURE 6 *Caries distribution by socio-economic 'deprivation categories' (DEPCAT) in Scottish schoolchildren aged 5 years.*[5] *DEPCAT 1 = most affluent postcode sections. DECAT 7 = most deprived postcode sectors.*

According to the UK 1998 Adult Dental Health Survey,[8] adults had an average of 1.5 decayed or unsound teeth (teeth with visual or cavitated caries or those with an unsound restoration) and 55% had at least one decayed or unsound tooth. The numbers of adults with decayed or unsound teeth varied according to the regions surveyed. The proportion of dentate adults with tooth decay in England, Wales, Scotland and Northern Ireland is shown in *Figure 8*.

The mean proportion of filled permanent teeth ranged from 9% for people aged 16–24 years to 39% for people aged 45–54 years (*Figure 9*).

Overall, 66% of the adult population showed at least one tooth with a root surface that was exposed, worn, decayed or filled. Overall, root surface fillings were found in 43% of people aged 65 and older.

Similarly, in the USA, NHANES III – Phase 1 found evidence of coronal carious lesions in 94% of the studied population. The mean score for decayed and filled surfaces (DFS) on permanent teeth in adults was 22.2. Carious lesions were found in 23% of all dentate adults and in 47% of people aged 65 years and over (NHANES III 1998–1991).[4]

Current service provision

Current management of dental caries
Increasing emphasis has been recently dedicated to the provision of caries prevention and

FIGURE 7 *Average number of decayed, missing or filled teeth in adolescents in the UK by social class (National Children's Dental Health Survey, 1993)[7]*

FIGURE 8 *Proportion of adults with decaying or unsound teeth by country (United Kingdom Adult Dental Health Survey, 1998)[8]*

FIGURE 9 *Mean proportion of filled teeth by age (United Kingdom Adult Dental Health Survey, 1998)[8]*

management strategies. In particular, attention to risk assessment and to preventive non-operative methods for assisting remineralisation of early caries has been advocated. Despite the acknowledged importance for the prevention of caries, non-operative, preventive treatments are not fully funded by the NHS at present. Changes are likely to be introduced with the implementation of the new contract in 2006.

Efficient management of dental caries depends on the knowledge of patients' dental and medical history and risk assessment, correct identification of carious lesions and identification of the best treatment options for dental caries. A thorough dental and medical history provides information about patients' previous experience of dental caries, number of active lesions and factors that may affect caries activity (e.g. general oral hygiene, diet and sugar intake, exposure to fluoride, salivary flow rate, certain medical conditions and medications). Caries risk assessment aims at identifying high-risk individuals who may benefit more from preventive treatments, and low-risk individuals for whom restorative treatments could be delayed. Carious lesions are first identified on the basis of the findings of the clinical examination (visual criteria). For visual detection of occlusal caries and for predicting their activity and severity, the ranked scoring system described by Ekstrand and colleagues[9] is recognised as a valid and reliable tool, although mainly used in clinical research. For assessing the extent and severity of root caries the tactile criteria of 'soft, leathery and hard' on probing are commonly used in dental practice and dental research. Radiographic investigations (X-rays) have been widely used for decades as an adjunct to clinical examination to estimate the depth of occlusal lesions into dentine or to identify lesions that are hidden from clinical examination. More recently, other quantitative, more advanced methods have been proposed for the diagnosis of dental caries. These include methods based on:

- digital radiology [e.g. digital image enhancement, digital subtraction radiography, tuned aperture computed tomography (TACT)]
- visible light [e.g. quantitative fibre-optic transillumination (QOTI/FOTI), quantitative light-induced fluorescence (QLF)]
- laser fluorescence (e.g. DIAGNOdent)
- electrical current [e.g. electrical conductance measurement (ECM)]
- ultrasound [e.g. ultrasound caries detector (UCD)].

However, with the exception of digital radiology, these diagnostic procedures are not widely used in dental practice. Some procedures need further investigation (e.g. QOTI/FOTI, QLF) or further development (e.g. UCD) before their use could be recommended in dental practice. Others are prone to false-positive measurements (e.g. small amount of plaque identified as a carious lesion by DIAGNOdent) or unreliable findings (e.g. because of inadequate tooth isolation during ECM),[10] which require a careful interpretation and sometimes correction by the dentist. In particular, to the authors' knowledge the validity of DIAGNOdent as an instrument for detecting occlusal caries has yet to be demonstrated in *in vivo* studies.

Treatment of early caries (non-cavitated pit and fissure caries and root caries)

Treatment options for early caries include the following:

- provision of information about oral hygiene
- dietary assessment and advice
- fluoride-delivery methods
- application of chlorhexidine
- pit and fissure sealants
- recall at regular intervals.

Oral hygiene

Instructions on oral hygiene aim at improving personal removal of plaque by toothbrushing. Regular toothbrushing in children may help to reduce the incidence of caries,[11] and children whose level of oral hygiene is good experience less decay.[12] Despite the lack of evidence on the effectiveness of oral hygiene instructions,[13] toothbrushing, together with the use of fluoride toothpaste and the advice of reducing sugar intake, is usually recommended in the dental practice for maintaining a good level of oral hygiene.

Dietary assessment and advice

Evidence from epidemiological and experimental studies indicates that frequent consumption of fermentable carbohydrates is associated with prevalence of dental caries. For some patients the frequency of intake of a certain type of food may primarily contribute to their caries risk and modification of this factor may be sufficient to change their risk. The diet–caries association is, however, complex and needs to be evaluated not only on the basis of the quantity and type of fermentable carbohydrates consumed, but also considering several other background factors such as age, total food intake, dietary habits, salivary flow rate, use and type of medications, and use of

fluoride products. Dietary assessment is usually recommended in patients with multiple active lesions. In contrast, no diet modifications are suggested for patients with inactive caries. The dentist, however, may still provide information on how unhealthy dietary habits may become a problem, especially when associated with a poor level of oral hygiene.[14]

Fluoride-delivery methods
Use of fluoride-delivery products and water fluoridation are among the factors that have contributed to the observed progressive improvement in oral health since the 1970s. Evidence indicates that fluoridation of the water supply is associated with an increased proportion of children without caries and a reduction in the number of teeth affected by caries.[1,15,16] Topical fluoride-delivery methods in the form of toothpastes, mouth rinses, gels or varnishes are effective measures to prevent dental caries. Their effectiveness has been established on evidence from randomised trials and more recently from a series of Cochrane systematic reviews of randomised trials.[17–22] Overall, fluoride toothpaste is the cheapest and the most widespread method to control dental caries.[23–25] A recent randomised, double-blind, clinical trial examined the anticaries effectiveness of fluoride dentifrices containing 1700, 2200 and 2800 ppm fluoride ion compared with a 1100 ppm fluoride control toothpaste, in schoolchildren aged 6–15 years.[24] The 1-year results demonstrated significant caries reductions for higher fluoride dentifrices for all tooth surfaces, but in particular for occlusal surfaces.[24] The use of fluoride mouth rinses and gels, as an adjunct to fluoride toothpaste, is usually advised for individuals at high risk of developing caries. Fluoride varnish is used to provide fluoride delivery to specific tooth sites and surfaces and is usually applied at intervals of 3 or 6 months. A recent systematic review by Marinho and colleagues[17] looked at the effectiveness of fluoride varnish in preventing dental caries in children and adults and commented on the ability of fluoride varnish to promote remineralisation of early caries. The included studies also considered "non-cavitated incipient enamel lesions", clinically visible as white spots or discoloured fissures, which would be included among those lesions eligible for ozone application. The treatment effect was measured in terms of 'prevented fraction' (mean increment in caries in controls minus mean increment in fluoride group divided by the mean increment in the controls). For the seven studies that contributed to the main meta-analysis, the decayed, missing and filled surfaces (DMFS)

prevented fraction pooled estimate was 0.46 [95% confidence interval (CI) 0.30 to 0.63, $p < 0.0001$], indicating a substantial benefit and demonstrating that fluoride varnish alone can result in reversal of early caries. Similarly, the meta-analysis of the three studies assessing the effect of fluoride varnish on deciduous teeth suggested a 0.33% (95% CI 0.19% to 0.48%, $p < 0.0001$) reduction in DMFS. Another recent systematic review[26] of selected caries prevention methods reached similar conclusions, demonstrating that there is a fair body of evidence on the effectiveness of fluoride varnish to arrest or reverse non-cavitated carious lesions in permanent teeth. Other fluoride products such as fluoride supplements (e.g. fluoride tablets or drops) are regarded as less effective methods of delivering fluoride because they rely entirely upon patient compliance. Their use is usually limited to high-risk categories of children, adults and, particularly, elderly people.[27]

Application of chlorhexidine
The effectiveness of chlorhexidine as an antimicrobial for preventing progression of non-cavitated caries has yet to be established. Current evidence is derived mainly from small studies evaluating the effects of different forms of chlorhexidine (varnish, gel or rinse) in combination with other concomitant preventive measures.[26,28]

Pit and fissure sealants
Pits and fissures are sealed to prevent caries development.[28] Evidence indicates that caries does not progress as long as the sealant remains in place.[29,30] Sealant applications may be suitable for both young children and older patients.[31] Materials that are currently used to seal a lesion include different types of composite resin and glass ionomer cement. The resin-based sealants are divided into generations according to their mechanism for polymerisation and their content. The first generation sealants which were activated by ultraviolet light are no longer available and the most recently developed fourth generation sealants contain fluoride. The effectiveness of resin sealants for the prevention of caries in the permanent teeth of children and adolescents was demonstrated by Ahovuo-Saloranta and colleagues[32] in a recent Cochrane systematic review. The review compared second, third and fourth generation resin-based sealants or glass ionomer sealants with a control (no sealant) and compared one type of fissure sealant with another type. The focus of the review was on prevention, and the children and adolescents included did not seem to present with obvious caries. The review

concluded that resin-based sealants are effective in preventing caries of the occlusal surfaces of permanent molars. Reduction of caries ranged from 86% at 12 months to 57% at 48–54 months. Resin sealant retention was good across studies and sealants were retained completely in 79% and 92% of cases at 12 months. Sealant retention decreased with time and at 36 months ranged from 61 to 80%. Evidence on the effects of glass ionomer-based sealants was less convincing.

Treatment of cavitated pit and fissure caries and root caries

For lesions that have progressed to the stage of cavity, restorative interventions are often used to remove the decayed tissue and fill the cavity to aid plaque control. However, cavitated root lesions that are still accessible to cleaning need not always be filled because cleaning alone can arrest caries. A number of different materials can be used to restore a tooth. These include composite resin, glass ionomer cement and amalgam. Amalgam is still the material of choice for large restoration of molar teeth. Root caries are usually restored with composite resin or glass ionomer cement. According to the NHS Dental Review 2002–2003,[33] in the quarter ending December 2002 the number of teeth filled was 4,896,951 and on average one tooth was filled for every two claims (55%). Overall, restorations showed a median survival interval to next restorative intervention of just over 8 years. The main factors associated with different likelihoods of re-intervention were the age of the patient at the date of restoration, the position of the tooth and the type/material of restoration.[33]

Description of new intervention

Rationale

The antimicrobial effects of ozone gas (O_3) have been known for many years. Direct application of ozone gas to the coronal or root tooth surface is claimed to have a sterilising effect. In particular, ozone is claimed to stop the action of the acidogenic and aciduric micro-organisms responsible for the tooth decay. It is consequently alleged to be able to reverse, arrest or slow down the progression of dental caries. It is also maintained that ozone is useful for reducing the microbial flora in cavitated lesions, before fillings are inserted.

Development of HealOzone

The ozone unit for dental use was initially developed by CurOzone Inc. (Canada) and subsequently manufactured under licence and distributed by KaVo-Dental GmbH & Co. (Germany) under the name 'HealOzone'. Its use has been pioneered by Professor Edward Lynch and his team at Queen's University in Belfast, Northern Ireland, and Barts and the London Queen Mary's School of Medicine and Dentistry in London, UK. HealOzone is a certified Medical Device [Conformité Européene (CE) marked] for the management of occlusal pit and fissure caries, and root caries. According to the manufacturer, 294 HealOzone units (as at June 2004) are currently in use in dental practices in the UK and more than one million people have already received HealOzone treatment. The HealOzone technology has not yet received Food and Drug Administration (FDA) approval in the USA.

The new version of HealOzone (Mark3) was launched in July 2004. According to the manufacturer previous models can be upgraded to the most recent technical functions.

HealOzone procedure

The HealOzone procedure consists of a package, which includes the application of ozone gas, the use of remineralising agents, a patient kit and information on oral hygiene. The HealOzone device comprises an air filter, a vacuum pump, an ozone generator, a handpiece fitted with a sealing silicone cup and a flexible hose. The silicone cups are available in a range of five sizes from 3 to 8 mm in diameter. The HealOzone unit requires high-voltage power to generate ozone from the air and to convert ozone back to oxygen when the process is completed. The air is exposed to high-voltage current to generate ozone at a concentration of 2100 ppm ± 10% and passes through the instrument hose and handpiece. The flow of air into the system, the delivery of ozone to the tooth and the removal of ozone from the system after completion of treatment are achieved by a vacuum pump, which works at an adjustable flow rate of 615 cm^3 per minute to maintain the ozone concentration at 2100 ppm.

The procedure usually takes between 20 and 120 seconds per tooth. Immediately after ozone application the tooth surface is treated with a remineralising solution (reductant) containing fluoride, calcium, zinc, phosphate and xylitol dispensed from a 2-ml ampoule. The reductant is supplied in packs of 100 ampoules. Patients are also supplied with a patient kit, which consists of toothpaste, oral rinse and oral spray, all containing fluoride, calcium, zinc, phosphate and

xylitol, and aims to enhance the remineralisation process. HealOzone application for the treatment of non-cavitated lesions is usually repeated at 3 and 6 months. There is no clear information on how delivery of ozone at the correct concentration can be ensured by the device.

Key questions

This review aims to answer the following questions:

- For the management of pit and fissure caries, is the HealOzone procedure more effective than the combination of oral hygiene, dietary advice, chlorhexidine/fluoride varnish and fissure sealant? If so, is it a cost-effective alternative?
- For the management of non-cavitated root caries, is the HealOzone procedure more clinically effective than the combination of oral hygiene, dietary advice and varnish? If so, is it cost-effective?
- For the management of cavitated caries, how often, if at all, is HealOzone procedure an alternative to fillings?
- For the management of cavitated caries, does the application of ozone gas and of a re-mineralising solution to the cavity before restoration prolong the life of a filling? If so, is it cost-effective?

Chapter 3

Effectiveness

Methods for reviewing effectiveness

Search strategy

Initial database searches were undertaken to identify relevant systematic reviews and other evidence-based reports. Several websites were also consulted to obtain background information. Full details of the main sources consulted are listed in Appendix 1.

Electronic searches were conducted to identify published and unpublished studies on the clinical and cost-effectiveness of ozone therapy for dental caries. The electronic databases searched are detailed in *Table 5*. Full details of the search strategies are documented in Appendix 1. It was anticipated that there was a small body of research available, therefore a sensitive search strategy for clinical effectiveness studies was undertaken to retrieve all useful information on ozone therapy for dental caries. Additional searches were carried out for economic data and these are detailed in Chapter 4. In addition, selected conferences proceedings that were not available electronically were handsearched. These were International Association for Dental Research (IADR) conference proceedings for 1999–2001 and the annual European Organisation for Caries Research (ORCA) Congresses 2000–2003. Research abstracts, published on industry and users' websites (KaVo Dental, CurOzone USA, HealOzone and

DentalOzone; see Appendix 1 for full details), were also identified. Reference lists of included studies were also checked for additional study reports.

Inclusion and exclusion criteria

All citations identified by the search strategy were assessed for relevance by two reviewers. Copies of the full-text, published papers of those considered to be relevant were then obtained. It was decided that studies reported in languages other than English would be identified but not included in the review.

For clinical effectiveness assessment, included studies were randomised controlled trials (RCTs) of ozone treatment (HealOzone) versus at least one comparator (nil, placebo or active treatment). Data from studies other than randomised trials were collected but not included in the review. The outcome measures were required to be measures of clinical effectiveness (e.g. reversal/progression of caries). Only *in vivo* studies involving human subjects were deemed to be suitable for inclusion, while studies reporting *in vitro* results were excluded. Studies were also excluded if their follow-up was less than 6 months or did not report clinically relevant outcome measures.

Data extraction strategy

A data abstraction form was designed (Appendix 2) to collect details from each individual study.

TABLE 5 *Electronic databases searched*

Database	Coverage
MEDLINE/EMBASE/MEDLINE Extra multifile search	MEDLINE: 1966 to May Week 1 2004
	EMBASE: 1980 to Week 20 2004
	MEDLINE: Extra: 17 May 2004
Science Citation Index (SCI)	1981 to 16 May 2004
BIOSIS	1985 to 12 May 2004
AMED	1985 to May 2004
Cochrane Controlled Trials Register (CCTR)	Cochrane Library, Issue 2, 2004
National Research Register (NRR)	Issue 2, 2004
Current Controlled Trials (CCT)	18 May 2004
Clinical Trials	18 May 2004
SCI Proceedings	1991 to 15 May 2004
Conference Papers Index	1982 to May 2002
ZETOC Conferences	1993 to May 2004
IADR Meetings Abstracts	2002 to 2004

13

TABLE 6 *Number of screened and selected reports according to database searched*

Database searched	Number screened	Number selected	Included studies
MEDLINE/EMBASE/MEDLINE Extra	46	4	1
SCI	38	7	1
BIOSIS	38	1	0
CENTRAL	8	1	0
IADR abstracts	175	43	12
Handsearch		14	2
Websites		15	5
Other databases	26	0	0
Total	**331**	**85**	**21**

These included the type of study design, number of participants and their characteristics, intervention characteristics, caries information including location and severity of lesion, patient outcomes such as reversal/progression of caries, and any reported adverse events.

In particular, the outcomes sought for the included studies were as follows:

(a) Non-cavitated caries

- reversal of caries
- progression of caries
- utilisation of dental services (e.g. visits to dental care units; duration of dental treatment)
- adverse events
- patient-centred measures (e.g. patient satisfaction and preference, relief of pain/discomfort)
- quality of life.

(b) Cavitated caries

- time to restorative interventions
- need for further restorative interventions and length of time between restorations
- symptoms of pulpal pathology.

Inclusion criteria were assessed independently by two reviewers. Any disagreements were resolved by consensus or referred to a third reviewer. Reviewers were not blinded to the names of study authors, institutions or publications.

Quality assessment strategy

Two reviewers assessed the methodological quality of all included studies and any disagreements were resolved by discussion. The quality assessment of RCTs was formally assessed using a published checklist modified by the reviewers for the purpose of this review.[34] The checklist consisted of 12 questions, which focus on the following methodological aspects: method of randomisation, unit of randomisation, concealment of allocation, comparability of groups at baseline, blinding procedures, number of withdrawals/dropouts and completeness of assessment at follow-up.

For each question a 'Yes', 'No' or 'Unclear' answer was required. The quality assessment checklist is presented in Appendix 3.

Results

Quantity and quality of research available

After removing duplicates a total of 331 reports was identified (*Table 6*): 78% (257) were abstracts and 22% (74) were full-text reports. Eighty-five reports (seven full-text papers and 78 abstracts) were selected for full assessment, of which 21 (three full-text papers and 18 abstracts) met the predefined criteria for inclusion in the review. In addition, two reports, both PhD theses, were identified from reference lists. All 23 identified reports were written in English.

Number of studies identified

In total, five studies reported in five full-text papers and 13 abstracts, and five studies reported only as abstracts, met the inclusion criteria for studies of clinical effectiveness. In case of multiple publications the report with the longest follow-up time and/or largest sample size was chosen as the main source of information.

Number and type of studies excluded

After identifying duplicates, several studies were excluded as they did not meet the inclusion criteria. The main reasons for exclusion, together with the corresponding number of studies excluded are listed in *Table 7*.

TABLE 7 *Number of studies and reasons for exclusion*

Reason for exclusion	Number of studies/abstracts
Follow-up less than 6 months	17
No HealOzone treatment; other experiments involving ozone	14
No measures of clinical effectiveness	6
HealOzone used on extracted teeth (*in vitro* studies)	4
Evaluation of diagnostic tests for detection of dental caries; no clinical effectiveness measures	5
Time studies, no clinical effectiveness measures	3
Discussion paper, no comparative information on clinical effectiveness	1
Costs, no clinical effectiveness measures	1
No random allocation	2
Patients' attitudes, no effectiveness measures	7
Studies not involving ozone	4

Number and type of studies included

The five full-text studies consisted of two RCTs assessing the use of HealOzone for the management of primary root caries – one published trial by Holmes[35] and one unpublished trial by Baysan and Lynch,[36] and two PhD theses assessing the use of HealOzone for the management of pit and fissure caries, one by Abu-Naba'a[37] reporting two unpublished trials and one by Abu-Salem[38] reporting one unpublished trial.

Root caries studies

Holmes (2003): this published randomised trial[35,39,40] of management of primary non-cavitated root caries had two treatment groups: ozone plus reductant plus patient care kit versus air treatment plus reductant plus patient care kit. This study was set in a general dental practice.

Baysan and Lynch (2004): this unpublished randomised trial on cavitated and non-cavitated root caries[36,41–44] had four treatment groups: ozone plus reductant versus reductant only, and ozone plus sealant versus sealant only. It recruited patients who attended the School of Dentistry in Belfast.

Pit and fissure caries studies

Abu-Naba'a PhD thesis[37] included two randomised studies: a main study (Abu-Naba'a, 2003) and a pilot study (Abu-Naba'a pilot study, 2003), which are considered separately as they do not include the same patient population. The main study assessed exclusively non-cavitated occlusal lesions, whereas the pilot study included cavitated occlusal lesions. Patients were recruited from the School of Dentistry in Belfast for both the main and pilot studies.

The Abu-Naba'a main study[37,45–50] had four treatment groups: ozone plus reductant versus air treatment plus reductant, and ozone plus reductant plus sealant versus reductant plus sealant only. It involved 90 patients with 254 lesions.

The Abu-Naba'a pilot study[37,51,52] had two treatment groups: ozone plus reductant versus reductant only. It involved eight patients with 34 lesions.

The Abu-Salem study[38] had two treatment groups: HealOzone plus reductant versus reductant only. It recruited 21 patients with 74 lesions, from Belfast primary schools.

Of the five studies published only as abstracts, four assessed the effects of HealOzone for the management of occlusal pit and fissure carious lesions,[53–56] and one assessed the effects of HealOzone on primary root carious lesions.[57]

Tabulation of quality of studies, characteristics of studies and evidence rating

The characteristics of the five full-text studies (type and number of participants and carious lesions, details of study design, inclusion criteria, characteristics of intervention and main results) are shown in Appendix 4.

Method of randomisation was reported in three studies.[35,37,38] Concealment of allocation was not specified in any of the included studies. One study was described as double blind[35] and another study stated that outcome assessment was undertaken by a blinded examiner.[38] In particular, the double-blind study by Holmes was reported to involve three dentists: the first dentist performed the

15

initial assessment of primary root carious lesions; the second randomised the lesions to treatment groups; the first then treated and assessed the result without knowing which were given ozone and which air, using a modified HealOzone machine; the third dentist independently assessed lesions in 15 patients. The practicality of the entire process is, however, doubtful. Holmes is the only author of the study and the other assessors are neither listed as authors nor acknowledged in the paper.

It was unclear whether blinding procedures were secured in the remaining three included studies. The total number of people in the studies was 287, with a total of 768 carious lesions. Across the studies, the ages of the participant groups ranged from 7 to 82 years. Only three studies provided information on the gender of the participants.[36–38] The length of follow-up ranged from 6 to 21 months.

Each study involved either two or four intervention groups. Ozone was always used in combination with other active interventions (i.e. ozone plus reductant, ozone plus reductant plus patient care kit, ozone plus sealant, ozone plus reductant plus sealant) and compared to the same intervention without ozone or to a sham procedure (air treatment). The dosage of ozone treatment varied between studies. In the Baysan and Lynch study,[36] the Abu-Salem study[38] and the Abu-Naba'a main study,[37] ozone was administered for 10 seconds, whereas in the Holmes study[35] and the Abu-Naba'a pilot study[37] ozone was administered for 40 seconds. In all studies ozone applications were repeated at some point before the final follow-up. None of the included studies provided information on the model/version of the HealOzone device.

The main outcome measure was reversal of caries. This included the proportion of carious lesions becoming hard and, for some of the included studies, the proportion of lesions reversing from 'leathery' to 'leathery approaching hard texture', but not necessarily hardening. The proportion of lesions that deteriorated from leathery to soft was also recorded, although not consistently. Where appropriate the proportion of intact sealants was documented. Changes in the ECM and DIAGNOdent readings were also reported in the identified studies, but not considered in this review, owing to the unreliability of their measurements (i.e. high-false positive rates) and poor correlation with clinical outcomes.[58]

In the majority of the included studies, data analysis was conducted at the level of the lesion. Holmes used χ^2 statistics, but did not specify whether they were for related samples (i.e. McNemar χ^2 test). In the Baysan and Lynch study no information was provided on the choice of statistical test used. In both Abu-Naba'a studies the unit of analysis was tooth-pair, but it was unclear whether the occurrence of multiple pairs of lesions per mouth was taken into account. Abu-Salem used a mixed-effects analysis of variance (ANOVA) with random effects for patient and teeth within patient, and fixed effects for group and time of treatment.

The characteristics of the five studies published as abstracts are shown in Appendix 5.

Tabulation of results and assessment of effectiveness
The clinical effectiveness results are presented according to type of carious lesions (root caries results are presented separately from occlusal caries results). Within this categorisation studies results are presented according to:

- type of outcome measures
- type of publication (results of full-text studies are presented separately from results of studies published as conference proceedings)
- type of dentition (treatment results of primary teeth are presented separately from treatment results of permanent teeth).

It was planned to undertake further statistical analyses of the data reported in the full-text studies and when appropriate to combine them quantitatively. However, owing to the limited raw data provided, this proved unfeasible. The *p*-values of statistical analyses in the results section are those originally quoted by the studies' authors. However, as the data were not analysed as 'paired data' on a patient basis, their validity and reliability are open to question.

Primary root carious lesions
Two full-text studies by Holmes[35] and Baysan and Lynch[36] and one abstract by Lynch and colleagues[57] assessed the use of ozone for the management of primary non-cavitated root carious lesions. The Baysan and Lynch study also included the assessment of a non-specified number of cavitated root lesions. In the Holmes studies the clinical criteria of 'soft, leathery and hard' were adopted for the assessment of carious lesions, whereas in the Baysan and Lynch study

TABLE 8 *Results of root carious lesions*

	Ozone final follow-up		Control final follow-up	
	No.	(%)	No.	(%)
PRCLs becoming hard				
Baysan and Lynch, 2004[36] (12 months)[a]	NR	(47)	NR	(0)
Holmes, 2003[35] (18 months)[b]	87/87	(100)	1/87	(1)
PRCLs becoming less severe (from index 2 to 1)				
Baysan and Lynch, 2004[36] (12 months)[a]	NR	(52)	NR	(12)
PRCLs becoming soft				
Holmes, 2003[35] (18 months)[b]	0/87	(0)	32/87	(37)

NR, not reported (the denominator was not clearly reported in the study, so the number of caries cannot be calculated, hence only percentages are given).
[a] Baysan and Lynch: non-cavitated and cavitated primary root carious lesions.
[b] Holmes: non-cavitated primary root carious lesions.

TABLE 9 *Results of the Holmes study at each recall visit[35]*

	Ozone at follow-up		Control at follow-up	
	No.	(%)	No.	(%)
PRCLs becoming hard				
12 months	85/87	(98)	1/87	(1)
18 months	87/87	(100)	1/87	(1)
21 months	81/81	(100)	6/81	(8)
PRCLs remaining leathery				
12 months	2/87	(2)	65/87	(75)
18 months	0/87	(0)	54/87	(62)
21 months	0/81	(0)	65/81	(80)
PRCLs becoming soft				
12 months	0/87	(0)	21/87	(24)
18 months	0/87	(0)	32/87	(37)
21 months	0/81	(0)	10/81	(12)

lesions were classified according to a five-point severity index as follows:

0 all 'hard' lesions
1 'leathery' lesions considered to be small, easily cleanable and approaching a 'hard' texture
2 'leathery' lesions judged to be shallow and where the surface of the exposed sound dentine could be easily maintained plaque free
3 'leathery' lesions judged to be in surfaces that were difficult to maintain plaque free, and large, cavitated 'leathery' lesions where pulpal integrity was judged to be at risk
4 all 'soft' lesions.

No information was provided on the validity and reproducibility of the above severity index, or on how lesions were clinically identified as 'leathery' 'soft' or 'hard'. In particular, the distinction

between three degrees of 'leathery' seemed rather artificial.

Change in clinical severity Table 8 shows for each of the included studies the proportions of carious lesions that according to the studies' authors reversed (became hard), improved (became less severe) or deteriorated in the ozone-treated group and the control group. The Holmes study[35] reported that 100% of ozone-treated primary root carious lesions (PRCLs) had reversed by 18 months, while 37% of PRCLs in the control group had worsened from leathery to soft and 1% had reversed. However, comparisons of results at different follow-up points show some inconsistencies in the way data were reported (*Table 9*). In particular, the results at 21 months (published as an abstract) showed an increase in the number of control lesions that stabilised

17

(from 54/87 at 18 months to 65/81 at 21 months) and a subsequent decrease in the number of control lesions that had become soft (from 32/87 at 18 months to 10/81 at 21 months), indicating an improvement over time in lesions receiving treatment other than ozone. No comments on these changes were provided by the authors.

In the Baysan and Lynch study,[36] 47% of the ozone-treated lesions had arrested by 12 months, whereas none had become hard in the control group ($p < 0.001$), and 52% had reversed from index 2 (leathery) to index 1 (leathery approaching hard texture) in the ozone group compared with 12% of lesions in the control group ($p < 0.001$). So, if one combines the 'approaching hard' (from index 2 to 1) and 'hard' lesions (from index 2 to 0), 99% of lesions improved, as in the Holmes study. This study included both cavitated and non-cavitated root lesions, but results were not clearly presented according to the type of lesions and it is unclear how many cavitated and non-cavitated lesions were assessed in each intervention group. Only one figure in the paper presented results for both types of lesions in the ozone group: the percentage of cavitated lesions that had reversed (become hard) decreased from 9.1% at 1 month to 1.4% at 9 months, indicating an increase/progression in the severity of cavitated root lesions treated with ozone. No statistical analysis was undertaken by the authors, no corresponding data were given for the control group, and no comments on reversal/progression of cavitated lesions were provided in the text of the paper.

In addition, the abstract by Lynch and colleagues[57] indicated that 80% (48/60) of non-cavitated PRCLs treated with ozone reversed from severity index 4 to 3, whereas none of the soft lesions in the control group significantly changed, and that 94% (189/200) of leathery lesions became hard and arrested in the ozone group, whereas those in the control group did not significantly change.

Marginal adaptation of the root sealant The Baysan and Lynch study[36] also assessed the effects of ozone with or without a fissure sealant using the modified US Public Health Service (USPHS) criteria. In the ozone plus sealant group 61% of sealants were retained compared with 42% in the sealant only group ($p < 0.05$) at 12 months.

It is worth noticing that both groups had the same other active interventions such as reductant, patient care kits and sealants. The very low

improvement rates in the control groups are therefore surprising.

Summary: root carious lesions The two full-text studies assessing the use of ozone for root carious lesions both report very high success rates with ozone and very low improvement rates in the controls.

Fissure sealants after application of ozone for the preventive treatment of non-cavitated root lesions are more likely to remain intact (61% versus 42%, $p < 0.05$).

Pit and fissure carious lesions
The three remaining studies – the Abu-Naba'a main study (2003),[37] Abu-Naba'a pilot study (2003)[37] and Abu-Salem (2004) study[38] – assessed the effects of ozone on pit and fissure carious lesions. Both Abu-Naba'a studies involved patients aged over 12 years with primary lesions in the permanent posterior teeth, while the Abu-Salem study involved children 7–9 years old with carious lesions in the posterior primary teeth. The Abu-Naba'a main study and the Abu-Salem study assessed non-cavitated lesions, while the Abu-Naba'a pilot study included lesions with cavitation.

Change in clinical severity: permanent dentition
Results of full-text studies Tables 10 and *11* illustrate the results of the Abu-Naba'a main study.[37] Clinical severity of non-cavitated pit and fissure lesions was assessed using the criteria described by Ekstrand and colleagues (0 = least severe, 1, 2, 3, 4 = most severe).[9] The change in severity score is calculated as the score at follow-up minus the score at baseline. Thus, a negative change indicates an improvement, while a positive change implies a worsening of lesion severity. The mean change from baseline in clinical severity score at 12 months was not significantly different ($p = 0.112$) between the two intervention groups: ozone (10 seconds) plus reductant group versus reductant only group (*Table 10*).

It was also reported that a greater proportion of ozone-treated lesions improved or stabilised compared with control lesions at all recalls (*Table 11*). However, statistical analyses of these data were not provided. The relationship between clinical severity score and the need for future fillings was not explained.

No significant difference in the clinical severity score was found between the ozone and control groups in the Abu-Naba'a main study. The

TABLE 10 *Mean change in clinical severity score of pit/fissure lesions from baseline (Abu-Naba'a main study)[37]*

Change in clinical severity score	Ozone group (*n* = 106)	Control group (*n* = 106)	*p*-Value
Mean change from baseline	0.283	0.443	0.112
Standard deviation	0.64	0.74	
Standard error	0.06	0.07	

TABLE 11 *Percentage of pit/fissure lesions that improved, remained stable, or increased in clinical severity at each recall visit (Abu-Naba'a main study)[37]*

Month(s) of follow-up	Treatment group	Decreased severity (improvement)	Stable	Increased severity (worsening)
1	Ozone	11.4%	74.6%	14.0%
	Control	5.3%	81.6%	13.2%
3	Ozone	17.7%	63.9%	18.5%
	Control	8.4%	73.1%	17.6%
6	Ozone	10.8%	55.9%	33.3%
	Control	5.9%	59.8%	34.3%
9	Ozone	7.8%	57.8%	34.5%
	Control	6.9%	56.0%	37.1%
12	Ozone	7.4%	56.5%	36.1%
	Control	5.6%	48.6%	45.8%

reported proportions of lesions improved, stabilised and deteriorated appeared similar between groups, but no statistical analyses were undertaken and the clinical relevance of these findings was not explained in terms of fillings avoided.

Abu-Naba'a pilot study In the Abu-Naba'a pilot study,[37] 17 lesions (with cavitation) were treated with ozone plus reductant and 17 reserved as controls (reductant only) in eight patients. Outcomes were measured using Ekstrand and colleagues' clinical index[9] as well as the following clinical indices: hardness index (hard, leathery, soft), visual index (sound, arrested, active), cavitation score (1 = no cavitation, 2 = microcavitation, 3 = frank cavitation), colour index (normal, yellow, light brown, grey, dark brown, black), frosted enamel measure (mm), stained enamel measure (mm) and perceived treatment need index (e.g. requiring no intervention, requiring preventive resin restoration, requiring drilling and filling). Thirteen lesions in the treatment group and 12 lesions in the control group were assessed at 6 months. Lesions treated with ozone showed a significant reduction in the hardness and visual indices (*Table 12*). No significant differences between groups were found for any other indices or for the Ekstrand clinical index (*p* > 0.05).

This study was only a pilot study, which did not add much to the results of the Abu-Naba'a main study.[37]

Results of abstracts The abstracts gave little detail of studies, their methodology could not be easily assessed and therefore their findings must be interpreted with caution. They are included here for completeness and as a guide to emerging research.

Three abstracts compared pit and fissure lesions receiving ozone (at different concentrations) with pit and fissure lesions receiving no-ozone treatment.[54–56] Their results are presented in *Table 13*. The proportion of lesions reported as clinically reversed, the extent of which was not specified, ranged from 86.6 to 99% in the ozone-treated groups. All studies reported that no significant clinical changes were observed in the control group, but no numerical information was given.

Another abstract[53] compared the use of ozone versus conventional treatment in 35 patients, each with two occlusal lesions extending radiographically 2–4 mm into dentine. The authors defined the occlusal lesions as non-cavitated, but lesions 2–4 mm into dentine on radiographs are likely to have small cavities that

TABLE 12 *Number of pit/fissure lesions showing a reduction in the clinical indices at 6 months (Abu-Naba'a pilot study)*[37]

| | Hardness index[a] | Visual index[b] | Cavitation score[c] | Colour index | | Perceived treatment need[f] |
				Darker[d]	Lighter[e]	
Treatment	11/13 (84.6%)	8/13 (61.5%)	6/13 (46.2%)	3/13 (23.1%)	2/13 (15.4%)	12/13 (92%)
Control	4/12 (33.3%)	1/12 (8.3%)	5/12 (41.7%)	2/12 (16.7%)	6/12 (50%)	9/12 (75%)
p-Value	<0.05	<0.05	ns	0.084 (ns)		0.16 (ns)

[a] The proportion of lesions becoming hard
[b] The proportion of lesions with increasing score
[c] The proportion of lesions with reduction in cavity score
[d] The proportion of darker lesions
[e] The proportion of lighter lesions
[f] The proportion of lesions with a reduced treatment need

TABLE 13 *Reversal of pit/fissure caries: findings from abstracts*

| | Ozone at follow-up | | Control at follow-up | |
	No.	(%)	No.	(%)
Holmes 2003[54] (12 months)	1918/1937	(99)	0/427	(0)
Hamid, 2003[55] (6 months)	80/92	(86.9)	0/92	(0)
Megighian and Bertolini, 2004[56] (6 months)	$p < 0.05$		0/80	(0)
	(220 lesions treated)			

trap plaque and are likely to progress unless cleaned thoroughly. The ozone-treated lesions received ozone for 40 seconds and application of a glass ionomer preventive sealing, which was subsequently replaced with a posterior composite at 3 months. The control lesions received conventional drilling and filling (posterior composite). All the ozone-treated lesions were reported to have reversed at 3 months. Six complaints (17.1%) of postoperative sensitivity were reported after conventional drilling and filling at 6 months compared with none after ozone treatment ($p < 0.05$). Postoperative sensitivity is, however, a measure commonly used to assess large carious lesions and it is questionable whether it should be used for early carious lesions. Moreover, complaints of postoperative sensitivity after occlusal restorations are rare.

Clinical reversal of caries: primary dentition One full-text study assessed the use of ozone for the treatment of non-cavitated primary posterior teeth in children aged 7–9 years.[38] Occlusal lesions were assigned to receive ozone for 10 seconds followed by a reductant or a reductant only. The proportion of lesions that improved, remained stable or deteriorated in each intervention group was not provided and the clinical severity findings were only presented graphically. The graph showed a steady increase in the mean change from baseline clinical severity scores for the control group, compared with an initial slight decrease and a subsequent levelling in the ozone group at 12 months. The overall changes in the clinical severity scores[9] were analysed using a mixed-effects ANOVA. This analysis assumed that patients and teeth within patients had a random effect, while group and time of treatment had a fixed effect. There was overall little reduction in clinical severity scores in the ozone-treated group, while an overall increase was observed in the control group. There was a statistically significant effect of treatment upon clinical severity scores with time ($p < 0.01$).

Sealant retention The Abu-Naba'a main study[37] also assessed the use of ozone for 10 seconds with and without a fissure sealant. No sealants were reported to be lost in either the ozone plus sealant group or the sealant-only group. The percentage of partial loss in the ozone plus sealant group at 12 months was 32.7%, and in the sealant-only group was 29.8%, with no significant differences between groups (this indicates similar rates of reinterventions between groups for repairing partial sealant loss).

Discussion of results and conclusions on the evidence for and against the intervention

Only a limited number of RCTs (five full-text reports and five studies reported as abstracts) were available for assessing the effects of ozone for the management of root carious lesions and pit and fissure carious lesions. Of these only one was published in a refereed journal, but lacked some study details, while the remaining studies were derived from PhD theses, unpublished reports or conference proceedings. All full-text studies with the exception of the Holmes study were conducted by the same research team that developed the procedure, led by Professor Lynch of Queen's University, but Holmes was at one time part of the same group, having done his PhD in Belfast. The methodological quality varied across studies and information on method of randomisation, concealment of allocation, blinding procedures and statistical methods was lacking in many of them. Therefore, interpretation of studies results was not straightforward. A quantitative synthesis of results was not feasible owing to the differences among studies regarding intervention, dosage of ozone and outcome measures.

There were some concerns over the appropriateness of the methods of analysis adopted by study investigators. All studies in this review were of a hierarchical structure, although not necessarily treated as such for analysis. Specific types of analysis are required when data have a hierarchical structure. The hierarchy occurs as smaller units, such as lesions or teeth, are clustered together within a larger unit, the patient. In most studies included in this review, the statistical analysis was carried out at the lesion level. However, two lesions within one patient are not strictly independent, so analysis at the lesion level is inappropriate. A more suitable statistical analysis takes into account the hierarchical clustering of lesions within a subject.[59]

In the simple case of two lesions per person, one receiving control and one receiving the ozone treatment, paired data are produced. In this case, the appropriate paired analysis would be a McNemar χ^2 test for dichotomous data, a Wilcoxon signed rank test for ordinal data and a paired *t*-test for continuous data. The choice of statistical tests that ignore the pairing of the data is more conservative and may fail to detect important differences found by paired analysis.[59] In the case of more than two lesions per subject,

multilevel modelling procedures would need to be used.

Baysan and Lynch[36] stated that statistical tests were used, but they did not specify which particular tests. Holmes used χ^2 tests, but did not specify whether they were McNemar χ^2 tests. Abu-Naba'a[37] (main and pilot studies) recognised the fact that there were pairs of teeth. However, in some cases there were multiple pairs of teeth per person and it is not clear whether this was taken into account. Abu-Salem[38] used analysis of variance for a mixed effects model. This type of analysis is hierarchical in nature, with one component for the patients and one for the tooth within the patient. However, as not enough information was provided by the author it was not possible to determine whether the statistical analysis was conducted appropriately.

For primary non-cavitated root caries both the Holmes study[35] and the Baysan and Lynch study[36] reported high success rates for ozone-treated lesions compared with control lesions. However, the lack of reversal of caries among controls receiving conventional treatment (reductant) known to be efficacious is puzzling.

Cavitated root lesions did not seem to benefit from ozone application, showing indeed a negative effect over time, but no formal statistical analysis was presented.

Treatment results of pit and fissure caries of permanent teeth were not consistent across studies. The Abu-Naba'a main study did not show any significant differences between non-cavitated lesions treated with or without ozone. Similarly, the Abu-Naba'a pilot study,[37] which included lesions with cavitation, did not demonstrate any significant effect of ozone apart from an improvement in the hardness and visual clinical indices. In contrast, results from conference proceedings (methodologically less reliable) provided very high success rates (from 86.6% to 100% of reversal of caries).

Data on the use of ozone for the treatment of primary teeth were available from only one study, which suggested an overall reduction in clinical severity scores for non-cavitated occlusal lesions in primary molars treated with ozone ($p < 0.01$).[38]

The adjunct of ozone to a fissure sealant produced a better sealant retention in root carious lesions (61% of sealant retention versus 42%, $p < 0.05$),[36]

21

but not in pit and fissure carious lesions (32.7% versus 29.8%).[37]

On the whole, and despite the differences reported in some studies (e.g. Holmes), there are as yet insufficient published full-text studies (only one refereed journal article) to provide convincing evidence on the effectiveness of ozone for the management of caries.

This review was done independently of the Cochrane systematic review on ozone therapy for the treatment of dental caries,[60] which concluded that at present there is no reliable evidence on the effectiveness of ozone applications to arrest or reverse the decay process. The present version of the Cochrane review does not include the Holmes (2003) and Abu-Salem (2004) studies.

Important subgroup differences

There are not enough data on which to assess the effects of ozone on cavitated caries in the permanent dentition (both occlusal caries and root caries) or on non-cavitated occlusal caries in the deciduous dentition (only one study involved children with primary teeth[38]). No data are available on cavitated occlusal caries in deciduous teeth, secondary caries or high-risk patient categories.

Adverse effects of intervention

None of the studies reported any adverse events in the intervention group.

Chapter 4
Systematic review of economic evaluations

Methods

Search strategies
In addition to the electronic searches and handsearches detailed in Chapter 3, a search of the NHS Economic Evaluation Database (NHS EED) and the Health Management Information Consortium was undertaken for economic evaluations of ozone for dental caries. Details of the searches are provided in Appendix 1.

Studies that reported both costs and outcomes of HealOzone compared with any of the comparators were sought. The manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) was also scanned for relevant economic evidence.

Inclusion and exclusion criteria
To be included, studies needed to compare HealOzone with any of the existing comparators in terms of their costs and effectiveness. Studies reported in languages other than English were identified from the literature searches, but would not be included in the review unless a structured abstract was available from NHS EED. A single economist assessed all abstracts for relevance. Full-text papers were then obtained for all studies that appeared potentially relevant and were formally assessed for relevance.

Data abstraction
The following data were extracted for each included study:

- study characteristics:
  - research question
  - study design
  - comparison
  - setting
  - basis of costing
- characteristics of the study population or of the populations that formed the basis of data used in a modelling exercise:
  - numbers receiving or randomised to each intervention
  - dates to which data of effectiveness and costs relate
- duration of follow-up for both effectiveness and costs

- results
  - summary of effectiveness and costs (point estimate and, if reported, range or standard deviation)
  - summary of cost-effectiveness/utility (point estimate and, if reported, range or standard deviation)
  - sensitivity analysis
- conclusions as reported by the authors of the study.

Quality assessment
A single economist assessed the quality of included studies using a published checklist.[61] The questions were set out on a standard form generated before the review.

Data synthesis
Data from included studies were assessed and summarised by a single economist, and interpreted alongside the results of the systematic review of effectiveness so that conclusions could be drawn on the relative efficiency of HealOzone compared with alternative treatments.

Results

The search revealed no published economic evaluations of HealOzone. One published trial was found which discussed the costs and effectiveness of the management of primary root caries with HealOzone.[35] However, since the cost information is limited to estimates of the total cost of dentistry, with no detail of costs and consequences of the alternatives, the study did not meet all of the methodological criteria listed in *Table 14* to be classified as an economic evaluation and therefore was not further reviewed. Two abstracts concerning studies on the costs and benefits of HealOzone for dental caries were found, but did not provide sufficient details of study design or data for the purpose of this review.[62,63] However, the industry submission from KaVo Dental (August 2004) provided an economic evaluation. The remainder of this section provides a summary and critique of that submission.

The unpublished industry submission from KaVo Dental Ltd, UK (KaVo: Clinical and cost

TABLE 14 *Quality assessment of the economic evaluation presented in the industry submission by KaVo*

Quality component	Assessment and comments
1. Was a well-defined question posed in an answerable form?	Yes
2. Was a comprehensive description of the competing alternatives given (i.e. can you tell who did what, to whom, where and how often)?	Yes: current treatments were defined as: NC-PFC: sealants C-PFC: glass ionomer, composite resin and amalgam restoration RC: glass ionomer and composite resin restoration
3. Was there evidence that the programme's effectiveness had been established?	Limited owing to short follow-up of included studies and inability to compare/combine results from more than one study owing to differences in study characteristics. None of the studies used specifically considered C-PFC, although the model does include such effectiveness data based on assumptions outlined in the following critique
4. Were all the important and relevant costs and consequences for each alternative identified?	Yes: the base-case analysis assumes that the capital cost of HealOzone is borne by dental practices. This assumption is varied for sensitivity analysis
5. Were costs and consequences measured accurately in appropriate physical units?	Yes
6. Were costs and consequences valued credibly?	Not always: see critique of QALY estimation
7. Were costs and consequences adjusted for differential timing?	Yes: a discount rate of 3.5% was used
8. Was an incremental analysis of costs and consequences of alternatives performed?	Yes: see critique
9. Was allowance made for uncertainty in the estimates of costs and consequences?	Yes
10. Did the presentation and discussion of study results include all issues of concern to users?	Yes

C-PCF, cavitated pit and fissure caries; NC-PCF, non-cavitated pit and fissure caries; QALY, quality-adjusted life-year; RC, root caries.

effectiveness of HealOzone for the treatment and management of dental caries, 2004) included an economic model of HealOzone compared with current treatment for non-cavitated pit and fissure caries, cavitated pit and fissure caries, and root caries. Both a base-case and a probabilistic analysis were included. The submission comprised both a text document and supporting Excel spreadsheets.

Table 14 provides a summarised assessment of the KaVo industry submission based on the ten critical appraisal components.[61]

Review of industry submission

The first part of this section provides a summary of the methods and results from the economic evaluation of HealOzone reported in the industry submission. This is followed by a critical review of the evaluation.

Summary of the industry submission

The submission by KaVo included a cost-effectiveness analysis over a 5-year time horizon of HealOzone treatment versus current management for non-cavitated pit and fissure caries, cavitated pit and fissure caries, and cavitated root caries. The current management treatments were defined as follows:

- non-cavitated pit and fissure caries: sealants
- cavitated pit and fissure caries: glass ionomer, composite resin and amalgam fillings
- root caries glass ionomer and composite resin restorations.

These comparators were identified from the expert opinion of four dentists. The submission does not consider preventive treatments such as oral hygiene or advice on diet along with surface applications of fluoride and sealants as a comparator. The intervention with HealOzone is

defined as an initial treatment with HealOzone followed by 12 weeks of treatment with mineralising toothpaste, oral rinse and spray, with the possible addition of restorative treatments. An opinion survey of 243 dentists practising HealOzone treatment was used to estimate the proportion of teeth that would require additional restorative treatment at the same time as the HealOzone application or at any time subsequently, but only 48 provided usable responses.

Effectiveness data were obtained from a review of published evidence for HealOzone and the current management of dental caries. Clinical outcomes included caries progression and reversal.

Costs included those of comparators plus costs of rerestorations avoided. The costs of each current treatment comparator were estimated from published data for the treatments defined above. All cost data were estimated from the perspective of the NHS and were presented in UK pounds sterling (£) at 2003 prices. Their method was to translate the treatments into relevant treatment codes listed in the Statement of Dental Remuneration (SDR codes)[64] and then to use GDS[65] data to identify the total annual numbers of such treatments. These data are presented separately for patients aged less than 18 years and those aged 18 years and over. The same source (GDS) gives annual total treatment costs which, when combined with annual treatment numbers, gave a unit cost per treatment item. These figures were adjusted to take account of SDR codes relating to more than one tooth and more than one type of caries. The unit cost estimates do not appear to differentiate between primary restorations on virgin tooth surfaces and secondary restorations, the latter being outside the scope of the study since these would be unsuitable for treatment with HealOzone. Finally, these unit cost estimates were adjusted to reflect the fact that patients under 18 years receive free NHS dental care and those aged 18 years and over pay 80% of their NHS dental fees, unless they are eligible for free treatment. It was assumed that the dental practice and not the NHS would fund the capital cost and running cost of the actual HealOzone device.

Using these unit cost estimates the industry model assesses the annual cost to the NHS for each comparator. To estimate the annual cost to the NHS of the HealOzone comparator the industry submission carried out a survey of dentists to estimate the proportion of teeth currently treated

for either non-cavitated pit and fissure caries, cavitated pit and fissure caries or root caries that would be suitable for treatment with HealOzone. This survey also asked dentists to estimate the proportion of HealOzone-treated teeth that would require some restorative treatment either at the time of HealOzone treatment or sometime afterwards. These restorative treatments were defined similarly to current management treatments for each caries type.

The unit cost of HealOzone treatment was based on the cost of patient consumables and dentists' time (in practice, a dentist is remunerated by a fee per item of service as listed in the SDR and these fees are intended to reflect the costs incurred by dental practices). Using the results of a questionnaire survey of dentists who use HealOzone in their own dental practice the estimated unit cost for a course of HealOzone-treatment was then adjusted to reflect the estimated percentages of HealOzone-treated teeth that would require additional restorative treatment. On the basis of responses to this questionnaire an additional cost of restoration (using current management in addition to HealOzone) was applied to 44% of non-cavitated pit and fissure caries, 84% of cavitated pit and fissure caries and 47% of root caries.

The cost to the NHS of HealOzone also took into account the proportion of treatment fees paid by the NHS rather than by patients as described above for current treatment costs. The unit cost for a course of HealOzone procedure was based on an assumption of more than one HealOzone application per course of treatment. The model used a mean of 2.5 HealOzone applications per course of treatment (range 1–4). This was based on data from KaVo Dental.

An additional cost was added to reflect the weighted average cost per tooth year of rerestorations avoided. This was based on data from a study that reported the average cost per tooth year of restoration in teeth previously filled with amalgam or composite resin for each type of caries over 5 and 10 years. When calculating the cost of rerestorations avoided the costs of the original restoration are removed to avoid double counting.[66]

The model uses rates of caries progression and regression taken from a variety of unpublished and published clinical studies. The mean values for annual rates of caries progression for the current treatments assumed in the industry

submission, along with the study reference from which these values were obtained, are: non-cavitated pit and fissure caries 0%,[67] cavitated pit and fissure caries 4.9%,[68–70] and root caries 3.9%.[68,69]

The progression rates cited for HealOzone were all 0%, taken from studies with follow-up of 3–21 months.[35,40,42,44,53,71,72]

Caries reversal rates for non-HealOzone treatments were assumed to be zero. The industry submission does cite a 15% reversal rate found in a study reporting the use of varnish (chlorhexidine), but this value was excluded from the industry submission on the grounds that such varnish is not cited in the SDR codes. Rates of caries reversal in teeth treated with HealOzone were derived from 11 studies with follow-up times ranging from 3 to 21 months. The annualised mean values used for base-case analysis were: non-cavitated pit and fissure caries 93.3%,[53,55] cavitated pit and fissure caries 79.0%,[72–77] and root caries 84.5%.[35,40,42,44,57,71]

Although no evidence was available to estimate underlying QALY scores, the industry submission model estimated alternative cost per QALY thresholds of between £10,000 and £40,000 assuming quality of life benefits from 1 day to 1 month. The assumptions for QALY estimates were utility gains of 0.01, 0.02, 0.05 and 0.1 for restorations avoided.

The model was run to provide results using base-case data. The deterministic base-case analysis used mean values from the minimum and maximum values inputted for each parameter. Both one-way analysis and multivariate sensitivity analysis were also conducted. Stochastic analysis was conducted using Monte Carlo simulation over 10,000 cycles. Random numbers were used to select data inputs from those provided.

Results

The average baseline figure estimated in the industry model, across all caries types, for the incremental cost to the NHS per tooth treated with HealOzone was £6.24. Allowing for the cost of rerestorations avoided (see earlier description), the net incremental cost per tooth treated with HealOzone was 'minus' £9.70. The industry model also resulted in an estimated NHS cost of £61 per case of caries progression avoided (for all caries types) using a 5-year model time horizon, and assuming up to 35 cases per 1000 avoided per year (152 over 5 years). An estimated 846 cases of

caries reversal per 100 cases treated with HealOzone were reported, with an estimated NHS cost case of per caries reversal of £7.38, again for all caries types.

The estimated minimum utility gain (at 0.095) to achieve a cost per QALY of £30,000 was found to be for the use of HealOzone for root caries treatment. This was estimated using alternative cost-effectiveness acceptability thresholds based on varying the length of time over which a utility gain was accrued.

Sensitivity analysis indicated that the main drivers of cost and cost-effectiveness were numbers of teeth treated per treatment session and the numbers of treatments per course of therapy. Multivariate analysis revealed that despite uncertainty around the cost of HealOzone, HealOzone would be likely to be cost-effective over a 10-year follow-up period.

The report also discusses the wider implications to the NHS, impact on patient health and equity issues. The results of the economic evaluation are used to estimate the budget impact to the NHS from the use of HealOzone technology for all caries treatment of all eligible teeth. The figures include both initial treatment costs and the estimated costs of rerestorations avoided. On this basis, an annual net incremental cost of £48.1 million in year 1, reducing to £11.8 million by year 5, was estimated for HealOzone. These results assume that the capital and running costs of the HealOzone device are funded by dental practices, with no contribution from the NHS apart from the fee for service. If the exchequer provided additional funds for the device this would cost the NHS an additional £110.4 million, assuming one device per dental practice in England and Wales. Additional annual servicing costs are estimated at £10.8 million.

Although the evaluation does not include patient health as an outcome in the model, the results include a brief description of possible effects on patient health, based on studies of patient attitudes to dental treatment.

Equity issues are also briefly discussed in the results. The report cites evidence suggesting a link between caries incidence and deprivation, and that deprived populations would be one group less likely to benefit from HealOzone technology as long as it is only available through private dental treatment.

Critique of industry submission

On the whole, the economic evaluation submitted by KaVo Ltd is based on reasonable economic evaluation methodology. Nevertheless, a number of concerns can be raised relating to the choice of comparators and the quality of data used to parameterise the economic model.

The comparators used in the industry submission for non-cavitated caries were based on restorative treatment of caries. The evaluation did not consider preventive measures for early caries. However, the management of non-cavitated caries rarely requires fillings, as it is now well established that preventive treatments for early lesions can be effective in reversing and arresting further progression of caries. Furthermore, HealOzone has been cited as being "most effective in the role of prevention and early management of lesions".[78] It would therefore have been appropriate for the industry model to include conservative treatments aimed at ensuring reversal of early caries as additional comparators for non-cavitated caries.

The HealOzone comparator includes an assumption about the proportions of teeth that would require additional treatment to HealOzone treatment alone. These assumptions are taken from a survey of 243 dentists who currently use HealOzone, of whom only 48 provided usable responses. Given the absence of robust, objective clinical data, options to obtain relevant model parameter values are limited. Nonetheless, such data are potentially biased and unreliable and the considerable uncertainty would be reduced if actual clinical evidence were to exist. This was a non-randomised survey of opinion and cannot therefore be interpreted as having a strong evidence source. It does not appear that any random selection process was used to recruit dentists for the survey, and therefore it is unclear whether any attempt was made to obtain a balanced opinion.

The industry evaluation of implications to the NHS includes an assumption about the numbers of teeth suitable for treatment with HealOzone. These figures were again estimated from information taken from a survey of dentists who are users of HealOzone.

The assumption concerning the funding of the capital cost of providing a HealOzone device in dental surgeries was that this would not affect the fee for service. In reality, however, it would be expected that any additional contribution by the NHS towards capital costs incurred by dental practices would be offset by lowering subsequent fees paid to dentists for the associated therapy.

Estimates of caries progression and reversal rates were extracted from a range of studies of varying degrees of quality, including published and unpublished RCTs, conference abstracts and PhD theses. Some of the limitations of these data sources are discussed in Chapter 3. Caries progression rates for current management were extracted from studies that did not include HealOzone as a comparator and the patient mix may be different. Caries progression rates for HealOzone were estimated from studies with follow-up periods from as little as 3 months, all of which claimed a 0% caries progression rate. Other studies show higher caries progression rates. Selecting the most favourable studies biases the results.

Rates of caries reversal with current management were assumed to be zero despite a 15% reversal rate being reported in one study. This rate was excluded from the analysis on the grounds that it was associated with the application of chlorhexidine varnish and this was assumed by the authors of the industry report not to be a standard NHS dental treatment. However, dentists commonly rank application of varnish among 'treatments for sensitive cementum or dentine' (code 3631 in the SDR).

Source data for caries reversal associated with the use of HealOzone came from 14 studies, three of which had follow-up of less than 3 months. Only the latter were included in the sensitivity analysis. The remaining 11 studies differed in design and quality. For non-cavitated pit and fissure caries effectiveness data were extracted from studies with 3–6-month follow-up.[53,55] For cavitated pit and fissure caries, despite finding no available evidence, data from five studies were used in the model. The assumption used to justify this is the following:

> "None of the available studies specifically describes the treatment of cavitated pit and fissure caries. In the absence of such detail, the studies presented in this section refer to carious lesions, which are deemed to require drilling and filling. While non-cavitated caries may be treated in this way, drilling and filling is the conventional treatment for cavitated caries and it is therefore assumed that these studies included a proportion of cavitated caries." (KaVo Dental, 2004).

A further concern is that, although the industry submission report does acknowledge the limitation of combining data from more than one study,

given the disparity in inclusion/exclusion criteria and other study characteristics, the reversal rates and progression rates used as the mean rates for base-case analysis were calculated using the results from more than one study.

Estimates of the cost of rerestorations avoided are based on a number of assumptions and the report does acknowledge the absence of published data for rates of future rerestorations. Instead, the model uses published data for the average cost per tooth year of rerestoration in teeth previously filled with amalgam or composite resin over 5 and 10 years (KaVo industry submission, 2004). It is unclear in the report exactly how estimates of the numbers of future rerestorations would be avoided as a result of HealOzone treatment, although the report does provide estimates for the cost of such rerestorations avoided. Given the considerable uncertainty surrounding the rate of rerestorations,

the figures used should be interpreted with care. Realistically, such data could only be obtained from the outcomes of a long-term study of the effectiveness of the relevant comparators. QALY estimates are included in the economic evaluation, but are not based on quality of life data. Instead, assumptions concerning the amount of utility gain and duration of gain were used to derive QALY thresholds. Given the short duration of any potential intermittent change in quality of life, along with the high degree of uncertainty surrounding any estimates of QALY scores, the additional information value of such QALY thresholds is dubious.

Although the economic evaluation in the industry submission is well presented, the choice of comparator is questionable and considerable uncertainty surrounds many of the parameter values used in the model. Therefore, their results overestimate the benefits of HealOzone.

Chapter 5
Economic analysis

Given the current state of the clinical effectiveness evidence, with little published in full in peer-reviewed journals, it could be argued that economic analysis is premature. However, NICE always requests some attempt at economic appraisal, if only to clarify the data deficits. Therefore, the following analysis has been produced more as illustrative modelling than as hard evidence.

Methods for economic analysis

The economic evaluation aimed to assess the cost-effectiveness of HealOzone relative to the alternative interventions for the treatment of both occlusal pit and fissure caries and root caries. As identified in the previous section, economic evaluations of HealOzone versus conventional treatments of dental caries were virtually non-existent at the time of this review. This section provides an economic evaluation using cost-effectiveness analysis and presents economic models of the treatment of non-cavitated pit and fissure caries, and root caries. They compare current management versus current management plus HealOzone. The results over the extended period must be qualified by the fact that follow-up data on HealOzone are limited to 2 years. The results reported in this section should be interpreted on the understanding that they entirely depend on the model parameters and assumptions made. The authors recommend that the model be rerun in the future if evidence on clinical effectiveness is published.

Markov model framework
This section presents a description of the Markov model developed for the assessment, and of the parameters that were common across all models. Key parameters specific to each model and results are then presented separately for each comparator. The section concludes with a summary of the results for all comparators and of the factors deemed to be most critical in affecting the results.

Markov modelling techniques were used to assess the cost-effectiveness of HealOzone plus current management, relative to the standard current management of dental caries. A Markov model is composed of a set of defined health states among which a patient can move over successive periods and is run using a hypothetical cohort of patients. The model incorporates both the logical and temporal sequences of treatment, including the events that follow from the initial treatment procedure and the outcomes for the patient that are associated with each possible scenario or clinical pathway. Transition probabilities are used to allow patients to move within and between these states of health. A patient can only be in one state of health at any time and can only make one transition per cycle. A relevant period is chosen for the length of a cycle and the cycles then link together to form a Markov chain. The length of cycle used in this study was 1 year. When the model is run over the defined number of cycles, a discounted net present value (NPV) for the cost of an intervention is calculated, determined by the occurrence of different states and the length of time in various states.

The models were designed to estimate a typical patient's costs and outcomes for the alternative treatments over a 5-year period. A 5-year time horizon was chosen to facilitate comparison with the results from the industry model. *Figure 10* summarises the basic structure of the model. Similar models were developed to carry out the analysis for non-cavitated pit and fissure caries, and non-cavitated root caries

### Non-cavitated pit and fissure caries
The model for non-cavitated pit and fissure caries compares current management strategies (i.e. watchful waiting, oral hygiene/removal of plaque, fluoride applications and sealants) versus the same strategy plus HealOzone.

Non-cavitated root caries
The model for non-cavitated root caries compares current management strategies (i.e. removal of plaque, topical fluorides, chlorhexidine and a sealant) versus the same strategy plus HealOzone.

Model pathways
The pathways for each model were developed in accordance with the protocol for the assessment along with expert opinion from members of a

FIGURE 10 *Model for primary non-cavitated pit and fissure caries*

local dental school. All models have simplified clinical event pathways, but are designed to reflect those clinical events of importance to the evaluation (*Figures 15–18* in Appendix 6).

Non-cavitated pit and fissure caries and root caries

Following initial treatment carious lesions may either reverse or not reverse. Lesions that do not show reversal of caries progression after the initial intervention require additional treatment. This is a further application of the initial preventive/non-restorative treatment or a restorative treatment (i.e. drilling and filling). In those receiving further preventive/non-restorative treatments, caries can again be reversed or treated with filling (*Figure 10*). The event pathway is split into two mutually exclusive events, the reversal (cure) of caries and no reversal of caries. The arrows between these states represent the possible transitions between them. Movement between the different states is governed by the transition probabilities, such as the chance of the caries reversing. The absorbing state in this model is a tooth with a filling. While this is not an absorbing state in reality, given the

5-year timescale of the model, and that a typical filling would last longer than 5 years, no states beyond filling were included. It was assumed that once a tooth was cured it remained in a cured state for the rest of the 5 years. TREEAGE DATA 4.0 software (TREEAGE Software, 2001) was used to construct the model.

Estimation of parameters
Probabilities
The time horizon considered in the Markov model was a maximum of 5 years. The outcome considered in the economic evaluation was the numbers of carious lesions cured. The main probabilities used in the model were the rates of reversal (cure) of caries. These rates were derived from the effectiveness study (Chapter 3) and consultation with dental practitioners. The probability of cure rates (*Table 15*) obtained from the effectiveness studies and used in the first run of the economic model were: HealOzone 0.074 (7.4%) for the non-cavitated pit and fissure caries[37] and 0.98 (98%)[35] for the non-cavitated root caries. The rates used for current management were 0.056 (5.6%)[37] for non-

TABLE 15 *Probabilities used in the economic model*

Intervention	Probability	Source
HealOzone cure rate (non-cavitated pit fissures)	0.074	Table 11, Chapter 3
Current management cure rate (non-cavitated pit fissures)	0.056	Table 11, Chapter 3
HealOzone cure rate (non-cavitated root caries)	0.98	Table 9, Chapter 3
Current management cure rate (non-cavitated root caries)	0.01	Table 9, Chapter 3
Percentage being retreated with initial treatment	0.50	Discussions with expert
Percentage being retreated with filling	0.50	Discussions with expert

TABLE 16 *Unit cost per item*[a]

Type	Current treatment (SDR code)	Cost (£)
Non-cavitated pit and fissure caries		
	Hygiene/diet advice (0601)	7.70
	Chlorhexidine gel/varnish or fluoride varnish (3631)	4.60
	Fissure sealant (0701)	6.95
	Total (sum of above)	19.25
Non-cavitated root caries		
	Hygiene/diet advice (0601)	7.70
	Chlorhexidine gel/varnish or fluoride varnish (3631)	4.60
	Total (sum of above)	12.30
Cavitated pit and fissure caries		
	Sealant only (1441)	6.95
	Composite resin (1442)	9.80
	Glass-ionomer (1443)	10.55
	Amalgam (1401 or 1421)	7.15 (posterior) 14.15 (anterior)
	Total (average of above)	16.98
HealOzone	(No SDR code)	20 (estimate)

[a] Costs are those that would be incurred by the NHS and exclude patient contributions to dental fees. Further details of cost calculations are presented in Appendix 6.

cavitated pit and fissure caries and 0.01(1%) for non-cavitated root caries.[35] These values, which are highly favourable to HealOzone, were different to those used in the industry model, which aggregated data from a number of studies, some of which did not meet the inclusion criteria specified in this review. In the absence of any alternative information, it was assumed for the purposes of the model that, following initial treatment, there was a 0.50 (50%) chance of subsequent treatment being the same treatment as the initial one received or a filling.

The root caries cure rates are taken from the Holmes study,[54] the results of which seem puzzling; they reflect a best possible case for HealOzone.

Costs
The perspective adopted for the study is that of the NHS and Personal Social Services. The unit costs of dental treatments were taken directly from cost data published by the NHS.[65] *Table 16* provides details of the different treatments with corresponding codes from the NHS SDR for each treatment item. Unit costs are listed for each treatment item and represent the fee paid by the NHS to the dentist for each item of service.

Resource-use data were identified from existing literature, reports from manufacturers and advice from experts in this field. Based on existing evidence and clinical opinion, patients were assumed to visit the dentist every 6 months. Cost data were measured in pounds sterling (£) for the

TABLE 17 *Weighted average costs used in the model*[a]

	Cost (£)		
Intervention	Under 18	Over 18	Weighted
Current management			
Non-cavitated pit and fissure caries	19.25	7.70	9.02
Non-cavitated root caries	12.30	4.92	6.09
Current management plus HealOzone			
Non-cavitated pit and fissure caries	39.25	15.70	20.03
Non-cavitated root caries	32.30	12.92	17.10
Restorative interventions			
Filling	19.67	7.87	12.75

[a] Costs are those that would be incurred by the NHS excluding patient contributions to dental fees.

year 2004. As specified by the guidelines for conducting health technology assessment, cost-effectiveness results should reflect the present value of the stream of costs and benefit accruing over the time horizon of the analysis.[79] To make the analysis consistent with the model used in the industry submission the analysis was carried out over a period of 5 years. An annual discount rate of 3.5% was applied to both costs and benefits accrued, the rate currently specified in the HTA guidelines.[79]

The per-item fee for service paid by the NHS was used as a proxy for costs to the NHS of current management. Under the current NHS dental system patients pay 80% of the dentist's fee, with the remaining 20% being paid by the exchequer (except that there is a maximum charge for a course of dental treatment of £366). Some patients, including all those less than 18 years old, are entitled to free treatment and the exchequer pays the full cost of treatment. Recent figures report that 25% of all claims for patients aged 18 years and over were exempt from patient charges.[65] The other 75% of claims for patients aged 18 and over therefore include a patient contribution at 80% of the amount of the claim and an NHS contribution of 20%. Taking these data into account, the average net NHS contribution equates to 40% [25% + (20% of 75%)] of any NHS dental claim for patients aged 18 and over. As children (persons under 18 years of age) are exempt from paying NHS dental treatment fees, the full cost of all claims for those less than 18 years old was used as the cost to the NHS. The data used in the industry model indicated that the NHS contribution to those aged 18 and over was 52%.

In the absence of separate effectiveness data for adults and children it was decided to combine all age groups for the base-case analysis. A two-stage process was required to weight the unit costs to represent a mixed population of adults and children. Further details of the stages involved in the cost calculations are reported in Appendix 6. Published statistics[65] indicate that adults and children do not receive similar proportions of each treatment item among the different treatment items listed in *Table 16*. The first stage was therefore to calculate the percentage mix of children and adults for each identified SDR component of the treatment. These proportions were then weighted by the amount that the NHS contributed using the figures described earlier, at 100% of the amount of a claim per child and 40% per adult. Following this two-stage weighting process, the adjusted costs to the NHS used in the model were £9.02 for the non-cavitated pit and fissure caries and £6.09 for non-cavitated root caries, and a filling was estimated at £12.75. Details of the costs are included in *Table 17*.

The costs of HealOzone were calculated using the existing NHS methods and information from the manufacturer. Most of the studies indicated that HealOzone treatment is given at the start, and repeated at 3 and 6 months. The cost of HealOzone therefore took into account that patients could receive between one and three applications. The cost of HealOzone treatment also included that of current management as HealOzone was considered as an additional treatment and not as a stand-alone treatment. The weighted average cost of 'current management plus HealOzone treatment' used in the model was £20.03 for non-cavitated pit and fissure caries and

£17.10 for non-cavitated root caries. These values were not similar to those used in the industry model as they focused on costs and benefits to the NHS in England and Wales as a whole, rather than on costs and benefits faced by the average patient.

Quality of life

It was not possible to measure health benefits in terms of QALYs. This was mainly because the adverse events avoided are transient: a few seconds' pain from injection of local anaesthetic; the anxiety/fear of having a drill and numbness until the local anaesthesia wears off.

Sensitivity analysis

As every economic analysis contains some degree of uncertainty, imprecision or methodological controversy, and this one more than most, a sensitivity analysis was performed. Given the limited effectiveness data for estimating rates of caries reversal, the models were rerun using different probability values of reversal of caries. Assumptions were also made about what items to include in each of the interventions and sensitivity analysis was performed using different codes to determine the costs, namely the SDR codes used in the industry submission.

Results

The analysis, carried out over a 5-year period using the data reported in the trials, indicated that treatment using current management plus HealOzone cost more than current management alone for non-cavitated pit and fissure caries (£40.49 versus £24.78), but cost less for non-cavitated root caries (£14.63 versus £21.45). For non-cavitated pit and fissure caries 91.8% of the teeth treated using current management received a filling and 8.2% of teeth were cured. For teeth treated with current management plus HealOzone, 89.2% received fillings and 10.8% were cured. This was different from the results of the Cochrane review by Ahovuo-Saloranta and colleagues,[32] which reported that the reduction in caries ranged from 86% at 12 months to 57% at 48–54 months. This review focused, however, on the prevention (and not the treatment) of tooth decay in children and adolescents who presented with no obvious caries. Based on the Holmes study,[54] 1.5% of teeth were cured at 5 years in the non-cavitated root caries group treated with current management and 98.5% teeth were filled, while 99.9% of teeth were cured by the combination of current management and

HealOzone and 0.01% were filled. The present authors remain sceptical about these results.

Sensitivity analysis

There was very little suitable evidence on the effectiveness of the HealOzone comparator. One-way sensitivity analysis was applied to the model to assess the robustness of the results to variations in the underlying data. The probability of caries being cured was varied for each comparator separately, using the baseline cure rate for the alternative comparator. These results indicated that when higher probability cure rates were used the proportion of teeth filled was lower at 12 months. These results were similar to those of the Cochrane review by Ahovuo-Saloranta and colleagues.[32] However, as the focus of the Cochrane review was on the prevention of dental decay in the permanent teeth of children and adolescents, the extrapolation of its results to an adult population with dental caries might be questionable.

The results of the one-way sensitivity analyses are illustrated in *Figures 11–14* and presented in tabular form in Appendix 6 (*Tables 29–32*).

In *Figure 11* the costs refer to those of current management when the baseline cure rates of HealOzone are used (0.074). The discounted NPV for the cost of HealOzone was £40.49. The above results indicate that the discounted NPV of the cost of the HealOzone comparator, using baseline parameter values for HealOzone, was higher than that of current management at any probability of cure with current management. This is mainly attributable to the fact that the baseline cure rate used in the model is less than 10%. The results also indicate that as the probability of cure rate increases, the cost reduces and the number of teeth filled also reduces.

In *Figure 12* the costs refer to those of HealOzone plus current management when the baseline annual cure rate of current management is used (0.056). The discounted NPV for the cost of current management was £24.78. Varying the probability of the cure rates of HealOzone plus current management, and using the baseline cure rate probability for current management, indicated that the HealOzone option was always more expensive than current management when the probability of cure using the HealOzone option was 70% or lower.

In *Figure 13* the costs of HealOzone reflect the costs when the baseline probability of cure of

FIGURE 11 *One-way sensitivity analysis for non-cavitated pit and fissure caries: discounted NPV of each comparator at alternative cure rates for current management, holding the baseline cure rate for HealOzone plus current management constant*


FIGURE 12 *One-way sensitivity analysis for non-cavitated pit and fissure caries: discounted NPV of each comparator at alternative cure rates for HealOzone plus current management, holding the baseline cure rate for current management constant*

current management (0.01) was used and the probability of cure of HealOzone management was varied accordingly. The one-way sensitivity analysis results show that discounted NPVs for the costs of current management plus HealOzone were lower than those of current management only when cure rates from current management plus HealOzone were at least 80% and above.

In *Figure 14* the costs of current management reflect the costs when the baseline probability of cure of HealOzone (0.98) was used and the probability of cure of current management was varied accordingly. The discounted NPVs for the costs of current management were higher than those of current management plus HealOzone when the cure rate for current management was 40% or lower.

FIGURE 13 *One-way sensitivity analysis for non-cavitated root caries: discounted NPV of each comparator at alternative cure rates for HealOzone plus current management, holding the baseline cure rate for current management constant*

FIGURE 14 *One-way sensitivity analysis for non-cavitated root caries: discounted NPV of each comparator at alternative cure rates for current management, holding the baseline cure rate for HealOzone plus current management constant*

TABLE 18 *Industry submission model inputs for annual treatment items and cost for patients under 18 years of age*[a]

Procedure	SDR code	Unit cost (£)
Non-cavitated pit and fissure caries		
Fissure sealant: sealant only	1441	6.50
Fissure sealant: composite resin	1442	9.15
Fissure sealant: composite resin and glass ionomer	1444	13.71
Root caries		
Composite/synthetic: one filling	1421	13.22
Composite/synthetic: two or more fillings	1421	10.32
Glass ionomer: one filling	1426	12.08
Glass ionomer: two or more fillings	1426	8.22

[a] The current costs of treatment were estimated using the GDS treatment items reported for the year ending March 2003 (KaVo Dental Ltd, industry submission, 2004, p. 62).

One-way sensitivity analysis was also carried out using similar SDR codes to those used in the industry submission. *Table 18* shows the SDR codes used by the industry for patients under 18 years of age. The figures for those over 18 years were similar. This did not alter the results for non-cavitated pit fissure caries as the discounted NPV of current management remained lower than that of the HealOzone comparator (£22.65 versus £33.39). These results could be attributed to the fact that it was assumed that patients received the same treatment as the initial one and the cost of current management plus HealOzone is much higher than that of current management alone, given that HealOzone is an additional treatment rather than an alternative treatment. Results using the SDR codes used for non-cavitated root caries in the industry model gave similar results to those in the base-case analysis. HealOzone cost less than current management (£17.66 versus £30.41).

Discussion

The economic analysis was greatly constrained by the uncertainty over clinical effectiveness;

therefore, the results should be regarded mainly as illustrations of the key variables and hence interpreted cautiously as they reflect the parameter values and assumptions used in the model. A further constraint was the lack of long-term data on the effectiveness of HealOzone (it is not known whether caries that is reversed will always stay in the inactive/arrested state or whether future treatments will be required). To attempt to model longer term effects the available 12-month data were extrapolated to 5 years. It is not known at this stage whether this assumption is valid. Another possible area of uncertainty was related to whether the response to HealOzone treatment would increase with increasing dose levels.

It was not possible to model the treatment of cavitated caries since no effectiveness data on direct comparisons were available. The analysis was carried out on a hypothetical cohort of teeth with carious lesions and did into take into account the proportion of teeth that are unsuitable for HealOzone treatment. Further research is therefore necessary to support a complete economic evaluation.

Chapter 6
Implications for the NHS

National Service Framework

The majority of general dental practitioners in the UK are contracted to the NHS through GDS, although, as independent contractors, dentists who offer NHS treatment may also offer certain treatments on a private basis. Dentists receive fixed fees per item of treatment for adults, while for children they receive a combination of fixed fees per item and capitation fees. Under this NHS system patients can pay up to 80% of the cost of their treatment up to a maximum cost of around £366. Some patients are entitled to free NHS dental treatment, including children, young people in full-time education, pregnant women and those with a child under 1 year old, and people on low incomes. The costs of running a dental practice, including capital costs of equipment, are met by the dental practice rather than the NHS, and recovered from the fee for service charges paid by the patients and the NHS. In addition to dentists contracted to provide NHS treatment, some of whom also offer private treatment, there are many dentists in the UK who only provide treatment on a private basis. Currently, HealOzone treatment is only available as a private treatment from a limited number of dentists.

Health targets

There are no specific health targets, although in England the Department of Health set a target to reduce tooth decay in 5-year-olds to low levels by 2003, while in Wales the official target was to achieve no more than 48% of 5-year-olds having tooth decay by 2002.[80]

The new Base Dental Contract (based on the personal dental services model) will be introduced for all practices in April 2006. The new contract will be more likely to have a greater preventive and capitation element.[81]

Fair access

At the time of writing HealOzone treatment was only available through private dental care and it was estimated that there were 294 HealOzone units in the UK (at June 2004). Were ozone therapy to be made available, provision of HealOzone units would have to be increased much beyond this to allow all suitable patients fair access to the treatment.

Equity issues

The availability of HealOzone treatment is currently limited to those people who are able and willing to pay for the treatment privately. However, in the present state of knowledge, it cannot be said that people suffer by being unable to afford it.

Budget implications to the NHS

At present, HealOzone is only available to patients through private dental care. The aim of this section is to estimate what the implications would be to the NHS if HealOzone were made available as an NHS dental service.

The models used in the economic evaluation described in Chapter 5 considered the costs and effectiveness of current treatment with and without the addition of HealOzone for arresting the progression of dental caries (further details of these cost calculations are presented in Appendix 6). The evaluation does not consider those teeth with carious lesions, which would be unsuitable for HealOzone therapy. These could be considered in the estimated implications to the NHS for the total population of teeth with carious lesions if estimated numbers of such teeth were available. To achieve this it is necessary to make assumptions about the proportion of teeth currently treated for caries that would be suitable for alternative HealOzone treatment. This proportion would be used to calculate the total annual number of treated teeth.

Data from GDS provide statistics for the numbers of teeth treated by SDR code in a year for adults and children in England and Wales. At the time of writing the latest available GDS data were those pertaining to the year ending March 2003.

TABLE 19 *NHS annual cost for treatment of non-cavitated pit and fissure caries*

	NPV of treatment cost over 5 years (£)
Current management	8,565,765
HealOzone plus current management	13,996,280
Net difference in cost	5,430,515
Net difference in cost per tooth treated initially	15.71

TABLE 20 *NHS annual cost for treatment of non-cavitated root caries*

	NPV of treatment cost over 5 years (£)
Current management	7,371,882
HealOzone plus current management	5,876,885
Net difference in cost	–1,494,997
Net difference in cost per tooth treated initially	–4.35

The following results were calculated by combining the GDS data with assumptions about the SDR codes relevant to each caries type to estimate annual numbers of teeth treated for non-cavitated pit and fissure caries and non-cavitated root caries. Again, teeth with cavitated caries were not considered given the absence of evidence on the effectiveness of HealOzone as a comparator treatment for cavitated caries.

Non-cavitated pit and fissure caries

The discounted NPV for the cost over 5 years of teeth treated initially with current management or HealOzone plus current management was reported in Chapter 5. These figures were combined with the numbers of teeth treated initially using annual GDS data for the SDR codes in the present treatment definitions. The results should, however, be interpreted with extreme caution given that they are based on the limited effectiveness data available for the economic analysis, as reported in Chapters 3 and 5 of this report.

The total discounted NPV over 5 years for treating non-cavitated primary fissure caries was estimated at £8,565,765 for current management and £13,996,280 for HealOzone therapy (*Table 19*). The base-case results showed that by 5 years fillings were present in 91.8% of teeth treated with current management compared with 89.2% of teeth treated with HealOzone plus current management. Using these figures the incremental cost per tooth treated would be £15.71, at an initial total cost to the NHS of £5,430,515. The incremental cost over 5 years for the HealOzone comparator compared with current management (£13,996,280–£8,565,765) was divided by the

difference in numbers of teeth filled at 5 years for the HealOzone comparator and current management (308,340–317,327). The incremental cost per filling avoided, using these assumptions, would be estimated at £604.23.

The industry submission estimates for the percentage of teeth currently treated that would be suitable for HealOzone, obtained from the opinion of current users of HealOzone, were 92% for non-cavitated pit and fissure caries, 76% for cavitated pit and fissure caries, and 76% for root caries. These figures were derived from *Table 15* in the industry submission.

Non-cavitated root caries

The total discounted NPV over 5 years for treating non-cavitated root caries, using the best case for HealOzone again, would be estimated at £7,371,882 for current management and £5,876,885 for HealOzone therapy. The net difference in these two costs shows that HealOzone therapy would save the NHS £4.35 per tooth treated initially with HealOzone in addition to current management for root caries, a total cost saving over 5 years of £1,494,997 (*Table 20*).

These figures are estimated using base-case values for caries reversal rates. Limited suitable effectiveness data were available for reversal rates of root caries, apart from a single study reporting reversal rates of 1% for current management and 98% for HealOzone treatment. Given the extreme values of reversal rates for the comparators, based on the limited effectiveness data available at the time of analysis, these results need to be interpreted with caution. It was only possible to carry out limited one-way sensitivity analyses,

varying cure rates separately for the HealOzone and current management comparators (see Chapter 5). From the results of the sensitivity analyses it can be seen that the net difference in cost per tooth treated initially was higher for current management unless the probability of cure for the HealOzone comparator was lower than approximately 80%.

It is advisable that the reader interprets all such results merely as an illustration of possible scenarios. In the light of limited evidence on effectiveness, a more detailed analysis of budget implications was not considered likely to add any useful information to the evaluation.

The cost implications over time are difficult to ascertain since there are many uncertain factors to take into account. Further research is required to model the cost implications over time, taking into account the cost of rerestorations beyond the lifetime of first fillings and their effects over time

on the tooth population. For example, it is unknown how long an arrested carious lesion remains inactive. Any prospective trial should have sufficient follow-up to allow for this.

Importantly, the above results are based on the authors' assumptions for the management of the different types of caries.

In addition, it is difficult to estimate the actual cost of HealOzone to the NHS. Assuming that patients who pay some of their dental treatment fees are willing to pay no more than current treatment for the same condition initially, what would the cost-effectiveness ratio be? Would patients opt for this treatment if it was more expensive?

Finally, would patients be given a choice for caries management or would dentists have to follow some guidelines about the best treatment? This has implications on the numbers of teeth treated.

Chapter 7
Discussion

Main results

Clinical effectiveness

The literature on ozone treatment is still at a relatively early stage, in the sense that only one paper has been published in full in a refereed journal. Most of the reports are available only in abstract form, as conference proceedings, and inevitably give few details. Many trials are still very short term and none of the studies has followed up the patients after they have stopped ozone treatment for a reasonable length of time. It is also worthwhile remembering that caries is a dynamic process: a lesion can remineralise without the need for any intervention, and the rate of caries progression can be very slow.

HealOzone is supposed to kill the microorganisms (bacteria) responsible for dental plaque formation. However, unless patients have improved their plaque control and eliminated the causes of the increased numbers of microorganisms, the plaque will re-form and the lesion will progress again. This raises the question of whether HealOzone is a reasonable preventive technology. Furthermore, treatments based on HealOzone would need to be repeated for an indeterminate numbers of years to be beneficial, with obvious cost implications.

The available evidence is conflicting, with the root caries treatment showing much better results than treatment for pit and fissure caries. However, the results are surprising, partly because the ozone group did so well, with 99% cure or improvement, but mainly because the control group performed very badly, despite receiving the same care package (oral hygiene, topical fluoride, etc.) but without the application of ozone. Compliance of patients with treatment, however, was not assessed in the included studies.

In particular, it proved difficult to identify the additional role of ozone gas from the patient kit or the synergistic effect between ozone and the patient kit, which contained, among other elements, fluoride and xyliton. It would have been useful, for example, to know the effects of ozone alone, namely ozone gas, together with the patient's normal brushing or how HealOzone compares to professional plaque control (the removal of plaque by a dentist or hygienist), which has been used effectively in the management of dental caries in adults. A recent study assessing the outcomes of a 30-year preventive programme based on professional and self-performed plaque control has shown how high standards of oral hygiene are associated with a very low incidence of dental caries and periodontal disease in adults.[82]

Cost-effectiveness

If HealOzone led to a reduction in future fillings, then the extra cost might be justified. The authors do not believe that the evidence base yet supports that.

Need for further research

Nearly all the research to date comes from the same group who developed and pioneered the procedure, and have the greatest experience in its use. There is a need for large, well-conducted RCTs to assess the effectiveness and cost-effectiveness of HealOzone for the management of both occlusal and root caries. In particular, future trials:

- should be conducted by independent research teams
- should be properly randomised so that an equal number of lesions, or paired lesions, per mouth are allocated to intervention groups
- should apply appropriate statistical methods for the analysis of paired-data on a patient basis;
- should use validated and reproducible criteria for the assessment of caries
- should measure relevant outcomes such as reduction in caries incidence over a reasonable period (at least 2 years, but realistically much longer)
- should mask participants and outcome assessors
- should provide both a statistical and a clinical interpretation of their findings
- should conform to the CONSORT guidelines for the reporting of RCTs.[83]

Owing to the natural history of the caries process, any future trial would need to include a very long follow-up, which would have a significant impact on trial costs.

There also appears to be a need for evaluation of the different methods of assessing caries severity. The base case could be clinical examination, with the marginal benefits and costs of more sophisticated techniques assessed. Although the economic evaluation was not able to provide results that could be used by decision-makers, it was a valuable exercise in highlighting the paucity of good quality data on key parameters. In particular, the paucity of suitable data from published clinical trials comparing the effectiveness of HealOzone with appropriate comparators restricted the scope of the economic model. No comparable quality of life data were available for the comparators, thus limiting the range of outcomes available for an evaluation. These gaps in the data needed to undertake an informative economic evaluation of HealOzone can only be filled through further research in the form of prospective RCTs.

To provide adequate information to assess the cost-effectiveness of HealOzone, any future economic evaluation of HealOzone should feature the following characteristics:

- It should be based on data from properly conducted RCTs of HealOzone versus appropriate comparators (e.g. no treatment or current management).
- Follow-up of patients should be long enough to allow identification of both short-term and long-term resource use and effectiveness.
- Outcome data must include both short-term and long-term rates of caries reversal, caries progression, retreatment and/or rerestoration.
- Separate consideration is needed for cavitated and non-cavitated caries.
- Sufficient power is needed to allow for robust subgroup analyses for deciduous and permanent teeth, and for variation in caries severity.
- An estimate of the unit cost of HealOzone to the NHS should be based on calculations similar to those underlying the SDR figures for current dental treatments provided by the NHS.
- Factors affecting patients' quality of life should be considered, both at the point of treatment and during follow-up (e.g. the effect on quality of life due to pain from toothache).

Chapter 8
Conclusion

Any treatment that preserves teeth and avoids fillings is welcome. However, the current evidence base for HealOzone is insufficient to conclude that it is a cost-effective addition to the management and treatment of occlusal and root caries.

43

Acknowledgements

Grateful thanks to Heather Mackintosh for her secretarial support.

The views and opinions expressed are those of the authors and do not necessarily reflect those of the funding bodies.

Publication information

The Aberdeen Health Technology Assessment Group is part of the Institute of Applied Health Sciences (IAHS). The Institute of Applied Health Sciences within the College of Medicine and Life Sciences of the University of Aberdeen is made up of discrete but methodologically related research groups. The HTA Group is drawn mainly from the Health Services Research Unit, the Department of Public Health and the Health Economics Research Unit.

The HTA Group carries out independent health technology assessment reports (TARs) for the UK HTA Programme, which commissions TARs for the National Institute for Health and Clinical Excellence (NICE) and other bodies, such as the National Screening Committee. In addition, a joint venture between the Health Services Research Unit at Aberdeen and the Medical Care Research Unit at Sheffield University forms the Review Body for Interventional Procedures (ReBIP) Programme within NICE. ReBIP undertakes systematic reviews and, where appropriate, establishes UK registries to collect and analyse data on the efficacy and safety of selected procedures.

Contribution of authors

Miriam Brazzelli (Research Fellow) and Shona Fielding (Medical Statistician) completed the review of effectiveness. Lynda McKenzie (Research Fellow) conducted the review of economic evaluations. Lynda McKenzie and Mary Kilonzo (Research Fellow) conducted the economic evaluation. Cynthia Fraser (Information Scientist) developed and ran the search strategies. Norman Waugh (Professor of Public Health) provided oversight and contributed to drafting the review. Jan Clarkson (Honary Consultant in Paediatric Dentistry) provided clinical advice and commented on the draft review.

References

1. Modernising NHS Dentistry – implementing the NHS Plan. London: Department of Health; 2000.

2. Marthaler TM, O'Mullane DM, Vrbic V. The prevalence of dental caries in Europe 1990–1995. ORCA Saturday afternoon symposium 1995. *Caries Res* 1996;**30**:237–55.

3. *Children's Dental Health in the United Kingdom 2003. Obvious decay experience in children's teeth: preliminary findings*. London: Department of Health; 2004.

4. *Third National Health and Nutrition Examination survey (NHANES III)*. National Center for Health Statistics, Department of Health and Human Services. URL: from:http://www.cdc.gov/nchs/about/major/nhanes/datalink.htm#NHANESIII. Accessed July 2004.

5. Sweeney PC, Nugent Z, Pitts NB. Deprivation and dental caries status of 5-year-old children in Scotland. *Community Dent Oral Epidemiol* 1999; **27**:152–9.

6. Murray JJ, Pitts NB. Trends in oral health. In: Pine CM, editor. *Community oral health*. Oxford: Butterworth Heinemann; 1996. pp. 126–46.

7. Office for Population Censuses and Surveys. *Children's dental health in the United Kingdom 1993*. London: HMSO; 1994.

8. Kelly M, Walker A. *Adult Dental Health Survey: oral health in the United Kingdom 1998*. London: Department of Health; 2000.

9. Ekstrand KR, Ricketts DNJ, Kidd EAM, Qvist V, Schou S. Detection, diagnosing, monitoring and logical treatment of occlusal caries in relation to lesion activity and severity: an *in vivo* examination with histological validation. *Caries Res* 1998; **32**:247–54.

10. Ricketts DN, Kidd EA, Liepins PJ, Wilson RF. Histological validation of electrical resistance measurements in the diagnosis of occlusal caries. *Caries Res* 1996;**30**:148–55.

11. Chestnutt IG, Schafer F, Jacobson AP, Stephen KW. The influence of toothbrushing frequency and post-brushing rinsing on caries experience in a caries clinical trial. *Community Dent Oral Epidemiol* 1998; **26**:406–11.

12. Beal JF, James PM, Bradnock G, Anderson RJ. The relationship between dental cleanliness, dental caries incidence and gingival health. A longitudinal study. *Br Dent J* 1979;**146**:111–14.

13. Lewis DW, Ismail AI. Periodic health examination, 1995 update: 2. Prevention of dental caries. The Canadian Task Force on the Periodic Health Examination. *CMAJ* 1995;**152**:836–46.

14. Kidd E, Nyvad B. Caries control for the individual patient. In: Fejerskov O, Kidd E, editors. *Dental caries: the disease and its clinical management*. Oxford: Blackwell Munksgaard; 2003. pp. 303–11.

15. Kleijnen J, McDonagh M, Misso K, Whiting P, Wilson P, Chestnutt I, *et al*. *Fluoridation of drinking water: a systematic review of its efficacy and safety*. CRD Report 18. York: NHS Centre for Reviews and Dissemination; 2000.

16. McDonagh MS, Whiting PF, Wilson PM, Sutton AJ, Chestnutt I, Cooper J, *et al*. Systematic review of water fluoridation. *BMJ* 2000;**321**:855–9.

17. Marinho VC, Higgins JP, Logan S, Sheiham A. Fluoride varnishes for preventing dental caries in children and adolescents. *Cochrane Database Syst Rev* 2002; Issue 1. Art. No. CD002279. DOI 10.1002/14651858.CD002279.

18. Marinho VC, Higgins JP, Logan S, Sheiham A. Fluoride gels for preventing dental caries in children and adolescents. *Cochrane Database Syst Rev* 2002; Issue 1. Art. No. CD002280. DOI 10.1002/14651858.CD002280.

19. Marinho VC, Higgins JP, Logan S, Sheiham A. Topical fluoride (toothpastes, mouthrinses, gels or varnishes) for preventing dental caries in children and adolescents. *Cochrane Database Syst Rev* 2003; Issue 4. Art. No. CD002782. DOI 10.1002/14651858.CD002782.

20. Marinho VC, Higgins JP, Logan S, Sheiham A. Fluoride toothpastes for preventing dental caries in children and adolescents. *Cochrane Database Syst Rev* 2003; Issue 1. Art. No. CD002278. DOI 10.1002/14651858.CD002278.

21. Marinho VC, Higgins JP, Logan S, Sheiham A. Fluoride mouth rinses for preventing dental caries in children and adolescents. *Cochrane Database Syst Rev* 2003; Issue 3. Art. No. CD002284. DOI 10.1002/14651858.CD002284.

22. Marinho VC, Higgins JP, Logan S, Sheiham A. One topical fluoride (toothpastes, or mouth rinses, or gels, or varnishes) versus another for preventing dental caries in children and adolescents. *Cochrane Database Syst Rev* 2004; Issue 1. Art. No. CD002780. DOI: 10.1002/14651858.CD002780.pub2.

47

23. Clarkson JE, Ellwood RP, Chandler RE. A comprehensive summary of fluoride dentifrice caries clinical trials. *Am J Dent* 1993;**6** (Special No.): S59–106.

24. Biesbrock AR, Gerlach RW, Bollmer BW, Faller RV, Jacobs SA, Bartizek RD. Relative anti-caries efficacy of 1100, 1700, and 2800 ppm fluoride ion in a sodium fluoride dentifrice over 1 year. *Community Dent Oral Epidemiol* 2001;**29**:382–9.

25. Ripa LW. A critique of topical fluoride methods (dentifrices, mouthrinses, operator-applied, and self-applied gels) in an era of decreased caries and increased fluorosis prevalence. *J Public Health Dent* 1991;**1**:23–41.

26. Bader JD, Shugars DA, Bonito AJ. A systematic review of selected caries prevention and management methods. *Community Dent Oral Epidemiol* 2001;**29**:399–411.

27. Ellwood R, Fejerskov O. Clinical use of fluoride. In Fejerskov O, Kidd E, editors. *Dental caries: the disease and its clinical management*. Oxford: Blackwell Munksgaard; 2003. pp. 189–222.

28. *Diagnosis and management of dental caries throughout life*. NIH Consensus Statement 26–28 March 2001;**18**(1):1–30.

29. Handelman SL. Effect of sealant placement on occlusal caries progression. *Clinical Preventive Dentistry* 1982;**4**(5):11–16.

30. Mertz-Fairhurst EJ, Curtis JW Jr, Ergle JW, Rueggeberg FA, Adair SM. Ultraconservative and cariostatic sealed restorations: results at year 10. *J Am Dent Assoc* 1998;**129**:55–66.

31. Ripa LW. Sealants revisited: an update of the effectiveness of pit-and-fissure sealants. *Caries Res* 1993;**27** Suppl 1:77–82.

32. Ahovuo-Saloranta A, Hiiri A, Nordblad A, Worthington HV, Makela M. Pit and fissure sealants for preventing dental decay in the permanent teeth of children and adolescents. *Cochrane Database Syst Rev* 2004; Issue 3. Art. No. CD001830. DOI 10.1002/14651858.CD001830.pub2.

33. Dental Practice Board. *Dental review of the general and personal dental services of the NHS*. 2002–2003 [monograph on the Internet]. URL: http://www.dpb.nhs.uk/. Accessed July 2004.

34. Verhagen AP. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by the Delphi consensus. *J Clin Epidemiol* 1998; **51**:1235–41.

35. Holmes J. Clinical reversal of root caries using ozone, double-blind, randomised, controlled 18-month trial. *Gerodontology* 2003;**20**:106–14.

36. Baysan A, Lynch E. Management of root caries using ozone. KaVo Dental Ltd website.

URL: http://www.kavo.com/forum/upfiles/4/ Db84539.pdf. Accessed April 2004.

37. Abu-Naba'a LA. *Management of primary occlusal pit and fissure caries using ozone* [PhD thesis]. Queen's University Belfast; 2003.

38. Abu-Salem O. *Reversal of occlusal caries in primary teeth* [MPhil thesis]. Queen's University Belfast; 2004.

39. Holmes J. Ozone treatment of root caries after 18-months. IADR/AADR/CADR 82nd Annual Conference, Honolulu, Hawaii, March 2004 [conference proceedings on the Internet]. URL: http://iadr.confex.com/iadr/2004Hawaii/ techprogram/abstract_47251.htm.

40. Holmes J. Ozone treatment of root caries after 21-months. BSDR Annual Scientific Meeting, Birmingham, UK, April 2004 [Conference proceedings on the Internet]. URL: http://iadr.confex.com/iadr/bsdr04/techprogram/ abstract_49444.htm.

41. Baysan A, Lynch E. Clinical reversal of root caries using ozone. IADR/AADR/CADR 80th Annual Conference, San Diego, California, March 2002 [conference proceedings on the internet]. URL: http://iadr.confex.com/iadr/2002SanDiego/ techprogram/abstract_20439.htm.

42. Baysan A. *Management of primary root caries using ozone therapies* [PhD Thesis]. University of London; 2002.

43. Baysan A, Lynch E. 12-month assessment of ozone on root caries. 81st Annual Conference of IADR, Goteborg, Sweden, June 2003 [conference proceedings on the Internet]. URL: http://iadr.confex.com/iadr/2003Goteborg/ techprogram/abstract_36145.htm.

44. Baysan A, Lynch E. Clinical assessment of ozone on root caries. IADR/AADR/CADR 82nd Annual Conference, Honolulu, Hawaii, March 2004 [conference proceedings on the Internet]. URL: http://iadr.confex.com/iadr/2004Hawaii/ techprogram/abstract_47326.htm.

45. Abu-Naba'a LA, Al Shorman HM, Stevenson M, Lynch E. Ozone treatment of pit and fissure caries: 6-month results. 32nd Annual Meeting of AADR, San Antonio, Texas, March 2003 [conference proceedings on the Internet]. URL: http://iadr.confex.com/iadr/2003SanAnton/ techprogram/abstract_27269.htm.

46. Abu-Naba'a LA, Al Shorman HM, Lynch E. Ozone treatment of primary occlusal pit and fissure caries: 12 month clinical severity changes. *Caries Res* 2003; **37**:272.

47. Abu-Naba'a LA, Al Shorman HM, Lynch E. Ozone treatment of primary occlusal pit and fissure caries: 12 month electrical impedance results and clinical implications. *Caries Res* 2003;**37**:272.

48. Abu-Naba'a LA, Al Shorman HM. 6-months fissure sealant retention over ozone-treated occlusal caries. IADR/AADR/CADR 82nd Annual Conference, Honolulu, Hawaii, March 2004 [conference proceedings on the Internet]. URL: http://iadr.confex.com/iadr/2004Hawaii/techprogram/abstract_45125.htm.

49. Abu-Naba'a LA, Al Shorman HM, Lynch E. *Ozone management of occlusal pit & fissure caries (PFC): 12 month review*. DentalOzone website. London: Dental Clinique. URL: http://www.dentalozone.co.uk/research4.html.

50. Abu-Naba'a LA, Al Shorman HM, Lynch E. Ozone efficacy in the treatment of pit and fissure caries. *J Dent Res* 2003;**82**(Special Issue C):C-535.

51. Abu-Naba'a LA, Al Shorman HM, Lynch E. Clinical indices changes in ozone treatment of pit and fissure caries. 32nd Annual Meeting of AADR, San Antonio, Texas, March 2003 [conference proceedings on the Internet]. URL: http://iadr.confex.com/iadr/2003SanAnton/techprogram/abstract_27273.htm.

52. Abu-Naba'a LA, Al Shorman HM, Lynch E. 6-month clinical indices changes after ozone treatment of pit and fissure caries (PFC). 81st Annual Conference of IADR, Goteberg, Sweden, June 2003 [conference proceedings on the Internet]. URL: http://iadr.confex.com/iadr/2003Goteborg/techprogram/abstract_35236.htm.

53. Holmes J, Lynch E. Reversal of occlusal caries using air abrasion, ozone and sealing. IADR/AADR/CADR 82nd Annual Conference, Honolulu, Hawaii, March 2004 [conference proceedings on the Internet]. URL: http://iadr.confex.com/iadr/2004Hawaii/techprogram/abstract_47218.htm.

54. Holmes J. Clinical reversal of occlusal pit and fissure caries using ozone. 81st Annual Conference of the International Association for Dental Research, Goteberg, Sweden, June 2003.

55. Hamid A. Clinical reversal of occlusal pit and fissure caries using ozone. IADR/AADR/CADR 82nd Annual Conference, Honolulu, Hawaii, March 2004 [conference proceedings on the Internet]. URL: from: http://iadr.confex.com/iadr/2004Hawaii/techprogram/abstract_47414.htm.

56. Megighian GD, Bertolini L. In-vivo *reversal of occlusal caries with ozone after six months*. DentalOzone website. London: Dental Clinique. URL: http://www.dentalozone.co.uk/research8.html. Accessed August 2004.

57. Lynch E, Johnson J, Johnson J. *Clinical reversal of root caries using ozone*. *DentalOzone* website. London: Dental Clinique. URL: http://www.dentalozone.co.uk/research7.html. Assessed August 2004.

58. Kuhnisch J, Ziehe A, Brandstadt A, Heinrich-Weltzien R. An in vitro study of the reliability of DIAGNOdent measurements. *J Oral Rehabil* 2004; **31**:895–9.

59. Macfarlane TV, Worthington HV. Some aspects of data analysis in dentistry. *Community Dent Health* 1999;**16**:216–19.

60. Rickard GD, Richardson R, Johnson T, McColl D, Hooper L. Ozone therapy for the treatment of dental caries. *Cochrane Database Syst Rev* 2004; Issue 3. Art. No. CD004153. DOI 10.1002/14651858.CD004153.pub2.

61. Drummond M, O'Brien B, Stoddard G, Torrance G. *Critical assessment of economic evaluation. Methods for the economic evaluation of health care programmes*. Oxford: Oxford University Press; 1997. pp. 27–51.

62. Johnson N, Johnson J, Lynch E. Cost benefit assessment of a novel ozone delivery system vs conventional treatment. 32nd Annual Meeting of AADR, San Antonio, Texas, March 2003 [conference proceedings on the Internet]. URL: http://iadr.confex.com/iadr/2003SanAnton/techprogram/abstract_27588.htm.

63. Domingo H, Holmes J, Abu-Naba'a LA, Al Shorman HM, Baysan A, Freeman R. *Economic savings treating root caries with ozone*. DentalOzone website. URL: www.dentalozone.co.uk/research6.html. Accessed August 2004.

64. *Amendment 92 to the Statement of Dental Remuneration* [document on the Internet]. UK Department of Health. URL: http://www.dh.gov.uk/assetRoot/04/08/11/28/04081128.pdf. Accessed July 2004.

65. General dental services statistics. Dental Practice Board website. URL: http://www.dpb.nhs.uk/gds/index.shtml. Assessed July 2004.

66. NHS Centre for Reviews and Dissemination. Dental restorations: what type of filling? *Effective Health Care* 1999;**5**(2):1–12.

67. Florio FM, Pereira AC, Meneghim MC, Ramacciato JC. Evaluation of non-invasive treatment applied to occlusal surfaces. *Journal of Dentistry for Children* 2001;**68**:326–31.

68. Qvist V, Laurberg L, Poulsen A, Teglers PT. Eight-year study on conventional glass ionomer and amalgam restorations in primary teeth. *Acta Odontol Scand* 2004;**62**:37–45.

69. Vilkinis V, Horsted-Bindslev P, Baelum V. Two-year evaluation of class II resin-modified glass ionomer cement/composite open sandwich and composite restorations. *Clinical Oral Investigation* 2000;**4**:133–9.

70. Qvist V, Laurberg L, Poulsen A, Teglers PT. Longevity and cariostatic effects of everyday conventional glass-ionomer and amalgam restorations in primary teeth: three-year results. *J Dent Res* 1997;**76**:1387–96.

49

71. Baysan A, Lynch E. Effect of ozone on the oral microbiota and clinical severity of primary root caries. *American Journal Dentistry* 2004;**17**:56–60.

72. Morrison R, Lynch E. Remineralization of occlusal pit and fissure caries after using ozone. 32nd Annual Meeting of AADR, San Antonio, Texas, March 2003 [conference proceedings on the Internet]. URL: from:http://iadr.confex.com/iadr/2003SanAnton/techprogram/abstract_27482.htm.

73. Stinson P, Al Shorman HM, Abu-Naba'a LA. Lynch E. Clinical reversal of occlusal pit and fissure caries after using ozone. 32nd Annual Meeting of AADR, San Antonio, Texas, March 2003 [conference proceedings on the Internet]. URL: http://iadr.confex.com/iadr/2003SanAnton/techprogram/abstract_27499.htm.

74. Cronshaw MA. Treatment of primary occlusal pit and fissure caries with ozone: six-month results. 81st Annual Conference of the International Association for Dental Research, Goteberg, Sweden, June 2003 [conference proceedings on the Internet]. URL: http://iadr.confex.com/iadr/2003Goteborg/techprogram/abstract_34889.htm.

75. Domingo H, Abu-Naba'a LA, Al Shorman HM, Holmes J, Marashdeh M, Abu-Salem O, *et al*. Reducing barriers to care in patients managed with ozone. 32nd Annual Meeting of AADR, San Antonio, Texas, March 2003 [conference proceedings on the Internet]. URL: http://iadr.confex.com/iadr/2003SanAnton/techprogram/abstract_27392.htm.

76. Holmes J, Lynch E. Clinical reversal of occlusal fissure caries using ozone. 81st Annual Conference of the International Association for Dental Research, Goteberg, Sweden, June 2003 [conference proceedings on the Internet]. URL: http://iadr.confex.com/iadr/2003Goteborg/techprogram/abstract_36308.htm.

77. Megighian GD, Bertolini L, De Pieri A, Lynch E. *In-vivo* treatment of occlusal caries with ozone: one and two months effect with light induced fluorescence (QLF) as diagnostic methods. 81st Annual Conference of the International Association for Dental Research, Goteberg, Sweden, June 2003 [conference proceedings on the Internet]. URL: http://iadr.confex.com/iadr/2003Goteborg/techprogram/abstract_36918.htm.

78. Healozone Users Congresses. July 2003 [document on the Internet]. HealOzone website. URL: http://www.the-o-zone.cc/O3cong.doc. Accessed April 2004.

79. National Institute for Clinical Excellence. *Guide to the methods of technology appraisal* (reference N0515). London: NICE, 2004.

80. *Primary dental care services in England & Wales* [document on the Internet]. London: Audit Commission; 2002. URL: http://www.audit-commission.gov.uk/. Assessed August 2004.

81. *NHS Dentistry: next steps in local commissioning* [document on the Internet]. London: UK Department of Health; 2004. URL: http://www.dh.gov.uk/assetRoot/04/08/68/59/04086859.pdf. Accessed August 2004.

82. Axelsson P, Nystrom B, Lindhe J. The long-term effect of a plaque control program on tooth mortality, caries and periodontal disease in adults. Results after 30 years of maintenance. *J Clin Periodontol* 2004;**31**:749–57.

83. Moher D, Schulz KF, Altman D, for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. *JAMA* 2001;**285**:1987–91.

Appendix 1

Literature search strategies

Sources searched for systematic reviews, other evidence-based reports and background information

Databases
Cochrane Database of Systematic Reviews (CDSR). The Cochrane Library (Issue 2, 2004).
Database of Abstracts of Reviews of Effectiveness (NHS Centre for Reviews and Dissemination), April 2004.
HTA Database (NHS Centre for Reviews and Dissemination), April 2004.
Trip database. URL: http://www.tripdatabase.com/. Accessed May 2004.

Websites
The Dental, Oral and Craniofacial Data Resource Center (DRC). URL: http://drc.nidcr.nih.gov/default.htm. Accessed July 2004.
National Center for Health Statistics. URL: http://www.cdc.gov/nchs/nhanes.htm. Accessed July 2004.
British Association for the Study of Community Dentistry. URL: http://www.bascd.org/ Accessed July 2004.
KaVo Dental Ltd. URL: http://www.kavo.com/En/default.asp. Accessed April 2004.
CurOzone USA Inc. URL: http://www.curozone.com/. Accessed April 2004.
DentalOzone. London: Dental Clinique. URL: http://www.dentalozone.co.uk/. Accessed April 2004.
HealOzone. Dr Julian Holmes. URL: http://www.the-o-zone.cc/. Accessed April 2004.
NHS Dental Practice Board. URL: http://www.dpb.nhs.uk/gds/index.shtml. Accessed July 2004.
Department of Health. URL: http://www.dh.gov.uk/Home/fs/en. Accessed April 2004.

Search strategies used to identify reports assessing ozone therapy for dental caries

**MEDLINE (1966 to week 1 2004),
EMBASE (1980 to week 20 2004),
(MEDLINE Extra 17 May 2004)
Ovid Multifile Search.
URL: http://gateway.ovid.com/athens**

 1 (healozone or curazone).tw.
 2 ozone/ (14334)
 3 (ozone or o3).tw.
 4 (oxidat$ or oxidis$).tw.
 5 or/2-4
 6 exp tooth demineralization/ use mesz
 7 dental caries/ use emez
 8 demineralization/ use emez
 9 Dental Caries Susceptibility/ use mesz
10 Dental Enamel Solubility/
11 (caries or carious).tw.
12 ((tooth or teeth or dental or dentine or enamel or root? or occlusal) adj5 decay$).tw.
13 ((tooth or teeth or dental or dentine or enamel or root? or occlusal) adj5 cavit$).tw.
14 ((tooth or teeth or dental or root? or dentine or occlusal or enamel or cavitated) adj5 lesion?).tw.
15 ((tooth or teeth or dental or dentine or enamel) adj5 (minerali$ or demineralis$ or reminerali$)).tw.
16 or/6-15
17 1 or (5 and 16)
18 human/
19 animal/ use mesz
20 nonhuman/ use emez
21 (19 or 20) not 18
22 17 not 21
23 remove duplicates from 22

Science Citation Index 1981 to 16 May 2004)
Web of Science Proceedings 1990 to 15 May 2004)
Web of Knowledge.
URL: http://wok.mimas.ac.uk/

#1 TS= (Healozone or curazone)
#2 TS= (ozone or o3)
#3 TS=(oxidat* or oxidis*)
#4 #2 or #3
#5 TS=(caries or carious)
#6 TS=((tooth or teeth or dental or dentine or enamel or root* or occlusal) SAME decay*)
#7 TS=((tooth or teeth or dental or root* or dentine or occlusal or enamel or cavitated) SAME lesion*)
#8 TS=((tooth or teeth or dental or dentine or enamel or root* or occlusal) SAME cavit*)
#9 TS=((tooth or teeth or dental or dentine or enamel) SAME (minerali* OR demineralis* OR reminerali*))
#10 #5 OR #6 OR #7 OR #8 OR #9
#11 #4 AND #10
#12 #1 OR #11

BIOSIS (1985 to 12 May 2004)
Edina. URL: http://edina.ac.uk/biosis/

(tn: (humans)) and (((al: (healozone)) or al: (curazone)) or ((((al: (oxidat*)) or al: (oxidis*)) or ((al: (ozone)) or al: (o3))) and ((((((al: (caries)) or al: (carious)) or ((((al: (root n5 decay*)) or al: (roots n5 decay*)) or (((al: (dentine n5 decay*)) or al: (enamel n5 decay*)) or al: (occlusal n5 decay*))) or (((al: (tooth n5 decay*)) or al: (teeth n5 decay*)) or al: (dental n5 decay*)))) or ((((al: (root n5 cavit*)) or al: (roots n5 cavit*)) or (((al: (dentine n5 cavit*)) or al: (occlusal n5 cavit*)) or al: (enamel n5 cavit*))) or (((al: (tooth n5 cavi*)) or al: (teeth n5 cavit*)) or al: (dental n5 cavit*)))) or (((((al: (root n5 lesion*)) or al: (roots n5 lesion*)) or (((al: (dentine n5 lesion*)) or al: (enamel n5 lesion*)) or al: (occlusal n5 lesion*))) or (((al: (tooth n5 lesion*)) or al: (teeth n5 lesion*)) or al: (dental n5 lesion*))) or (al: (cavitated n5 lesion*)))) or ((((((al: (tooth n5 minerali*)) or al: (tooth n5 reminerali*)) or al: (tooth n5 demineralis*)) or (((al: (teeth n5 mineral*)) or al: (teeth n5 reminerali*)) or al: (teeth n5 demineralis*))) or (((al: (dent* n5 minerali*)) or al: (dent* n5 reminerali*)) or al: (dent* n5 demineralis*))) or (((al: (enamel n5 minerali*)) or al: (enamel n5 reminerali*)) or al: (enamel n5 deminerali*))))))

AMED (1985 to May 2004)
Ovid. URL: http://gateway.ovid.com/ athens

1 (healozone or curazone).tw
2 (ozone or o3).tw.
3 (oxidat$ or oxidis$).tw.
4 or/2-3
5 (caries or carious).tw
6 ((tooth or teeth or dental or dentine or enamel or root? or occlusal) adj5 decay$).tw
7 ((tooth or teeth or dental or dentine or enamel or root? or occlusal) adj5 cavit$).tw
8 ((tooth or teeth or dental or root? or dentine or occlusal or enamel or cavitated) adj5 lesion?).tw
9 ((tooth or teeth or dental or dentine or enamel) adj5 (minerali$ or demineralis$ or reminerali$)).tw
10 or/5-9
11 1 or (4 and 10)
12

Cochrane Library Issue 2, 2004
URL: http://www.update-software.com/ clibng/cliblogon.htm
National Research Register
(Issue 2, 2004)
URL: http://www.update-software.com/National/

#1. (healozone or curazone)
#2. OZONE single term (MeSH)
#3. (ozone or o3)
#4. (oxidat* or oxidis*)
#5. (#2 or #3 or #4)
#6. TOOTH DEMINERALIZATION explode tree 1 (MeSH)
#7. DENTAL CARIES SUSCEPTIBILITY single term (MeSH)
#8. DENTAL ENAMEL SOLUBILITY single term (MeSH)
#9. (caries or carious)
#10. ((tooth or teeth or dental or dentine or enamel or root* or occlusal) and decay*)
#11. ((tooth or teeth or dental or dentine or enamel or root* or occlusal) and cavit*)
#12. ((tooth or teeth or dental or dentine or enamel or root* or occlusal or cavitated) and lesion*)
#13. ((tooth or teeth or dental or dentine or enamel) and (mineralis* or demineralis* or remineralis*))
#14. ((tooth or teeth or dental or dentine or enamel) and (mineraliz* or demineraliz* or remineraliz*))
#15. (#6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14)
#16. (#5 and #15)
#17. (#1 or #16)

DARE, NHS Economic Evaluation Database and HTA Databases (April 2004)
NHS Centre for Reviews and Dissemination
URL: http://nhscrd.york.ac.uk/welcome.htm
Ozone or healozone or oxid* - all fields
Dental or caries or carious – all fields

Clinical Trials (18 May 2004)
URL: http://clinicaltrials.gov/ct/gui/c/r

Current Controlled Trials (18 May 2004)
URL: http://www.controlled-trials.com/
Ozone or healozone or oxid* – all fields

Health Management Information Consortium (May 2004)
 1 (healozone or curazone).tw.
 2 dental caries/
 3 (caries or carious).tw.
 4 ((tooth or teeth or dental or dentine or enamel or root? or occlusal) adj1 decay$).tw.
 5 ((tooth or teeth or dental or dentine or enamel or root? or occlusal) adj1 cavit$).tw.
 6 ((tooth or teeth or dental or dentine or enamel or cavitated) adj1 lesion?).tw.
 7 ((tooth or teeth or dental or dentine or enamel) adj1 (minerali$ or deminerali$ or reminerali$)).tw.
 8 or/1-7
 9 limit 8 to yr=1995 – 2004

Conference Papers Index (1982 to May 2002)
Cambridge Scientific Abstracts
URL: http://www.csa1.co.uk/
KW=(healozone or curazone) or (KW=(ozone or oxidat* or oxidis*) and KW=(caries or carious or dental)) or (KW=(ozone or oxidat* or oxidis*) and KW=(teeth or tooth or cavit*)) or (KW=(ozone or oxidat* or oxidis*) and KW=(occlusal or decay* or lesion*))

Zetoc Conference Search (1993 to May 2004)
MIMAS URL: http://zetoc.mimas.ac.uk/
Ozone or healoaone or oxid* and (conference: dental or dentist or caries)

IADR Meeting abstracts
URL: http://www.iadr.com/Meetings/index.html
IARD/AADR/CADR 80th General Session, San Diego, March 2002

IARD/AADR/CADR 82nd General Session, Honolulu, March2004
AADR 32nd Annual Meeting and Exhibition, San Antonio, March 2003
IADR 81st General Session, Goteberg 2003
IADR, Irish Division Annual Meeting, Belfast, 2004
BSDR Ann Scientific Meeting, Birmingham, April 2004

ozone or healozone or oxid*

Handsearching

Journal of Dental Research
Vol. 79 (Special Issue 2000): 78th General Session of IADR, Washington, USA, April 2000.
Vol. 79(5) 2000: British Section: Annual Scientific Session, Lancaster, UK, April 2000; Irish Section: Annual Scientific Meeting, Newcastle, Ireland, January 1999.
Vol. 80 (Special Issue, AADR Abstracts, January 2001): 30th Annual Meeting AADR/25th Annual Meeting CADR, Chicago, USA, March 2001.
Vol. 80(4) (April 2001): British Society for Dental Research and Irish Division, Continental European (1999 and 2000).

Caries Research
Vol. 37(4): 50th Annual ORCA Congress, Konstanz Germany, July 2003.
Vol. 36(3): 49th Annual ORCA Congress, Naantali Finland, July 2002.
Vol. 35(4): 48th Annual ORCA Congress, Graz, Austria, July 2001.
Vol 34(4): 47th Annual ORCA Congress, Alghero, Sardinia, July 2000.

Websites

KaVo Dental Ltd. URL: http://www.kavo.com/En/default.asp. Accessed April 2004.
CurOzone USA Inc.
    URL: http://www.curozone.com/. Accessed April 2004.
DentalOzone. London: Dental Clinique.
    URL: http://www.dentalozone.co.uk/. Accessed April 2004.
HealOzone. Dr Julian Holmes.
    URL: http://www.the-o-zone.cc. Accessed April 2004.

Appendix 2
Data extraction form

'HEALOZONE' TECHNOLOGY ASSESSMENT REVIEW

DATA EXTRACTION FORM

Reviewer ID: Date information extracted:

Study Details

Study ID: _____

Study identifier: _____
(Surname of first author + year of publication)

Study origin: _____

Language: _____

Published	☐	**Unpublished**	☐
Full text	☐	**Abstract only**	☐

Study Design

RCT	☐	Other _____
Quasi – RCT	☐	
Observational Study	☐	

For RCTs only: What is the unit of randomisation?

Patient	☐
Tooth/lesion	☐
Tooth/lesion pair	☐

Participants	
Number of eligible patients:	Number of patients randomised:
Inclusion criteria:	Exclusion criteria:

Interventions

	Type of intervention	Number of participants
Group 1:		
Group 2:		
Group 3:		

Patient Characteristics				
	Intervention 1	**Intervention 2**	**Intervention 3**	**Total**
Age (mean, range)				
Sex (M/F)				
Permanent/Deciduous teeth				
Primary or Secondary caries				
Comparability at baseline				

Characteristics of the intervention
Location of trial centre(s):
Source of participants:
Method of recruitment:

Method of randomisation:
Dosage of HealOzone application:
Repeated applications:
Was a reductant applied? If yes, what was its formulation?
Did patient receive the aftercare kit (e.g. toothpaste, mouth rinse and spray)?
Length of follow-up:
Compliance with the treatment:
Number lost to follow-up:

Caries Information
Method of caries examination:
Tooth location, lesion location, and type of lesion:
Severity of caries:

Outcomes			
	Intervention 1	**Intervention 2**	**Intervention 3**
Non-cavitated caries			
Reversal of caries			
Progression of caries			
Utilisation of dental resources			

Adverse reactions	
Patient–centred measures (e.g. patient satisfaction and preference, relief of pain/discomfort)	
Quality of life	
Cavitated caries	
Time to restorative interventions	
Need for further restorative interventions	
Symptoms of pulpal pathology	

Other comments

Appendix 3

Checklist for the quality assessment of randomised controlled trials

(adapted from Verhagen, 1998[34])

Criteria	Yes	No	Unclear	Comments
1. **Was the assignment to the treatment groups really random?** Adequate approaches to sequence generation • computer-generated random tables • random number tables Inadequate approaches to sequence generation • use of alternation, case record numbers, birth dates or week days				
2. **Was the unit of randomisation clear?**				
3. **Was the treatment allocation concealed?** Adequate approaches to concealment of randomisation • centralised or pharmacy-controlled randomisation • serially-numbered identical containers • on-site computer based system with a randomisation sequence that is not readable until allocation • other approaches with robust methods to prevent foreknowledge of the allocation sequence to clinicians and patients Inadequate approaches to concealment of randomisation • use of alternation, case record numbers, birth dates or week days • open random numbers lists • serially numbered envelopes (even sealed opaque envelopes can be subject to manipulation)				
4. **Were the groups similar at baseline in terms of prognostic factors?**				
5. **Were the eligibility criteria specified?**				
6. **Were the groups treated in the same way apart from the intervention received?**				
7. **Was the outcome assessor blinded to the treatment allocation?**				
8. **Was the care provider blinded?**				
9. **Were the patients blinded?**				
10. **Were the point estimates and measures of variability presented for the primary outcome measures?**				
11. **Was the withdrawal/dropout rate likely to cause bias?**				
12. **Did the analyses include an intention-to-treat analysis?**				

Appendix 4

Characteristics of included studies:

full-text reports

TABLE 21 Characteristics of full-text reports

Root caries: permanent dentition

Author(s)	No. and characteristics of participants and carious lesions	Design	Inclusion criteria	Interventions	Results	Notes and caveats
Baysan and Lynch, 2004[36,41–44] (Belfast, UK)	n = 79 (220 primary cavitated and non-cavitated root carious lesions) Age, mean ± SD (range): 65 ± 14.76 (30–72) years Gender (M/F): 49/30 Tooth and lesion location: root surface lesions. Caries risk assessment: NS	Design: RCT (unpublished) Unit of randomisation: lesion Method of randomisation: NS Concealment of allocation: NS Blinding: unclear ITT: no Length of follow-up: 12 months Lost at follow-up: five subjects Comparability of groups at baseline: unclear Setting: general dental practices	Two or four primary non-cavitated and cavitated root carious lesions with severity index II (leathery lesions)	Group 1: cleaning of the tooth surface, application of O_3 + reductant The procedure was repeated after 1 month without ozone and at 3 months with ozone Group 2: reductant only. The procedure was repeated after 1 month and at the 3-month follow-up Group 3: O_3 + sealant (Seal & Protect, Dentsply, Germany) The procedure was repeated at 3 months. Sealants were reapplied only if a partial or complete loss of the sealant was suspected Group 4: sealant only (Seal & Protect, Dentsply, Germany) Sealants were reapplied after 1 and 3 months only if a partial or complete loss of the sealant was suspected Reductant formulation: Sodium fluoride (1100 ppm F), xylitol, sodium benzoate, among other active ingredients Ozone dosage: 10 seconds	Reversal of caries, groups 1 and 2: at 12 months 47% of PRCLs reversed from severity index 1 to 0 (hard) in the ozone group, while none became hard in the control group ($p < 0.001$). 52% of lesions reversed from 2 to 1 in the ozone group compared with 11.6% in the control group ($p < 0.001$) Cavitated lesions in the ozone group did not show the same trend of improvement of non-cavitated lesions. Percentage of lesions that became hard decreased from 9.1 at 1 month to 1.4 at 9 months, suggesting worsening of cavitated carious lesions. Data for the control group were not given Marginal adaptation of the root sealant (modified USPHS criteria): 61% intact sealants in the O_3 + sealant group compared with 26.1% in the sealant-only group ($p < 0.001$) Significant differences in the changes in both the ECM readings and DIAGNOdent readings in the ozone and control groups ($p < 0.001$) Adverse events: none observed	The number of lesions in each intervention group was not clearly reported All subjects enrolled in the study received preventive advice, including oral hygiene and dietary advice, and were given a toothbrush and toothpaste (Natural White, Natural White Inc., USA, 1100 ppm F) Unclear whether cleaning of the root surface was performed before treatment in groups 2, 3 and 4 It was reported that subjects who "presented with any form of discomfort were immediately treated with conventional drilling and filling procedures", but no further information was provided Methods for statistical analyses not clearly reported. Unclear whether the results were adjusted for covariates/risk factors Emphasis on non-cavitated lesions

TABLE 21 *Characteristics of full-text reports (cont'd)*

Author(s)	No. and characteristics of participants and carious lesions	Design	Inclusion criteria	Interventions	Results	Notes and caveats
				Caries assessment: ECM III (Lode Diagnostics BV, The Netherlands), DIAGNodent (KaVo, Germany) and clinical criteria. The severity of lesions was assessed on a four-point scale (0 = hard lesions; 4 = soft lesions). In addition, modified USPHS criteria were used for assessing groups 3 and 4		
				Assessors/operators: single operator (A. Baysan)		
				Ozone device output: NS		

TABLE 21 Characteristics of full-text reports (cont'd)

Author(s)	No. and characteristics of participants and carious lesions	Design	Inclusion criteria	Interventions	Results	Notes and caveats
Holmes, 2003[35,39,40] (Berkshire, UK)	*n* = 89 (178 primary non-cavitated root carious lesions, 89 lesions in each group) Age, mean ± SD (range): 70.8 ± 6 (60–82) **Tooth and lesion location:** leathery roof surface lesions (severity index II) Caries risk assessment: NS	Design: RCT Unit of randomisation: lesion Method of randomisation: computer-generated random tables Concealment of allocation: NS Blinding: double blind ITT: no Length of follow-up: 3, 6, 12, 18 and 21 months Lost at follow-up: two at 18 months Comparability of groups at baseline: unclear Setting: general dental practice	Adults with two leathery non-cavitated PRCLs	Group 1: application of O₃ + reductant + patient care kit Group 2: air treatment + reductant only + patient care kit Repeated applications of O₃ + reductant at 3, 6, 12 and 18 months Reductant formulation: xylitol, fluoride, calcium, phosphate and zinc (no concentrations provided) Ozone dosage: 40 seconds Caries assessment: ECM (Lode Diagnostics BV, The Netherlands), DIAGNodent (KaVo, Germany) and visual/tactile examination method Assessors/operators: the ozone treatment was applied by a different operator to the one recording the severity of lesions. Unclear whether the operator who assessed outcomes was the same one who did allocated subjects to intervention groups. A sample of 15 subjects (30 lesions) was examined by a third dentist to test reproducibility of results	*18 months follow-up.* Reversal of caries: 87/87 lesions in the ozone group reversed (became hard) compared with 1/87 in the control group (*p* < 0.01) Progression of caries: 32/87 lesions in the control group worsened from leathery to soft and 54/87 did not change Adverse events: none observed	All subjects enrolled in the study received information on oral hygiene, brushing techniques and diet. In particular, all subjects received instructions on how to use the remineralising toothpaste twice a day, the mineral mouthwash twice a day and the remineralising spray four times a day All subjects were offered a pharmacological treatment, which they all accepted as an alternative to the traditional drilling and filling. No details of the pharmacological treatment were provided The two dentists who allocated subjects to intervention groups and assessed severity of lesions, and the third dentist who assessed reproducibility of data, were not acknowledged in the paper The 21-month findings published in abstract format (Holmes, 2004[40]) seem to contradict those reported in the full text

TABLE 21 *Characteristics of full-text reports (cont'd)*

Author(s)	No. and characteristics of participants and carious lesions	Design	Inclusion criteria	Interventions	Results	Notes and caveats
				Ozone device output: it was reported that the HealOzone unit was fitted with a modified control integrated electronic chip. Unclear whether this modified chip could allow better calibration and monitoring of ozone doses		

65

TABLE 21 Characteristics of full-text reports (cont'd)

Author(s)	No. and characteristics of participants and carious lesions	Design	Inclusion criteria	Interventions	Results	Notes and caveats
Pit and fissure caries: permanent dentition						
Abu-Naba'a, 2003, main study[37,45–50] (Belfast, UK)	$n = 90$ (258 primary occlusal pit and fissure carious lesions) Age: 79 subjects between 12 and 31 years, 8 subjects between 32 and 41 years, and 3 subjects >41 years Gender (M/F): 35/55 Tooth and lesion location: all posterior teeth in the upper and lower jaws. Central grooves and pits were the most commonly observed lesions Caries risk assessment: NS	Design: RCT (unpublished) Unit of randomisation: lesion Method of randomisation: random sampling digit tables Concealment of allocation: NS Blinding: unclear ITT: no Length of follow-up: 1, 3, 6, 9 and 12 months Lost at follow-up: 32 subjects Comparability of groups at baseline: more severe lesions (index scores of 2 and 3) in the treatment group ($p = 0.055$). More molars in the treatment group than in the control group. Setting: general dental practice	Males and females >12 years old with primary occlusal pit and fissure carious lesions in at least two teeth of the permanent posterior dentition, which were accessible for the diagnostic procedures	Before treatment all lesions were disclosed and cleaned with an air-abrasive system (PROPHYflex 2, KaVo, Germany) Group 1: application of O_3 + reductant Group 2: reductant only/control Group 3: O_3 + reductant + fissure sealant (Guardian, Kerr) Group 4: reductant + sealant Reductant formulation: Sodium fluoride (1100 ppm F), xylitol and zinc chloride among other active ingredients Ozone dosage: 10 seconds Caries assessment: ECM (Lode Diagnostics BV, The Netherlands), DIAGNodent (KaVo, Germany) and clinical severity (Ekstrand, 1998).[9] In addition, modified USPHS criteria + radiographic assessments were used for assessing groups 3 and 4	*Groups 1 and 2* Reversal of caries: no significant differences between groups in the mean change from baseline: Group 1: 0.283 (0.64) Group 2: 0.443 (0.74); ($p = 0.112$) ECM values: no significant differences in the mean change from baseline values between groups: Group 1 (109 lesions): mean $\log_e$ change 0.020 (1.4) Group 2 (109 lesions): 0.073 (1.61) ($p = 0.75$) Excluding teeth with baseline ECM score 0: Group 1 (77 lesions): 0.327 (1.32) Group 2 (69 lesions): 0.073 (1.37); $p = 0.54$ DIAGNOdent values: no significant differences between groups ($p > 0.05$) at any follow-up visits *Groups 3 and 4* Secondary caries: no significant differences between groups (two secondary caries in the ozone group and two secondary caries in the control group)	All subjects enrolled in the study received preventive advice and were given a toothbrush and toothpaste (Natural White; Natural White Inc., UK, 1100 ppm F) Sealant was reapplied if necessary and O_3 application repeated Subjects' attendance to follow-up visits varied. The number of subjects assessed by ECM differed from the number of subjects assessed by DIAGNOdent at follow-up visits

TABLE 21 Characteristics of full-text reports (cont'd)

Author(s)	No. and characteristics of participants and carious lesions	Design	Inclusion criteria	Interventions	Results	Notes and caveats
				Assessors/operators: three operators were reported to assess radiographs. A single operator assessed the lesions and interpreted ECM and DIAGNOdent findings (L. Abu-Naba'a) Ozone device output: NS	Sealant retention: partial loss in the margins of the sealants in 32.7% in the O_3 + sealant group compared with 29.8% in the sealant-only group ($p > 0.05$) No significant differences in terms of fissure sealant colour and radiographic depth of radiolucency between groups	

TABLE 21 Characteristics of full-text reports (cont'd)

Author(s)	No. and characteristics of participants and carious lesions	Design	Inclusion criteria	Interventions	Results	Notes and caveats
Abu-Naba'a, 2003, pilot study[37,51,52] (Belfast, UK)	*n* = 8 (38 occlusal pit and fissure lesions, 19 in each group)	Design: RCT (unpublished) Unit of randomisation: lesion Method of randomisation: random sampling digit tables Concealment of allocation: NS Blinding: unclear ITT: no Length of follow-up: 1, 3 and 6 months Lost at follow-up: unclear Comparability of groups at baseline: more severe lesions (index score of 3) in the control group Setting: general dental practice	Males and females > 12 years old with primary occlusal pit and fissure carious lesions in at least two teeth of the permanent posterior dentition, which were accessible for the diagnostic procedures	Before treatment all lesions were disclosed and cleaned with an air-abrasive system (PROPHYflex 2, KaVo, Germany) Group 1: application of O₃ + reductant Group 2: reductant only At 3 months group 1 received another application of O₃ Reductant formulation: sodium fluoride (1100 ppm F), xylitol and zinc chloride among other active ingredients Ozone dosage: 40 seconds Caries assessment: ECM (Lode Diagnostics BV, The Netherlands), DIAGNOdent (KaVo, Germany), and clinical criteria (Ekstrand, 1998)[9] Assessors/operators: Unclear. It would seem that a single operator assessed the lesions and interpreted ECM and DIAGNOdent findings (L. Abu-Naba'a) Ozone device output: 33% of the outcome expected	Clinical severity scores: not significant differences between groups at any follow-up visits ($p > 0.05$) ECM and DIAGNOdent readings: no significant differences between groups ($p > 0.05$) *Clinical indices* Hardness index score: 11 lesions in the ozone group became harder compared with four in the control group ($p < 0.05$) Two lesions in the control group became softer Change in the visual index score: eight teeth in the treatment group changed positively at the 6-month follow-up compared with one tooth in the control group ($p < 0.05$) Change in the cavitation score: six teeth had a decreased cavity score in the ozone group compared with five teeth in the control group. The difference between intervention groups was not significant ($p > 0.05$) Change in colour: no significant differences between groups ($p > 0.05$) Change in frosted enamel and undermined enamel: no significant differences between groups ($p > 0.05$)	All subjects enrolled in the study received preventive advice and were given a toothbrush and toothpaste (1100 ppm F)

TABLE 21 Characteristics of full-text reports (cont'd)

Pit and fissure caries: primary dentition

Author(s)	No. and characteristics of participants and carious lesions	Design	Inclusion criteria	Interventions	Results	Notes and caveats
Abu-Salem, 2004[38] (Belfast, UK)	*n* = 21 (74 non-cavitated occlusal carious lesions in primary molars) Age range: 7–9 years (7 years 28%, 8 years 48%, 9 years 24%) Gender (M/F): 9/21 Caries risk assessment: NS	Design: RCT (unpublished) Unit of randomisation: lesion Method of randomisation: computer-generated random tables Concealment of allocation: NS Blinding: examiner blinded to results of previous tests and outcomes of previous records ITT: no Length of follow-up: 3, 6, 9 and 12 months Lost at follow-up: four subjects (16 lesions) Comparability of groups at baseline: there was a significant difference in mean DIAGNOdent scores at baseline ($p < 0.01$). Lesions in ozone group appeared to be more severe than those in the control group. Setting: general dental practice	Children 7–9 years old with at least two carious lesions in the posterior primary teeth and absence of occlusal restoration, fissure sealants, hypoplastic pits and fractures extending into dentine or cavitations resulting from carious attack on the occlusal surface	Before treatment, teeth were cleaned using the PROPHYflex-2 system for 5 seconds Group 1: O_3 + reductant Group 2: reductant only Reductant formulation: sodium benzoate (1100 ppm F), xylitol, zinc chloride and sodium citrate among other active ingredients Ozone dosage: 10 seconds Caries assessment: ECM (Lode Diagnostics BV, The Netherlands), DIAGNOdent (KaVo, Germany) and clinical criteria (Ekstrand, 1998)[9]	12-month follow-up Clinical severity scores: overall there was a little reduction in clinical severity scores in the ozone group and an increase in scores in the control group. There was a significant effect of treatment on clinical severity scores over time (mixed models ANOVA $p < 0.01$) Log ECM and DIAGNOdent readings: there was a significant effect of time and treatment on the mean $\log_e$ ECM readings ($p < 0.001$) and the mean DIAGNOdent readings ($p < 0.001$). There was also an overall significant effect of time and treatment on ECM scores ($p < 0.001$) and an overall increase in the DIAGNOdent scores in the control group compared with the ozone group ($p < 0.05$)	All subjects received preventive advice and were given a toothbrush (Brilliant, soft toothbrush; Brilliant Products, UK) and toothpaste (Natural White, Natural White Inc., UK 1100 ppm F) at each recall to be used throughout the study The mean $\log_e$ ECM readings, mean DIAGNOdent readings, ECM scores, DIAGNOdent scores and clinical severity index were analysed using ANOVA (mixed effect model) Results reported in a format that did not allow any further analysis

NS, not stated; ITT, intention-to-treat; O_3, ozone gas.

Appendix 5

Characteristics of included studies:

abstracts

72

TABLE 22 Characteristics of abstracts

Author(s)	No. of participants (no. and type of lesions)	Design	Inclusion criteria	Interventions	Results	Notes
Root caries						
Lynch et al., 2004[57] (Belfast, UK)	260 (two PRCLs: 60 subjects with two soft PRCLs and 200 with two leathery non-cavitated PRCLs, least severe category)	Design: RCT Unit of randomisation: lesion Concealment of allocation: NS Blinding: blinded outcome assessor ITT: no Length of follow-up: 6 months Lost at follow-up: NS Setting: NS	Two primary root carious lesions	Group 1: O$_3$ (260 lesions) Group 2: no treatment (260 lesions) Ozone dosage: NS Caries assessment: clinical assessment	Reversal of caries: *Soft lesions*: at 6 months, 48/60 of ozone-treated soft PRCLs had reversed (from index 4 to 3), no significant changes in control soft lesions ($p < 0.01$) *Leathery lesions*: 189/200 of ozone-treated PRCLs had reversed from index 1 to 0 (hard to arrested), no significant changes for control lesions ($p < 0.01$) Adverse events: none observed	
Pit and fissure caries						
Holmes and Lynch, 2004[53] (Belfast, UK)	38 (76 non-cavitated occlusal caries lesions)	Design: RCT Unit of randomisation: lesion Concealment of allocation: NS Blinding: NS ITT: no Length of follow-up: 6 months Lost at follow-up: three subjects Setting: general dental practice	Two non-cavitated early occlusal carious lesions with radiographic radiolucencies extending 2–4 mm into dentine	Group 1: air abrasion + O$_3$ + mineral wash + glass ionomer sealant. After 3 months the glass ionomer sealant was dissected and replaced with a posterior composite Group 2: conventional drilling and filling using posterior composite Ozone dosage: 40 seconds Caries assessment: radiographic and clinical assessment	No post-operative sensitivity was associated with ozone treatment, while 6/35 subjects in the conventional treatment group complained of some post-operative sensitivity Reversal of caries: at 3 months all ozone dentine caries was hard and required no additional removal Adverse events: none observed	Progression of caries in the conventional treatment group not reported 'Sensitivity' is a measure used to assess large necrotic lesions and it is considered inappropriate for assessing early carious lesions

TABLE 22 *Characteristics of abstracts (cont'd)*

Author(s)	No. of participants (no. and type of lesions)	Design	Inclusion criteria	Interventions	Results	Notes
Holmes, 2003[54] (Berkshire, UK)	376 (2364 primary non-cavitated occlusal fissure lesions)	Design: RCT Unit of randomisation: lesion Concealment of allocation: NS Blinding: NS ITT: no Length of follow-up: 12 months Lost at follow-up: 61 Setting: general dental practice	Primary occlusal fissure lesions with caries judged to extend 2 mm into dentine (1170 teeth)	Group 1: O_3 treatment Group 2: no treatment Ozone dosage: 10, 20, 30 or 40 seconds depending on the clinical severity. Applications were repeated every 3 months if reversal had not occurred Caries assessment: DIAGNOdent (KaVo, Germany) and clinical assessment	Reversal of caries: 99% in the ozone group (1918 lesions); the control lesions did not change significantly The DIAGNOdent values correlated with the clinical findings ($p < 0.01$) Adverse events: none observed	A total of 1937/2364 received ozone application. Unclear how many lesions were randomly allocated to each group (unbalanced randomisation?)
Hamid, 2003[55] (London, UK)	184 (184 non-cavitated pit and fissure carious lesions)	Design: RCT Unit of randomisation: patient Concealment of allocation: NS Blinding: NS ITT: unclear Length of follow-up: 6 months Lost at follow-up: unclear Setting: NS	Primary early occlusal pit/fissure lesions with caries extending up to 1 mm into dentine	Group 1: O_3 treatment (92 lesions) Group 2: no treatment (92 lesions) Ozone dosage: 40 seconds at baseline and at 3 months Caries assessment: clinical assessment and DIAGNOdent (KaVo, Germany)	Reversal of caries: 86.6% in the ozone group; the control lesions did not change significantly ($p < 0.05$) The DIAGNOdent values correlated with the clinical findings Adverse events: none observed	

TABLE 22 Characteristics of abstracts (cont'd)

Author(s)	No. of participants (no. and type of lesions)	Design	Inclusion criteria	Interventions	Results	Notes
Megighian and Bertolini, 2004[56] (Verona, Italy)	80 (300 pit and fissure carious lesions)	Design: randomised clinical trial Unit of randomisation: lesion Concealment of allocation: NS Blinding: double blind ITT: no Length of follow-up: 6 months Lost at follow-up: NS Setting: private practice, Italy	Pit and fissure carious lesions	Group 1: O_3 (220 lesions) Group 2: no treatment (80 lesions) Ozone dosage: 20, 30 or 40 seconds according to clinical severity Caries assessment: clinical assessment and DIAGNOdent (KaVo, Germany)	Reversal of caries: ozone-treated lesions clinically reversed ($p < 0.05$), while control lesions did not DIAGNOdent: significant overall reduction in readings for ozone-treated lesions, while control lesions showed an increase in DIAGNOdent readings 85% of teeth clinically reversed and showed a DIAGNOdent reduction	Unclear whether the proportion of lesions that clinically reversed or showed a reduction in DIAGNOdent readings were all ozone-treated lesions or included some control lesions

Appendix 6

Structure of the economic model

Decision models to assess costs and benefits of HealOzone

The four models depicted in *Figures 15–18* have a similar structure; therefore, only current management plus HealOzone is described here. Markov models can be used to estimate costs and consequences that occur over a series of years (in this study up to 5 years). At the beginning of the first year each patient receives current management plus HealOzone and hence a probability of 1 is attached. At the end of the first year there is a chance that the patients are cured (caries are reversed) or they have progressed. If

FIGURE 15 *Decision model to assess the cost and benefits of current management plus HealOzone of non-cavitated root caries (Markov model)*

FIGURE 16 *Decision model to assess the costs and benefits of current management of non-cavitated root caries*

FIGURE 17 *Decision model to assess the costs and benefits of current management of non-cavitated pit and fissure caries*

FIGURE 18 *Decision model to assess the costs and benefits of current management plus HealOzone of non-cavitated pit and fissure caries*

they have progressed there is a chance that they receive the same treatment or a new treatment (filling). The chance of a patient being cured is 'pbcure1' and not being cured is '1-pbcure1'. The chance that a patient will receive the same treatment is 'probretreat'. In the model it is assumed that the patient has a 50% chance of receiving the same treatment or having a filling. If the first treatment fails the patient moves to the third branch or the fifth branch. The probability

of cure does not change in the third branch and those who go into the third branch are either cured or filled. The filled tooth state is a terminal state and patients do not leave it. The model also assumes that when a patient is cured they remain cured for as long as the model runs.

Details of cost calculations are shown in *Tables 23–30*.

TABLE 23 *Annual treatment numbers for non-cavitated caries based on each relevant SDR code by age group for year ending March 2003*[65]

	SDR code	Treatment numbers	No. of caries types	No. of teeth	Total teeth treated
Age <18 years					
Non-cavitated pit and fissure caries	601	3,930	2	1	1,965
	3631	2,393	2	1	1,196.5
	701	73	1	1	73
Total					3,234.5
Non-cavitated root caries	601	3,930	2	1	1,965
	3631	2,393	2	1	1,196.5
Total					3,161.5
Age ≥18 years					
Non-cavitated pit and fissure caries	601	11,728	2	1	5,864
	3631	669,304	2	1	334,652
	701	1,922	1	1	1,922
Total					342,438
Non-cavitated root caries	601	11,728	2	1	5,864
	3631	669,304	2	1	334,652
Total					340,516

Where one SDR code was relevant to more than one type of caries the published treatment numbers were divided by the number of relevant types of caries. Similar adjustments were provided for the numbers of teeth to which any one SDR code applied.

TABLE 24 *Percentage teeth treated by age group of patient, based on numbers in Table 23*

	SDR code	<18 years (%)	≥18 years (%)
Non-cavitated pit and fissure caries	601	25.1	74.9
	3631	0.4	99.6
	701	3.7	96.3
Non-cavitated root caries	601	25.1	74.9
	3631	0.4	99.6

TABLE 25 *Calculation for cost to NHS based on 100% treatment items paid for those <18 years and 40% all treatment items paid for those ≥18 years*

	SDR code	<18 years	≥18 years	Unit cost (£)	NHS cost (£)		Weighted average NHS fee across all age (£)
					<18 years	≥18 years	
Non-cavitated pit and fissure caries	601	25.1%	74.9%	7.70	7.70	3.08	4.24
	3631	0.4%	99.6%	4.60	4.60	1.84	1.85
	701	3.7%	96.3%	6.95	6.95	2.78	2.93
	Total				19.25	7.70	9.02
Non-cavitated root caries	601	25.1%	74.9%	7.70	7.70	3.08	4.24
	3631	0.4%	99.6%	4.60	4.60	1.84	1.85
	Total				12.30	4.92	6.09

TABLE 26 *Cost calculations for treatment of cavitated caries*

	SDR code	Total annual treatment numbers	Annual treatment numbers	No. of caries types	No. of teeth	Total teeth treated
Age <18 years						
Cavitated pit and fissure caries	1441		1,025,404	1	1	
	1442		201,308	1	1	201,308
	1443		163,379	1	1	163,379
Anterior teeth	1401[a]	557,753	278,876.5	1	1	278,876.5
Posterior teeth	1421[a]	386,061	193,030.5	1	1	193,030.5
	1421[a]	35,681	17,840.5	1	2	35,681
Age ≥18 years						
Cavitated pit and fissure caries	1441		147,980	1	1	147,980
	1442		86,667	1	1	86,667
	1443		68,353	1	1	68,353
	1401[a]	1,671,224	835,612	1	1	835,612
	1421[a]	4,141,954	2,070,977	1	1	2,070,977
	1421[a]	346,816	173,408	1	2	346,816

Figures assume a treatment mix of SDR codes 1441, 1442 and 1443 plus either 1401 or 1421. All patients also receive SDR code 0101 (initial dental assessment).
It is also assumed that 50% of treatments are for anterior and 50% for posterior teeth.
[a] 50% mix assumed.

TABLE 27 *Steps used to calculate the mean cost of a filling when different proportions of children and adults receive different treatment mixes by SDR code*

	% treatment for cavitated caries (fillings)			NHS cost (£)			
SDR code	<18 years	≥18 years	Unit cost (£)	<18 years	≥18 years	Weighted average NHS fee across all age (£)
1441	87.4	12.6	6.95	6.95	2.78	6.42
1442	69.9	30.1	9.80	9.80	3.92	8.03
1443	70.5	29.5	10.55	10.55	4.22	8.68
1401[a]	25.0	75.0	7.50	7.50	3.00	4.13
1421[a]	8.5	91.5	14.15	14.15	5.66	6.38
1421[a]	9.3	90.6	14.15	14.15	5.66	6.45
			63.10	63.10	25.24	40.10
Overall % mix children/adults for fillings and mean cost per filling	45.1	54.9	12.62	12.62	5.05	8.02
Initial dental assessment 101	100	100	7.05	7.05	2.82	4.73
Total average cost per filling visit			19.67		7.87	12.75

[a] 50% mix assumed.

TABLE 28 *HealOzone cost calculations*

1st year initial treatment option	Unit cost (£)	Cost to NHS (£)		% who have caries treatment[a]		Weighted average cost to NHS (£)
		<18 years	≥18 years	<18 years	≥18 years	
Non-cavitated pit and fissure caries						
Current[b]	19.25	19.25	7.70			9.02
HealOzone	20.00	20.00	8.00	25.1	74.9	11.01
Current + HealOzone		39.25	15.70			20.03
Non-cavitated root caries						
Current[b]	12.30	12.30	4.92			6.09
HealOzone	20.00	20.00	8.00	25.1	74.9	11.01
Current + HealOzone		32.30	12.92			17.10

[a] Non-cavitated pit and fissure caries treatment or non-cavitated root caries treatment (see *Table 25*).
[b] See *Tables 24* and *25*.

Non-cavitated pit and fissure caries

The combined cost of HealOzone and current management is £40.49 and the cost of current management alone is £24.78.

TABLE 29 *Results of one-way sensitivity analysis for non-cavitated pit fissure caries (current management versus current management and HealOzone) holding 'current management plus HealOzone' cost constant*

Probability	Proportion cured	Proportion filled	Current management	HealOzone	Additional cost of HealOzone
0	0	1	£26.06	£40.49	£14.43
0.1	0.015	0.985	£23.81	£40.49	£16.68
0.2	0.145	0.855	£21.67	£40.49	£18.82
0.3	0.28	0.72	£19.66	£40.49	£20.83
0.4	0.405	0.595	£17.77	£40.49	£22.72
0.5	0.52	0.48	£16.00	£40.49	£24.49
0.6	0.625	0.375	£14.36	£40.49	£26.13
0.7	0.72	0.28	£12.84	£40.49	£27.65
0.8	0.805	0.195	£11.44	£40.49	£29.05
0.9	0.88	0.12	£10.17	£40.49	£30.32
1	1	0	£9.02	£40.49	£31.47

TABLE 30 *Results of one-way sensitivity analysis for non-cavitated pit fissure caries (current management versus current management and HealOzone) holding current management cost constant*

Probability	Proportion cured	Proportion filled	Current management	HealOzone	Additional cost of HealOzone
0	0	1	£24.78	£42.58	£17.80
0.1	0.015	0.985	£24.78	£39.77	£14.99
0.2	0.145	0.855	£24.78	£37.08	£12.30
0.3	0.28	0.72	£24.78	£34.52	£9.74
0.4	0.405	0.595	£24.78	£32.08	£7.30
0.5	0.52	0.48	£24.78	£29.76	£4.98
0.6	0.625	0.375	£24.78	£27.57	£2.79
0.7	0.72	0.28	£24.78	£25.50	£0.72
0.8	0.805	0.195	£24.78	£23.55	–£1.23
0.9	0.88	0.12	£24.78	£21.73	–£3.05
1	1	0	£24.78	£20.03	–£4.75

Non-cavitated root caries

The combined cost of HealOzone and current management is £14.63 and the cost of current management alone is £21.45 (*Tables 31* and *32*).

TABLE 31 *Results of one-way sensitivity analysis for non-cavitated root caries (current management versus current management and HealOzone) holding current management cost constant*

Probability	Proportion cured	Proportion filled	Current management	HealOzone	Additional cost of HealOzone
0	0	1	£21.45	£38.18	£16.73
0.1	0.145	0.855	£21.45	£35.52	£14.07
0.2	0.28	0.72	£21.45	£32.98	£11.53
0.3	0.405	0.595	£21.45	£30.57	£9.12
0.4	0.52	0.48	£21.45	£28.27	£6.82
0.5	0.625	0.375	£21.45	£26.10	£4.65
0.6	0.72	0.28	£21.45	£24.06	£2.61
0.7	0.805	0.195	£21.45	£22.13	£0.68
0.8	0.88	0.12	£21.45	£20.33	–£1.12
0.9	0.945	0.055	£21.45	£18.65	–£2.80
1	1	0	£21.45	£17.10	–£4.35

TABLE 32 *Results of one-way sensitivity analysis for non-cavitated root caries (current management versus current management and HealOzone) holding 'current management plus HealOzone' cost constant*

Probability	Proportion cured	Proportion filled	Current management	HealOzone	Additional cost of HealOzone
0	0	1	£21.67	£14.63	–£7.04
0.1	0.145	0.855	£19.56	£14.63	–£4.93
0.2	0.28	0.72	£17.57	£14.63	–£2.94
0.3	0.405	0.595	£15.70	£14.63	–£1.07
0.4	0.52	0.48	£13.96	£14.63	£0.67
0.5	0.625	0.375	£12.34	£14.63	£2.29
0.6	0.72	0.28	£10.84	£14.63	£3.79
0.7	0.805	0.195	£9.47	£14.63	£5.16
0.8	0.88	0.12	£8.22	£14.63	£6.41
0.9	0.945	0.055	£7.09	£14.63	£7.54
1	1	0	£6.09	£14.63	£8.54

Health Technology Assessment reports published to date

Volume 1, 1997

No. 1
Home parenteral nutrition: a systematic review.
By Richards DM, Deeks JJ, Sheldon TA, Shaffer JL.

No. 2
Diagnosis, management and screening of early localised prostate cancer.
A review by Selley S, Donovan J, Faulkner A, Coast J, Gillatt D.

No. 3
The diagnosis, management, treatment and costs of prostate cancer in England and Wales.
A review by Chamberlain J, Melia J, Moss S, Brown J.

No. 4
Screening for fragile X syndrome.
A review by Murray J, Cuckle H, Taylor G, Hewison J.

No. 5
A review of near patient testing in primary care.
By Hobbs FDR, Delaney BC, Fitzmaurice DA, Wilson S, Hyde CJ, Thorpe GH, *et al*.

No. 6
Systematic review of outpatient services for chronic pain control.
By McQuay HJ, Moore RA, Eccleston C, Morley S, de C Williams AC.

No. 7
Neonatal screening for inborn errors of metabolism: cost, yield and outcome.
A review by Pollitt RJ, Green A, McCabe CJ, Booth A, Cooper NJ, Leonard JV, *et al*.

No. 8
Preschool vision screening.
A review by Snowdon SK, Stewart-Brown SL.

No. 9
Implications of socio-cultural contexts for the ethics of clinical trials.
A review by Ashcroft RE, Chadwick DW, Clark SRL, Edwards RHT, Frith L, Hutton JL.

No. 10
A critical review of the role of neonatal hearing screening in the detection of congenital hearing impairment.
By Davis A, Bamford J, Wilson I, Ramkalawan T, Forshaw M, Wright S.

No. 11
Newborn screening for inborn errors of metabolism: a systematic review.
By Seymour CA, Thomason MJ, Chalmers RA, Addison GM, Bain MD, Cockburn F, *et al*.

No. 12
Routine preoperative testing: a systematic review of the evidence.
By Munro J, Booth A, Nicholl J.

No. 13
Systematic review of the effectiveness of laxatives in the elderly.
By Petticrew M, Watt I, Sheldon T.

No. 14
When and how to assess fast-changing technologies: a comparative study of medical applications of four generic technologies.
A review by Mowatt G, Bower DJ, Brebner JA, Cairns JA, Grant AM, McKee L.

Volume 2, 1998

No. 1
Antenatal screening for Down's syndrome.
A review by Wald NJ, Kennard A, Hackshaw A, McGuire A.

No. 2
Screening for ovarian cancer: a systematic review.
By Bell R, Petticrew M, Luengo S, Sheldon TA.

No. 3
Consensus development methods, and their use in clinical guideline development.
A review by Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CFB, Askham J, *et al*.

No. 4
A cost–utility analysis of interferon beta for multiple sclerosis.
By Parkin D, McNamee P, Jacoby A, Miller P, Thomas S, Bates D.

No. 5
Effectiveness and efficiency of methods of dialysis therapy for end-stage renal disease: systematic reviews.
By MacLeod A, Grant A, Donaldson C, Khan I, Campbell M, Daly C, *et al*.

No. 6
Effectiveness of hip prostheses in primary total hip replacement: a critical review of evidence and an economic model.
By Faulkner A, Kennedy LG, Baxter K, Donovan J, Wilkinson M, Bevan G.

No. 7
Antimicrobial prophylaxis in colorectal surgery: a systematic review of randomised controlled trials.
By Song F, Glenny AM.

No. 8
Bone marrow and peripheral blood stem cell transplantation for malignancy.
A review by Johnson PWM, Simnett SJ, Sweetenham JW, Morgan GJ, Stewart LA.

No. 9
Screening for speech and language delay: a systematic review of the literature.
By Law J, Boyle J, Harris F, Harkness A, Nye C.

No. 10
Resource allocation for chronic stable angina: a systematic review of effectiveness, costs and cost-effectiveness of alternative interventions.
By Sculpher MJ, Petticrew M, Kelland JL, Elliott RA, Holdright DR, Buxton MJ.

No. 11
Detection, adherence and control of hypertension for the prevention of stroke: a systematic review.
By Ebrahim S.

No. 12
Postoperative analgesia and vomiting, with special reference to day-case surgery: a systematic review.
By McQuay HJ, Moore RA.

No. 13
Choosing between randomised and nonrandomised studies: a systematic review.
By Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C.

No. 14
Evaluating patient-based outcome measures for use in clinical trials.
A review by Fitzpatrick R, Davey C, Buxton MJ, Jones DR.

No. 15
Ethical issues in the design and conduct of randomised controlled trials.
A review by Edwards SJL, Lilford RJ, Braunholtz DA, Jackson JC, Hewison J, Thornton J.

No. 16
Qualitative research methods in health technology assessment: a review of the literature.
By Murphy E, Dingwall R, Greatbatch D, Parker S, Watson P.

No. 17
The costs and benefits of paramedic skills in pre-hospital trauma care.
By Nicholl J, Hughes S, Dixon S, Turner J, Yates D.

No. 18
Systematic review of endoscopic ultrasound in gastro-oesophageal cancer.
By Harris KM, Kelly S, Berry E, Hutton J, Roderick P, Cullingworth J, *et al*.

No. 19
Systematic reviews of trials and other studies.
By Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F.

No. 20
Primary total hip replacement surgery: a systematic review of outcomes and modelling of cost-effectiveness associated with different prostheses.
A review by Fitzpatrick R, Shortall E, Sculpher M, Murray D, Morris R, Lodge M, *et al*.

Volume 3, 1999

No. 1
Informed decision making: an annotated bibliography and systematic review.
By Bekker H, Thornton JG, Airey CM, Connelly JB, Hewison J, Robinson MB, *et al*.

No. 2
Handling uncertainty when performing economic evaluation of healthcare interventions.
A review by Briggs AH, Gray AM.

No. 3
The role of expectancies in the placebo effect and their use in the delivery of health care: a systematic review.
By Crow R, Gage H, Hampson S, Hart J, Kimber A, Thomas H.

No. 4
A randomised controlled trial of different approaches to universal antenatal HIV testing: uptake and acceptability. Annex: Antenatal HIV testing – assessment of a routine voluntary approach.
By Simpson WM, Johnstone FD, Boyd FM, Goldberg DJ, Hart GJ, Gormley SM, *et al*.

No. 5
Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review.
By Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ.

No. 6
Assessing the costs of healthcare technologies in clinical trials.
A review by Johnston K, Buxton MJ, Jones DR, Fitzpatrick R.

No. 7
Cooperatives and their primary care emergency centres: organisation and impact.
By Hallam L, Henthorne K.

No. 8
Screening for cystic fibrosis.
A review by Murray J, Cuckle H, Taylor G, Littlewood J, Hewison J.

No. 9
A review of the use of health status measures in economic evaluation.
By Brazier J, Deverill M, Green C, Harper R, Booth A.

No. 10
Methods for the analysis of quality-of-life and survival data in health technology assessment.
A review by Billingham LJ, Abrams KR, Jones DR.

No. 11
Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis.
By Zeuner D, Ades AE, Karnon J, Brown J, Dezateux C, Anionwu EN.

No. 12
Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses.
A review by Moher D, Cook DJ, Jadad AR, Tugwell P, Moher M, Jones A, *et al*.

No. 13
'Early warning systems' for identifying new healthcare technologies.
By Robert G, Stevens A, Gabbay J.

No. 14
A systematic review of the role of human papillomavirus testing within a cervical screening programme.
By Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, *et al*.

No. 15
Near patient testing in diabetes clinics: appraising the costs and outcomes.
By Grieve R, Beech R, Vincent J, Mazurkiewicz J.

No. 16
Positron emission tomography: establishing priorities for health technology assessment.
A review by Robert G, Milne R.

No. 17 (Pt 1)
The debridement of chronic wounds: a systematic review.
By Bradley M, Cullum N, Sheldon T.

No. 17 (Pt 2)
Systematic reviews of wound care management: (2) Dressings and topical agents used in the healing of chronic wounds.
By Bradley M, Cullum N, Nelson EA, Petticrew M, Sheldon T, Torgerson D.

No. 18
A systematic literature review of spiral and electron beam computed tomography: with particular reference to clinical applications in hepatic lesions, pulmonary embolus and coronary artery disease.
By Berry E, Kelly S, Hutton J, Harris KM, Roderick P, Boyce JC, *et al*.

No. 19
What role for statins? A review and economic model.
By Ebrahim S, Davey Smith G, McCabe C, Payne N, Pickin M, Sheldon TA, *et al*.

No. 20
Factors that limit the quality, number and progress of randomised controlled trials.
A review by Prescott RJ, Counsell CE, Gillespie WJ, Grant AM, Russell IT, Kiauka S, *et al*.

No. 21
Antimicrobial prophylaxis in total hip replacement: a systematic review.
By Glenny AM, Song F.

No. 22
Health promoting schools and health promotion in schools: two systematic reviews.
By Lister-Sharp D, Chapman S, Stewart-Brown S, Sowden A.

No. 23
Economic evaluation of a primary care-based education programme for patients with osteoarthritis of the knee.
A review by Lord J, Victor C, Littlejohns P, Ross FM, Axford JS.

Volume 4, 2000

No. 1
The estimation of marginal time preference in a UK-wide sample (TEMPUS) project.
A review by Cairns JA, van der Pol MM.

No. 2
Geriatric rehabilitation following fractures in older people: a systematic review.
By Cameron I, Crotty M, Currie C, Finnegan T, Gillespie L, Gillespie W, *et al*.

No. 3
Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research.
By Davies SC, Cronin E, Gill M, Greengross P, Hickman M, Normand C.

No. 4
Community provision of hearing aids and related audiology services.
A review by Reeves DJ, Alborz A, Hickson FS, Bamford JM.

No. 5
False-negative results in screening programmes: systematic review of impact and implications.
By Petticrew MP, Sowden AJ, Lister-Sharp D, Wright K.

No. 6
Costs and benefits of community postnatal support workers: a randomised controlled trial.
By Morrell CJ, Spiby H, Stewart P, Walters S, Morgan A.

No. 7
Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraceptives: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness.
By French RS, Cowan FM, Mansour DJA, Morris S, Procter T, Hughes D, *et al*.

No. 8
An introduction to statistical methods for health technology assessment.
A review by White SJ, Ashby D, Brown PJ.

No. 9
Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
By Clegg A, Bryant J, Milne R.

No. 10
Publication and related biases.
A review by Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ.

No. 11
Cost and outcome implications of the organisation of vascular services.
By Michaels J, Brazier J, Palfreyman S, Shackley P, Slack R.

No. 12
Monitoring blood glucose control in diabetes mellitus: a systematic review.
By Coster S, Gulliford MC, Seed PT, Powrie JK, Swaminathan R.

No. 13
The effectiveness of domiciliary health visiting: a systematic review of international studies
and a selective review of the British literature.
By Elkan R, Kendrick D, Hewitt M, Robinson JJA, Tolley K, Blair M, *et al*.

No. 14
The determinants of screening uptake and interventions for increasing uptake: a systematic review.
By Jepson R, Clegg A, Forbes C, Lewis R, Sowden A, Kleijnen J.

No. 15
The effectiveness and cost-effectiveness of prophylactic removal of wisdom teeth.

A rapid review by Song F, O'Meara S, Wilson P, Golder S, Kleijnen J.

No. 16
Ultrasound screening in pregnancy: a systematic review of the clinical effectiveness, cost-effectiveness and women's views.
By Bricker L, Garcia J, Henderson J, Mugford M, Neilson J, Roberts T, *et al*.

No. 17
A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
By Lister-Sharp D, McDonagh MS, Khan KS, Kleijnen J.

No. 18
Liquid-based cytology in cervical screening: a rapid and systematic review.
By Payne N, Chilcott J, McGoogan E.

No. 19
Randomised controlled trial of non-directive counselling, cognitive–behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care.
By King M, Sibbald B, Ward E, Bower P, Lloyd M, Gabbay M, *et al*.

No. 20
Routine referral for radiography of patients presenting with low back pain: is patients' outcome influenced by GPs' referral for plain radiography?
By Kerry S, Hilton S, Patel S, Dundas D, Rink E, Lord J.

No. 21
Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration.
By O'Meara S, Cullum N, Majid M, Sheldon T.

No. 22
Using routine data to complement and enhance the results of randomised controlled trials.
By Lewsey JD, Leyland AH, Murray GD, Boddy FA.

No. 23
Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review.
By Meads C, Cummins C, Jolly K, Stevens A, Burls A, Hyde C.

No. 24
Outcome measures for adult critical care: a systematic review.
By Hayes JA, Black NA, Jenkinson C, Young JD, Rowan KM, Daly K, *et al*.

No. 25
A systematic review to evaluate the effectiveness of interventions to promote the initiation of breastfeeding.
By Fairbank L, O'Meara S, Renfrew MJ, Woolridge M, Sowden AJ, Lister-Sharp D.

No. 26
Implantable cardioverter defibrillators: arrhythmias. A rapid and systematic review.
By Parkes J, Bryant J, Milne R.

No. 27
Treatments for fatigue in multiple sclerosis: a rapid and systematic review.
By Brañas P, Jordan R, Fry-Smith A, Burls A, Hyde C.

No. 28
Early asthma prophylaxis, natural history, skeletal development and economy (EASE): a pilot randomised controlled trial.
By Baxter-Jones ADG, Helms PJ, Russell G, Grant A, Ross S, Cairns JA, *et al*.

No. 29
Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
By Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HAW.

No. 30
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina.
By McDonagh MS, Bachmann LM, Golder S, Kleijnen J, ter Riet G.

No. 31
A randomised controlled trial of prehospital intravenous fluid replacement therapy in serious trauma.
By Turner J, Nicholl J, Webber L, Cox H, Dixon S, Yates D.

No. 32
Intrathecal pumps for giving opioids in chronic pain: a systematic review.
By Williams JE, Louw G, Towlerton G.

No. 33
Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.
By Shepherd J, Waugh N, Hewitson P.

83

No. 34
A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies.
By MacLehose RR, Reeves BC, Harvey IM, Sheldon TA, Russell IT, Black AMS.

No. 35
Intravascular ultrasound-guided interventions in coronary artery disease: a systematic literature review, with decision-analytic modelling, of outcomes and cost-effectiveness.
By Berry E, Kelly S, Hutton J, Lindsay HSJ, Blaxill JM, Evans JA, *et al*.

No. 36
A randomised controlled trial to evaluate the effectiveness and cost-effectiveness of counselling patients with chronic depression.
By Simpson S, Corney R, Fitzgerald P, Beecham J.

No. 37
Systematic review of treatments for atopic eczema.
By Hoare C, Li Wan Po A, Williams H.

No. 38
Bayesian methods in health technology assessment: a review.
By Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR.

No. 39
The management of dyspepsia: a systematic review.
By Delaney B, Moayyedi P, Deeks J, Innes M, Soo S, Barton P, *et al*.

No. 40
A systematic review of treatments for severe psoriasis.
By Griffiths CEM, Clark CM, Chalmers RJG, Li Wan Po A, Williams HC.

Volume 5, 2001

No. 1
Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
By Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, *et al*.

No. 2
The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review.
By Stewart A, Sandercock J, Bryan S, Hyde C, Barton PM, Fry-Smith A, *et al*.

No. 3
Equity and the economic evaluation of healthcare.
By Sassi F, Archard L, Le Grand J.

No. 4
Quality-of-life measures in chronic diseases of childhood.
By Eiser C, Morse R.

No. 5
Eliciting public preferences for healthcare: a systematic review of techniques.
By Ryan M, Scott DA, Reeves C, Bate A, van Teijlingen ER, Russell EM, *et al*.

No. 6
General health status measures for people with cognitive impairment: learning disability and acquired brain injury.
By Riemsma RP, Forbes CA, Glanville JM, Eastwood AJ, Kleijnen J.

No. 7
An assessment of screening strategies for fragile X syndrome in the UK.
By Pembrey ME, Barnicoat AJ, Carmichael B, Bobrow M, Turner G.

No. 8
Issues in methodological research: perspectives from researchers and commissioners.
By Lilford RJ, Richardson A, Stevens A, Fitzpatrick R, Edwards S, Rock F, *et al*.

No. 9
Systematic reviews of wound care management: (5) beds; (6) compression; (7) laser therapy, therapeutic ultrasound, electrotherapy and electromagnetic therapy.
By Cullum N, Nelson EA, Flemming K, Sheldon T.

No. 10
Effects of educational and psychosocial interventions for adolescents with diabetes mellitus: a systematic review.
By Hampson SE, Skinner TC, Hart J, Storey L, Gage H, Foxcroft D, *et al*.

No. 11
Effectiveness of autologous chondrocyte transplantation for hyaline cartilage defects in knees: a rapid and systematic review.
By Jobanputra P, Parry D, Fry-Smith A, Burls A.

No. 12
Statistical assessment of the learning curves of health technologies.
By Ramsay CR, Grant AM, Wallace SA, Garthwaite PH, Monk AF, Russell IT.

No. 13
The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review.
By Dinnes J, Cave C, Huang S, Major K, Milne R.

No. 14
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of debriding agents in treating surgical wounds healing by secondary intention.
By Lewis R, Whiting P, ter Riet G, O'Meara S, Glanville J.

No. 15
Home treatment for mental health problems: a systematic review.
By Burns T, Knapp M, Catty J, Healey A, Henderson J, Watt H, *et al*.

No. 16
How to develop cost-conscious guidelines.
By Eccles M, Mason J.

No. 17
The role of specialist nurses in multiple sclerosis: a rapid and systematic review.
By De Broe S, Christopher F, Waugh N.

No. 18
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.
By O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G.

No. 19
The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review.
By Chilcott J, Wight J, Lloyd Jones M, Tappenden P.

No. 20
Extended scope of nursing practice: a multicentre randomised controlled trial of appropriately trained nurses and preregistration house officers in pre-operative assessment in elective general surgery.
By Kinley H, Czoski-Murray C, George S, McCabe C, Primrose J, Reilly C, *et al*.

No. 21
Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) Acute day hospital versus admission; (2) Vocational rehabilitation; (3) Day hospital versus outpatient care.
By Marshall M, Crowther R, Almaraz-Serrano A, Creed F, Sledge W, Kluiter H, *et al*.

No. 22
The measurement and monitoring of surgical adverse events.
By Bruce J, Russell EM, Mollison J, Krukowski ZH.

No. 23
Action research: a systematic review and guidance for assessment.
By Waterman H, Tillen D, Dickson R, de Koning K.

No. 24
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer.
By Ward S, Morris E, Bansback N, Calvert N, Crellin A, Forman D, *et al*.

No. 25
A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.
By Lloyd Jones M, Hummel S, Bansback N, Orr B, Seymour M.

No. 26
Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
By Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, *et al.*

No. 27
The cost-effectiveness of magnetic resonance imaging for investigation of the knee joint.
By Bryan S, Weatherburn G, Bungay H, Hatrick C, Salas C, Parry D, *et al.*

No. 28
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
By Forbes C, Shirran L, Bagnall A-M, Duffy S, ter Riet G.

No. 29
Superseded by a report published in a later volume.

No. 30
The role of radiography in primary care patients with low back pain of at least 6 weeks duration: a randomised (unblinded) controlled trial.
By Kendrick D, Fielding K, Bentley E, Miller P, Kerslake R, Pringle M.

No. 31
Design and use of questionnaires: a review of best practice applicable to surveys of health service staff and patients.
By McColl E, Jacoby A, Thomas L, Soutter J, Bamford C, Steen N, *et al.*

No. 32
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
By Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N.

No. 33
Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
By Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G.

No. 34
Depot antipsychotic medication in the treatment of patients with schizophrenia: (1) Meta-review; (2) Patient and nurse attitudes.
By David AS, Adams C.

No. 35
A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression.
By Churchill R, Hunot V, Corney R, Knapp M, McGuire H, Tylee A, *et al.*

No. 36
Cost analysis of child health surveillance.
By Sanderson D, Wright D, Acton C, Duree D.

Volume 6, 2002

No. 1
A study of the methods used to select review criteria for clinical audit.
By Hearnshaw H, Harker R, Cheater F, Baker R, Grimshaw G.

No. 2
Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment.
By Hyde C, Wake B, Bryan S, Barton P, Fry-Smith A, Davenport C, *et al.*

No. 3
Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation.
By Wake B, Hyde C, Bryan S, Barton P, Song F, Fry-Smith A, *et al.*

No. 4
A systematic review of discharge arrangements for older people.
By Parker SG, Peet SM, McPherson A, Cannaby AM, Baker R, Wilson A, *et al.*

No. 5
The clinical effectiveness and cost-effectiveness of inhaler devices used in the routine management of chronic asthma in older children: a systematic review and economic evaluation.
By Peters J, Stevenson M, Beverley C, Lim J, Smith S.

No. 6
The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment.
By O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G.

No. 7
The cost-effectiveness of magnetic resonance angiography for carotid artery stenosis and peripheral vascular disease: a systematic review.
By Berry E, Kelly S, Westwood ME, Davies LM, Gough MJ, Bamford JM, *et al.*

No. 8
Promoting physical activity in South Asian Muslim women through 'exercise on prescription'.
By Carroll B, Ali N, Azam N.

No. 9
Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation.
By Burls A, Clark W, Stewart T, Preston C, Bryan S, Jefferson T, *et al.*

No. 10
A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models.
By Richards RG, Sampson FC, Beard SM, Tappenden P.

No. 11
Screening for gestational diabetes: a systematic review and economic evaluation.
By Scott DA, Loveman E, McIntyre L, Waugh N.

No. 12
The clinical effectiveness and cost-effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation.
By Clegg AJ, Colquitt J, Sidhu MK, Royle P, Loveman E, Walker A.

No. 13
The clinical effectiveness of trastuzumab for breast cancer: a systematic review.
By Lewis R, Bagnall A-M, Forbes C, Shirran E, Duffy S, Kleijnen J, *et al.*

No. 14
The clinical effectiveness and cost-effectiveness of vinorelbine for breast cancer: a systematic review and economic evaluation.
By Lewis R, Bagnall A-M, King S, Woolacott N, Forbes C, Shirran L, *et al.*

No. 15
A systematic review of the effectiveness and cost-effectiveness of metal-on-metal hip resurfacing arthroplasty for treatment of hip disease.
By Vale L, Wyness L, McCormack K, McKenzie L, Brazzelli M, Stearns SC.

No. 16
The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation.
By Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ, *et al.*

No. 17
A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept.
By Cummins C, Connock M, Fry-Smith A, Burls A.

No. 18
Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation.
By Bryant J, Cave C, Mihaylova B, Chase D, McIntyre L, Gerard K, *et al.*

No. 19

Clinical effectiveness and cost-effectiveness of growth hormone in adults in relation to impact on quality of life: a systematic review and economic evaluation.

By Bryant J, Loveman E, Chase D, Mihaylova B, Cave C, Gerard K, *et al.*

No. 20

Clinical medication review by a pharmacist of patients on repeat prescriptions in general practice: a randomised controlled trial.

By Zermansky AG, Petty DR, Raynor DK, Lowe CJ, Freementle N, Vail A.

No. 21

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.

By Jobanputra P, Barton P, Bryan S, Burls A.

No. 22

A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety.

By Kaltenthaler E, Shackley P, Stevens K, Beverley C, Parry G, Chilcott J.

No. 23

A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer.

By Forbes C, Wilby J, Richardson G, Sculpher M, Mather L, Reimsma R.

No. 24

A systematic review of the effectiveness of interventions based on a stages-of-change approach to promote individual behaviour change.

By Riemsma RP, Pattenden J, Bridle C, Sowden AJ, Mather L, Watt IS, *et al.*

No. 25

A systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists.

By Robinson M, Ginnelly L, Sculpher M, Jones L, Riemsma R, Palmer S, *et al.*

No. 26

A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS.

By Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, *et al.*

No. 27

A randomised controlled crossover trial of nurse practitioner versus doctor-led outpatient care in a bronchiectasis clinic.

By Caine N, Sharples LD, Hollingworth W, French J, Keogan M, Exley A, *et al.*

No. 28

Clinical effectiveness and cost – consequences of selective serotonin reuptake inhibitors in the treatment of sex offenders.

By Adi Y, Ashcroft D, Browne K, Beech A, Fry-Smith A, Hyde C.

No. 29

Treatment of established osteoporosis: a systematic review and cost–utility analysis.

By Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M.

No. 30

Which anaesthetic agents are cost-effective in day surgery? Literature review, national survey of practice and randomised controlled trial.

By Elliott RA Payne K, Moore JK, Davies LM, Harper NJN, St Leger AS, *et al.*

No. 31

Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice.

By Stein K, Dalziel K, Walker A, McIntyre L, Jenkins B, Horne J, *et al.*

No. 32

The measurement of satisfaction with healthcare: implications for practice from a systematic review of the literature.

By Crow R, Gage H, Hampson S, Hart J, Kimber A, Storey L, *et al.*

No. 33

The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.

By Garside R, Round A, Dalziel K, Stein K, Royle R.

No. 34

A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis.

By Suri R, Wallis C, Bush A, Thompson S, Normand C, Flather M, *et al.*

No. 35

A systematic review of the costs and effectiveness of different models of paediatric home care.

By Parker G, Bhakta P, Lovett CA, Paisley S, Olsen R, Turner D, *et al.*

Volume 7, 2003

No. 1

How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study.

By Egger M, Jüni P, Bartlett C, Holenstein F, Sterne J.

No. 2

Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure.

By Mowatt G, Vale L, Perez J, Wyness L, Fraser C, MacLeod A, *et al.*

No. 3

Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease.

By Clark W, Raftery J, Barton P, Song F, Fry-Smith A, Burls A.

No. 4

A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus negative.

By Chilcott J, Lloyd Jones M, Wight J, Forman K, Wray J, Beverley C, *et al.*

No. 5

Systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma.

By Riley RD, Burchill SA, Abrams KR, Heney D, Lambert PC, Jones DR, *et al.*

No. 6

The cost-effectiveness of screening for *Helicobacter pylori* to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model.

By Roderick P, Davies R, Raftery J, Crabbe D, Pearce R, Bhandari P, *et al.*

No. 7

The clinical effectiveness and cost-effectiveness of routine dental checks: a systematic review and economic evaluation.

By Davenport C, Elley K, Salas C, Taylor-Weetman CL, Fry-Smith A, Bryan S, *et al.*

No. 8

A multicentre randomised controlled trial assessing the costs and benefits of using structured information and analysis of women's preferences in the management of menorrhagia.

By Kennedy ADM, Sculpher MJ, Coulter A, Dwyer N, Rees M, Horsley S, *et al.*

No. 9

Clinical effectiveness and cost–utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation.

By Meads C, Salas C, Roberts T, Moore D, Fry-Smith A, Hyde C.

No. 10

Evaluation of molecular tests for prenatal diagnosis of chromosome abnormalities.

By Grimshaw GM, Szczepura A, Hultén M, MacDonald F, Nevin NC, Sutton F, *et al.*

No. 11
First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS).
By Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM.

No. 12
The effectiveness and cost-effectiveness of ultrasound locating devices for central venous access: a systematic review and economic evaluation.
By Calvert N, Hind D, McWilliams RG, Thomas SM, Beverley C, Davidson A.

No. 13
A systematic review of atypical antipsychotics in schizophrenia.
By Bagnall A-M, Jones L, Lewis R, Ginnelly L, Glanville J, Torgerson D, *et al*.

No. 14
Prostate Testing for Cancer and Treatment (ProtecT) feasibility study.
By Donovan J, Hamdy F, Neal D, Peters T, Oliver S, Brindle L, *et al*.

No. 15
Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.
By Boland A, Dundar Y, Bagust A, Haycox A, Hill R, Mujica Mota R, *et al*.

No. 16
Screening for fragile X syndrome: a literature review and modelling.
By Song FJ, Barton P, Sleightholme V, Yao GL, Fry-Smith A.

No. 17
Systematic review of endoscopic sinus surgery for nasal polyps.
By Dalziel K, Stein K, Round A, Garside R, Royle P.

No. 18
Towards efficient guidelines: how to monitor guideline use in primary care.
By Hutchinson A, McIntosh A, Cox S, Gilbert C.

No. 19
Effectiveness and cost-effectiveness of acute hospital-based spinal cord injuries services: systematic review.
By Bagnall A-M, Jones L, Richardson G, Duffy S, Riemsma R.

No. 20
Prioritisation of health technology assessment. The PATHS model: methods and case studies.
By Townsend J, Buxton M, Harper G.

No. 21
Systematic review of the clinical effectiveness and cost-effectiveness of tension-free vaginal tape for treatment of urinary stress incontinence.
By Cody J, Wyness L, Wallace S, Glazener C, Kilonzo M, Stearns S, *et al*.

No. 22
The clinical and cost-effectiveness of patient education models for diabetes: a systematic review and economic evaluation.
By Loveman E, Cave C, Green C, Royle P, Dunn N, Waugh N.

No. 23
The role of modelling in prioritising and planning clinical trials.
By Chilcott J, Brennan A, Booth A, Karnon J, Tappenden P.

No. 24
Cost–benefit evaluation of routine influenza immunisation in people 65–74 years of age.
By Allsup S, Gosney M, Haycox A, Regan M.

No. 25
The clinical and cost-effectiveness of pulsatile machine perfusion versus cold storage of kidneys for transplantation retrieved from heart-beating and non-heart-beating donors.
By Wight J, Chilcott J, Holmes M, Brewer N.

No. 26
Can randomised trials rely on existing electronic data? A feasibility study to explore the value of routine data in health technology assessment.
By Williams JG, Cheung WY, Cohen DR, Hutchings HA, Longo MF, Russell IT.

No. 27
Evaluating non-randomised intervention studies.
By Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, *et al*.

No. 28
A randomised controlled trial to assess the impact of a package comprising a patient-orientated, evidence-based self-help guidebook and patient-centred consultations on disease management and satisfaction in inflammatory bowel disease.
By Kennedy A, Nelson E, Reeves D, Richardson G, Roberts C, Robinson A, *et al*.

No. 29
The effectiveness of diagnostic tests for the assessment of shoulder pain due to soft tissue disorders: a systematic review.
By Dinnes J, Loveman E, McIntyre L, Waugh N.

No. 30
The value of digital imaging in diabetic retinopathy.
By Sharp PF, Olson J, Strachan F, Hipwell J, Ludbrook A, O'Donnell M, *et al*.

No. 31
Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy.
By Law M, Wald N, Morris J.

No. 32
Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
By Ward S, Kaltenthaler E, Cowan J, Brewer N.

No. 33
Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review.
By Hummel S, Paisley S, Morgan A, Currie E, Brewer N.

No. 34
Literature searching for clinical and cost-effectiveness studies used in health technology assessment reports carried out for the National Institute for Clinical Excellence appraisal system.
By Royle P, Waugh N.

No. 35
Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.
By Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K.

No. 36
A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses.
By Boland A, Haycox A, Bagust A, Fitzsimmons L.

No. 37
Redesigning postnatal care: a randomised controlled trial of protocol-based midwifery-led care focused on individual women's physical and psychological health needs.
By MacArthur C, Winter HR, Bick DE, Lilford RJ, Lancashire RJ, Knowles H, *et al*.

No. 38
Estimating implied rates of discount in healthcare decision-making.
By West RR, McNabb R, Thompson AGH, Sheldon TA, Grimley Evans J.

87

No. 39
Systematic review of isolation policies in the hospital management of methicillin-resistant *Staphylococcus aureus*: a review of the literature with epidemiological and economic modelling.
By Cooper BS, Stone SP, Kibbler CC, Cookson BD, Roberts JA, Medley GF, *et al*.

No. 40
Treatments for spasticity and pain in multiple sclerosis: a systematic review.
By Beard S, Hunn A, Wight J.

No. 41
The inclusion of reports of randomised trials published in languages other than English in systematic reviews.
By Moher D, Pham B, Lawson ML, Klassen TP.

No. 42
The impact of screening on future health-promoting behaviours and health beliefs: a systematic review.
By Bankhead CR, Brett J, Bukach C, Webster P, Stewart-Brown S, Munafo M, *et al*.

Volume 8, 2004

No. 1
What is the best imaging strategy for acute stroke?
By Wardlaw JM, Keir SL, Seymour J, Lewis S, Sandercock PAG, Dennis MS, *et al*.

No. 2
Systematic review and modelling of the investigation of acute and chronic chest pain presenting in primary care.
By Mant J, McManus RJ, Oakes RAL, Delaney BC, Barton PM, Deeks JJ, *et al*.

No. 3
The effectiveness and cost-effectiveness of microwave and thermal balloon endometrial ablation for heavy menstrual bleeding: a systematic review and economic modelling.
By Garside R, Stein K, Wyatt K, Round A, Price A.

No. 4
A systematic review of the role of bisphosphonates in metastatic disease.
By Ross JR, Saunders Y, Edmonds PM, Patel S, Wonderling D, Normand C, *et al*.

No. 5
Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda®) for locally advanced and/or metastatic breast cancer.
By Jones L, Hawkins N, Westwood M, Wright K, Richardson G, Riemsma R.

No. 6
Effectiveness and efficiency of guideline dissemination and implementation strategies.
By Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, *et al*.

No. 7
Clinical effectiveness and costs of the Sugarbaker procedure for the treatment of pseudomyxoma peritonei.
By Bryant J, Clegg AJ, Sidhu MK, Brodin H, Royle P, Davidson P.

No. 8
Psychological treatment for insomnia in the regulation of long-term hypnotic drug use.
By Morgan K, Dixon S, Mathers N, Thompson J, Tomeny M.

No. 9
Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome.
By Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ.

No. 10
A systematic review and economic evaluation of magnetic resonance cholangiopancreatography compared with diagnostic endoscopic retrograde cholangiopancreatography.
By Kaltenthaler E, Bravo Vergel Y, Chilcott J, Thomas S, Blakeborough T, Walters SJ, *et al*.

No. 11
The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
By Barton P, Jobanputra P, Wilson J, Bryan S, Burls A.

No. 12
Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review.
By Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S.

No. 13
Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.
By Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J.

No. 14
Routine examination of the newborn: the EMREN study. Evaluation of an extension of the midwife role including a randomised controlled trial of appropriately trained midwives and paediatric senior house officers.
By Townsend J, Wolke D, Hayes J, Davé S, Rogers C, Bloomfield L, *et al*.

No. 15
Involving consumers in research and development agenda setting for the NHS: developing an evidence-based approach.
By Oliver S, Clarke-Jones L, Rees R, Milne R, Buchanan P, Gabbay J, *et al*.

No. 16
A multi-centre randomised controlled trial of minimally invasive direct coronary bypass grafting versus percutaneous transluminal coronary angioplasty with stenting for proximal stenosis of the left anterior descending coronary artery.
By Reeves BC, Angelini GD, Bryan AJ, Taylor FC, Cripps T, Spyt TJ, *et al*.

No. 17
Does early magnetic resonance imaging influence management or improve outcome in patients referred to secondary care with low back pain? A pragmatic randomised controlled trial.
By Gilbert FJ, Grant AM, Gillan MGC, Vale L, Scott NW, Campbell MK, *et al*.

No. 18
The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
By Clark W, Jobanputra P, Barton P, Burls A.

No. 19
A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.
By Bridle C, Palmer S, Bagnall A-M, Darba J, Duffy S, Sculpher M, *et al*.

No. 20
Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.
By Karnon J, Peters J, Platt J, Chilcott J, McGoogan E, Brewer N.

No. 21
Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
By Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, *et al*.

No. 22
Autoantibody testing in children with newly diagnosed type 1 diabetes mellitus.
By Dretzke J, Cummins C, Sandercock J, Fry-Smith A, Barrett T, Burls A.

No. 23
Clinical effectiveness and cost-effectiveness of prehospital intravenous fluids in trauma patients.
By Dretzke J, Sandercock J, Bayliss S, Burls A.

No. 24
Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.
By Dündar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, *et al*.

No. 25
Development and validation of methods for assessing the quality of diagnostic accuracy studies.
By Whiting P, Rutjes AWS, Dinnes J, Reitsma JB, Bossuyt PMM, Kleijnen J.

No. 26
EVALUATE hysterectomy trial: a multicentre randomised trial comparing abdominal, vaginal and laparoscopic methods of hysterectomy.
By Garry R, Fountain J, Brown J, Manca A, Mason S, Sculpher M, *et al*.

No. 27
Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis.
By Tappenden P, Chilcott JB, Eggington S, Oakley J, McCabe C.

No. 28
Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
By Dalziel K, Round A, Stein K, Garside R, Price A.

No. 29
VenUS I: a randomised controlled trial of two types of bandage for treating venous leg ulcers.
By Iglesias C, Nelson EA, Cullum NA, Torgerson DJ on behalf of the VenUS Team.

No. 30
Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction.
By Mowatt G, Vale L, Brazzelli M, Hernandez R, Murray A, Scott N, *et al*.

No. 31
A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme.
By Claxton K, Ginnelly L, Sculpher M, Philips Z, Palmer S.

No. 32
The Social Support and Family Health Study: a randomised controlled trial and economic evaluation of two alternative forms of postnatal support for mothers living in disadvantaged inner-city areas.
By Wiggins M, Oakley A, Roberts I, Turner H, Rajan L, Austerberry H, *et al*.

No. 33
Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review.
By Green JM, Hewison J, Bekker HL, Bryant, Cuckle HS.

No. 34
Evaluation of abnormal uterine bleeding: comparison of three outpatient procedures within cohorts defined by age and menopausal status.
By Critchley HOD, Warner P, Lee AJ, Brechin S, Guise J, Graham B.

No. 35
Coronary artery stents: a rapid systematic review and economic evaluation.
By Hill R, Bagust A, Bakhai A, Dickson R, Dündar Y, Haycox A, *et al*.

No. 36
Review of guidelines for good practice in decision-analytic modelling in health technology assessment.
By Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, *et al*.

No. 37
Rituximab (MabThera®) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
By Knight C, Hind D, Brewer N, Abbott V.

No. 38
Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
By Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, *et al*.

No. 39
Pegylated interferon α-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
By Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

No. 40
Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.
By Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, *et al*.

No. 41
Provision, uptake and cost of cardiac rehabilitation programmes: improving services to under-represented groups.
By Beswick AD, Rees K, Griebsch I, Taylor FC, Burke M, West RR, *et al*.

No. 42
Involving South Asian patients in clinical trials.
By Hussain-Gambles M, Leese B, Atkin K, Brown J, Mason S, Tovey P.

No. 43
Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes.
By Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N.

No. 44
Identification and assessment of ongoing trials in health technology assessment reviews.
By Song FJ, Fry-Smith A, Davenport C, Bayliss S, Adi Y, Wilson JS, *et al*.

No. 45
Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine
By Warren E, Weatherley-Jones E, Chilcott J, Beverley C.

No. 46
Supplementation of a home-based exercise programme with a class-based programme for people with osteoarthritis of the knees: a randomised controlled trial and health economic analysis.
By McCarthy CJ, Mills PM, Pullen R, Richardson G, Hawkins N, Roberts CR, *et al*.

No. 47
Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation.
By Green C, Colquitt JL, Kirby J, Davidson P, Payne E.

No. 48
Acupuncture of chronic headache disorders in primary care: randomised controlled trial and economic analysis.
By Vickers AJ, Rees RW, Zollman CE, McCarney R, Smith CM, Ellis N, *et al*.

No. 49
Generalisability in economic evaluation studies in healthcare: a review and case studies.
By Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, *et al*.

No. 50
Virtual outreach: a randomised controlled trial and economic evaluation of joint teleconferenced medical consultations.
By Wallace P, Barber J, Clayton W, Currell R, Fleming K, Garner P, *et al*.

Volume 9, 2005

No. 1
Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne.
By Ozolins M, Eady EA, Avery A, Cunliffe WJ, O'Neill C, Simpson NB, *et al*.

No. 2
Do the findings of case series studies vary significantly according to methodological characteristics?
By Dalziel K, Round A, Stein K, Garside R, Castelnuovo E, Payne L.

No. 3
Improving the referral process for familial breast cancer genetic counselling: findings of three randomised controlled trials of two interventions.
By Wilson BJ, Torrance N, Mollison J, Wordsworth S, Gray JR, Haites NE, *et al*.

No. 4
Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia.
By Fowler C, McAllister W, Plail R, Karim O, Yang Q.

No. 5
A pragmatic randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer.
By Shenfine J, McNamee P, Steen N, Bond J, Griffin SM.

No. 6
Impact of computer-aided detection prompts on the sensitivity and specificity of screening mammography.
By Taylor P, Champness J, Given-Wilson R, Johnston K, Potts H.

No. 7
Issues in data monitoring and interim analysis of trials.
By Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Darbyshire JH, *et al*.

No. 8
Lay public's understanding of equipoise and randomisation in randomised controlled trials.
By Robinson EJ, Kerr CEP, Stevens AJ, Lilford RJ, Braunholtz DA, Edwards SJ, *et al*.

No. 9
Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies.
By Greenhalgh J, Knight C, Hind D, Beverley C, Walters S.

No. 10
Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology.
By Smith SC, Lamping DL, Banerjee S, Harwood R, Foley B, Smith P, *et al*.

No. 11
Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris®) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.
By Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, *et al*.

No. 12
A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy.
By Dinnes J, Deeks J, Kirby J, Roderick P.

No. 13
Cervical screening programmes: can automation help? Evidence from systematic reviews, an economic analysis and a simulation modelling exercise applied to the UK.
By Willis BH, Barton P, Pearmain P, Bryan S, Hyde C.

No. 14
Laparoscopic surgery for inguinal hernia repair: systematic review of effectiveness and economic evaluation.
By McCormack K, Wake B, Perez J, Fraser C, Cook J, McIntosh E, *et al*.

No. 15
Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.
By Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, *et al*.

No. 16
A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.
By Peveler R, Kendrick T, Buxton M, Longworth L, Baldwin D, Moore M, *et al*.

No. 17
Clinical effectiveness and cost-effectiveness of immediate angioplasty for acute myocardial infarction: systematic review and economic evaluation.
By Hartwell D, Colquitt J, Loveman E, Clegg AJ, Brodin H, Waugh N, *et al*.

No. 18
A randomised controlled comparison of alternative strategies in stroke care.
By Kalra L, Evans A, Perez I, Knapp M, Swift C, Donaldson N.

No. 19
The investigation and analysis of critical incidents and adverse events in healthcare.
By Woloshynowych M, Rogers S, Taylor-Adams S, Vincent C.

No. 20
Potential use of routine databases in health technology assessment.
By Raftery J, Roderick P, Stevens A.

No. 21
Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
By Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, *et al*.

No. 22
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
By Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J.

No. 23
A systematic review to examine the impact of psycho-educational interventions on health outcomes and costs in adults and children with difficult asthma.
By Smith JR, Mugford M, Holland R, Candy B, Noble MJ, Harrison BDW, *et al*.

No. 24
An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales.
By Roderick P, Nicholson T, Armitage A, Mehta R, Mullee M, Gerard K, *et al*.

No. 25
Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
By Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, *et al*.

No. 26
Indirect comparisons of competing interventions.
By Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, *et al*.

No. 27
Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.
By Robinson M, Palmer S, Sculpher M, Philips Z, Ginnelly L, Bowens A, *et al*.

No. 4

A systematic review of the effectiveness and cost-effectiveness of neuroimaging assessments used to visualise the seizure focus in people with refractory epilepsy being considered for surgery.

By Whiting P, Gupta R, Burch J, Mujica Mota RE, Wright K, Marson A, *et al.*

No. 5

Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies.

By Dundar Y, Dodd S, Dickson R, Walley T, Haycox A, Williamson PR.

No. 6

Systematic review and evaluation of methods of assessing urinary incontinence.

By Martin JL, Williams KS, Abrams KR, Turner DA, Sutton AJ, Chapple C, *et al.*

No. 7

The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review.

By Connock M, Frew E, Evans B-W, Bryan S, Cummins C, Fry-Smith A, *et al.*

No. 8

Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.

By Garside R, Pitt M, Somerville M, Stein K, Price A, Gilbert N.

No. 9

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

By Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, *et al.*

No. 10

Evaluation of molecular techniques in prediction and diagnosis of cytomegalovirus disease in immunocompromised patients.

By Szczepura A, Westmoreland D, Vinogradova Y, Fox J, Clark M.

No. 11

Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study.

By Wu O, Robertson L, Twaddle S, Lowe GDO, Clark P, Greaves M, *et al.*

No. 12

A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers.

By Nelson EA, O'Meara S, Craig D, Iglesias C, Golder S, Dalton J, *et al.*

No. 13

Randomised clinical trial, observational study and assessment of cost-effectiveness of the treatment of varicose veins (REACTIV trial).

By Michaels JA, Campbell WB, Brazier JE, MacIntyre JB, Palfreyman SJ, Ratcliffe J, *et al.*

No. 14

The cost-effectiveness of screening for oral cancer in primary care.

By Speight PM, Palmer S, Moles DR, Downer MC, Smith DH, Henriksson M *et al.*

No. 15

Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis.

By Goodacre S, Sampson F, Stevenson M, Wailoo A, Sutton A, Thomas S, *et al.*

No. 16

Systematic review of the effectiveness and cost-effectiveness of HealOzone® for the treatment of occlusal pit/fissure caries and root caries.

By Brazzelli M, McKenzie L, Fielding S, Fraser C, Clarkson J, Kilonzo M, *et al.*

Health Technology Assessment Programme

Director,
Professor Tom Walley,
Director, NHS HTA Programme,
Department of Pharmacology &
Therapeutics,
University of Liverpool

Deputy Director,
Professor Jon Nicholl,
Director, Medical Care Research
Unit, University of Sheffield,
School of Health and Related
Research

Prioritisation Strategy Group

Members

Chair,
Professor Tom Walley,
Director, NHS HTA Programme,
Department of Pharmacology &
Therapeutics,
University of Liverpool

Professor Bruce Campbell,
Consultant Vascular & General
Surgeon, Royal Devon & Exeter
Hospital

Dr Edmund Jessop, Medical
Advisor, National Specialist,
Commissioning Advisory Group
(NSCAG), Department of
Health, London

Professor Jon Nicholl, Director,
Medical Care Research Unit,
University of Sheffield, School
of Health and Related Research

Dr John Reynolds, Clinical
Director, Acute General
Medicine SDU, Radcliffe
Hospital, Oxford

Dr Ron Zimmern, Director,
Public Health Genetics Unit,
Strangeways Research
Laboratories, Cambridge

HTA Commissioning Board

Members

Programme Director,
Professor Tom Walley,
Director, NHS HTA Programme,
Department of Pharmacology &
Therapeutics,
University of Liverpool

Chair,
Professor Jon Nicholl,
Director, Medical Care Research
Unit, University of Sheffield,
School of Health and Related
Research

Deputy Chair,
Professor Jenny Hewison,
Professor of Health Care
Psychology, Academic Unit of
Psychiatry and Behavioural
Sciences, University of Leeds
School of Medicine

Dr Jeffrey Aronson
Reader in Clinical
Pharmacology, Department of
Clinical Pharmacology,
Radcliffe Infirmary, Oxford

Professor Deborah Ashby,
Professor of Medical Statistics,
Department of Environmental
and Preventative Medicine,
Queen Mary University of
London

Professor Ann Bowling,
Professor of Health Services
Research, Primary Care and
Population Studies,
University College London

Dr Andrew Briggs, Public
Health Career Scientist, Health
Economics Research Centre,
University of Oxford

Professor John Cairns, Professor
of Health Economics, Public
Health Policy, London School of
Hygiene and Tropical Medicine,
London

Professor Nicky Cullum,
Director of Centre for Evidence
Based Nursing, Department of
Health Sciences, University of
York

Mr Jonathan Deeks,
Senior Medical Statistician,
Centre for Statistics in
Medicine, University of Oxford

Dr Andrew Farmer, Senior
Lecturer in General Practice,
Department of Primary
Health Care,
University of Oxford

Professor Fiona J Gilbert,
Professor of Radiology,
Department of Radiology,
University of Aberdeen

Professor Adrian Grant,
Director, Health Services
Research Unit, University of
Aberdeen

Professor F D Richard Hobbs,
Professor of Primary Care &
General Practice, Department of
Primary Care & General
Practice, University of
Birmingham

Professor Peter Jones, Head of
Department, University
Department of Psychiatry,
University of Cambridge

Professor Sallie Lamb,
Professor of Rehabilitation,
Centre for Primary Health Care,
University of Warwick

Professor Stuart Logan,
Director of Health & Social
Care Research, The
Peninsula Medical School,
Universities of Exeter &
Plymouth

Dr Linda Patterson,
Consultant Physician,
Department of Medicine,
Burnley General Hospital

Professor Ian Roberts, Professor
of Epidemiology & Public
Health, Intervention Research
Unit, London School of
Hygiene and Tropical Medicine

Professor Mark Sculpher,
Professor of Health Economics,
Centre for Health Economics,
Institute for Research in the
Social Services, University of York

Dr Jonathan Shapiro, Senior
Fellow, Health Services
Management Centre,
Birmingham

Ms Kate Thomas,
Deputy Director,
Medical Care Research Unit,
University of Sheffield

Ms Sue Ziebland,
Research Director, DIPEx,
Department of Primary Health
Care, University of Oxford,
Institute of Health Sciences

Current and past membership details of all HTA 'committees' are available from the HTA website (www.hta.ac.uk)

Diagnostic Technologies & Screening Panel

Members

Chair,
Dr Ron Zimmern, Director of the Public Health Genetics Unit, Strangeways Research Laboratories, Cambridge

Ms Norma Armston, Lay Member, Bolton

Professor Max Bachmann Professor of Health Care Interfaces, Department of Health Policy and Practice, University of East Anglia

Professor Rudy Bilous Professor of Clinical Medicine & Consultant Physician, The Academic Centre, South Tees Hospitals NHS Trust

Dr Paul Cockcroft, Consultant Medical Microbiologist and Clinical Director of Pathology, Department of Clinical Microbiology, St Mary's Hospital, Portsmouth

Professor Adrian K Dixon, Professor of Radiology, University Department of Radiology, University of Cambridge Clinical School

Dr David Elliman, Consultant Paediatrician/ Hon. Senior Lecturer, Population Health Unit, Great Ormond St. Hospital, London

Professor Glyn Elwyn, Primary Medical Care Research Group, Swansea Clinical School, University of Wales Swansea

Mr Tam Fry, Honorary Chairman, Child Growth Foundation, London

Dr Jennifer J Kurinczuk, Consultant Clinical Epidemiologist, National Perinatal Epidemiology Unit, Oxford

Dr Susanne M Ludgate, Medical Director, Medicines & Healthcare Products Regulatory Agency, London

Professor William Rosenberg, Professor of Hepatology, Liver Research Group, University of Southampton

Dr Susan Schonfield, Consultant in Public Health, Specialised Services Commissioning North West London, Hillingdon Primary Care Trust

Dr Phil Shackley, Senior Lecturer in Health Economics, School of Population and Health Sciences, University of Newcastle upon Tyne

Dr Margaret Somerville, PMS Public Health Lead, Peninsula Medical School, University of Plymouth

Dr Graham Taylor, Scientific Director & Senior Lecturer, Regional DNA Laboratory, The Leeds Teaching Hospitals

Professor Lindsay Wilson Turnbull, Scientific Director, Centre for MR Investigations & YCR Professor of Radiology, University of Hull

Professor Martin J Whittle, Associate Dean for Education, Head of Department of Obstetrics and Gynaecology, University of Birmingham

Dr Dennis Wright, Consultant Biochemist & Clinical Director, Pathology & The Kennedy Galton Centre, Northwick Park & St Mark's Hospitals, Harrow

Pharmaceuticals Panel

Members

Chair,
Dr John Reynolds, Chair Division A, The John Radcliffe Hospital, Oxford Radcliffe Hospitals NHS Trust

Professor Tony Avery, Head of Division of Primary Care, School of Community Health Services, Division of General Practice, University of Nottingham

Ms Anne Baileff, Consultant Nurse in First Contact Care, Southampton City Primary Care Trust, University of Southampton

Professor Stirling Bryan, Professor of Health Economics, Health Services Management Centre, University of Birmingham

Mr Peter Cardy, Chief Executive, Macmillan Cancer Relief, London

Professor Imti Choonara, Professor in Child Health, Academic Division of Child Health, University of Nottingham

Dr Robin Ferner, Consultant Physician and Director, West Midlands Centre for Adverse Drug Reactions, City Hospital NHS Trust, Birmingham

Dr Karen A Fitzgerald, Consultant in Pharmaceutical Public Health, National Public Health Service for Wales, Cardiff

Mrs Sharon Hart, Head of DTB Publications, *Drug & Therapeutics Bulletin*, London

Dr Christine Hine, Consultant in Public Health Medicine, South Gloucestershire Primary Care Trust

Professor Stan Kaye, Cancer Research UK Professor of Medical Oncology, Section of Medicine, The Royal Marsden Hospital, Sutton

Ms Barbara Meredith, Lay Member, Epsom

Dr Andrew Prentice, Senior Lecturer and Consultant Obstetrician & Gynaecologist, Department of Obstetrics & Gynaecology, University of Cambridge

Dr Frances Rotblat, CPMP Delegate, Medicines & Healthcare Products Regulatory Agency, London

Professor Jan Scott, Professor of Psychological Treatments, Institute of Psychiatry, University of London

Mrs Katrina Simister, Assistant Director New Medicines, National Prescribing Centre, Liverpool

Dr Richard Tiner, Medical Director, Medical Department, Association of the British Pharmaceutical Industry, London

Dr Helen Williams, Consultant Microbiologist, Norfolk & Norwich University Hospital NHS Trust

Current and past membership details of all HTA 'committees' are available from the HTA website (www.hta.ac.uk)

Therapeutic Procedures Panel

Current and past membership details of all HTA 'committees' are available from the HTA website (www.hta.ac.uk)

Expert Advisory Network

Members

Professor Douglas Altman,
Director of CSM & Cancer
Research UK Med Stat Gp,
Centre for Statistics in
Medicine, University of Oxford,
Institute of Health Sciences,
Headington, Oxford

Professor John Bond,
Director, Centre for Health
Services Research, University of
Newcastle upon Tyne, School of
Population & Health Sciences,
Newcastle upon Tyne

Mr Shaun Brogan,
Chief Executive, Ridgeway
Primary Care Group, Aylesbury

Mrs Stella Burnside OBE,
Chief Executive, Office of the
Chief Executive. Trust
Headquarters, Altnagelvin
Hospitals Health & Social
Services Trust, Altnagelvin Area
Hospital, Londonderry

Ms Tracy Bury,
Project Manager, World
Confederation for Physical
Therapy, London

Professor Iain T Cameron,
Professor of Obstetrics and
Gynaecology and Head of the
School of Medicine,
University of Southampton

Dr Christine Clark,
Medical Writer & Consultant
Pharmacist, Rossendale

Professor Collette Clifford,
Professor of Nursing & Head of
Research, School of Health
Sciences, University of
Birmingham, Edgbaston,
Birmingham

Professor Barry Cookson,
Director, Laboratory of
Healthcare Associated Infection,
Health Protection Agency,
London

Professor Howard Cuckle,
Professor of Reproductive
Epidemiology, Department of
Paediatrics, Obstetrics &
Gynaecology, University of
Leeds

Dr Katherine Darton,
Information Unit, MIND –
The Mental Health Charity,
London

Professor Carol Dezateux,
Professor of Paediatric
Epidemiology, London

Mr John Dunning,
Consultant Cardiothoracic
Surgeon, Cardiothoracic
Surgical Unit, Papworth
Hospital NHS Trust, Cambridge

Mr Jonothan Earnshaw,
Consultant Vascular Surgeon,
Gloucestershire Royal Hospital,
Gloucester

Professor Martin Eccles,
Professor of Clinical
Effectiveness, Centre for Health
Services Research, University of
Newcastle upon Tyne

Professor Pam Enderby,
Professor of Community
Rehabilitation, Institute of
General Practice and Primary
Care, University of Sheffield

Mr Leonard R Fenwick,
Chief Executive, Newcastle
upon Tyne Hospitals NHS Trust

Professor David Field,
Professor of Neonatal Medicine,
Child Health, The Leicester
Royal Infirmary NHS Trust

Mrs Gillian Fletcher,
Antenatal Teacher & Tutor and
President, National Childbirth
Trust, Henfield

Professor Jayne Franklyn,
Professor of Medicine,
Department of Medicine,
University of Birmingham,
Queen Elizabeth Hospital,
Edgbaston, Birmingham

Ms Grace Gibbs,
Deputy Chief Executive,
Director for Nursing, Midwifery
& Clinical Support Services,
West Middlesex University
Hospital, Isleworth

Dr Neville Goodman,
Consultant Anaesthetist,
Southmead Hospital, Bristol

Professor Alastair Gray,
Professor of Health Economics,
Department of Public Health,
University of Oxford

Professor Robert E Hawkins,
CRC Professor and Director of
Medical Oncology, Christie CRC
Research Centre, Christie
Hospital NHS Trust, Manchester

Professor Allen Hutchinson,
Director of Public Health &
Deputy Dean of ScHARR,
Department of Public Health,
University of Sheffield

Dr Duncan Keeley,
General Practitioner (Dr Burch
& Ptnrs), The Health Centre,
Thame

Dr Donna Lamping,
Research Degrees Programme
Director & Reader in Psychology,
Health Services Research Unit,
London School of Hygiene and
Tropical Medicine, London

Mr George Levvy,
Chief Executive, Motor
Neurone Disease Association,
Northampton

Professor James Lindesay,
Professor of Psychiatry for the
Elderly, University of Leicester,
Leicester General Hospital

Professor Julian Little,
Professor of Human Genome
Epidemiology, Department of
Epidemiology & Community
Medicine, University of Ottawa

Professor Rajan Madhok,
Medical Director & Director of
Public Health, Directorate of
Clinical Strategy & Public
Health, North & East Yorkshire
& Northern Lincolnshire Health
Authority, York

Professor David Mant,
Professor of General Practice,
Department of Primary Care,
University of Oxford

Professor Alexander Markham,
Director, Molecular Medicine
Unit, St James's University
Hospital, Leeds

Dr Chris McCall,
General Practitioner, The
Hadleigh Practice, Castle Mullen

Professor Alistair McGuire,
Professor of Health Economics,
London School of Economics

Dr Peter Moore,
Freelance Science Writer, Ashtead

Dr Sue Moss, Associate Director,
Cancer Screening Evaluation
Unit, Institute of Cancer
Research, Sutton

Mrs Julietta Patnick,
Director, NHS Cancer Screening
Programmes, Sheffield

Professor Tim Peters,
Professor of Primary Care
Health Services Research,
Academic Unit of Primary
Health Care, University of
Bristol

Professor Chris Price,
Visiting Chair – Oxford, Clinical
Research, Bayer Diagnostics
Europe, Cirencester

Professor Peter Sandercock,
Professor of Medical Neurology,
Department of Clinical
Neurosciences, University of
Edinburgh

Dr Eamonn Sheridan,
Consultant in Clinical Genetics,
Genetics Department,
St James's University Hospital,
Leeds

Dr Ken Stein,
Senior Clinical Lecturer in
Public Health, Director,
Peninsula Technology
Assessment Group,
University of Exeter

Professor Sarah Stewart-Brown,
Professor of Public Health,
University of Warwick,
Division of Health in the
Community Warwick Medical
School, LWMS, Coventry

Professor Ala Szczepura,
Professor of Health Service
Research, Centre for Health
Services Studies, University of
Warwick

Dr Ross Taylor,
Senior Lecturer, Department of
General Practice and Primary
Care, University of Aberdeen

Mrs Joan Webster,
Consumer member, HTA –
Expert Advisory Network

Current and past membership details of all HTA 'committees' are available from the HTA website (www.hta.ac.uk)

Feedback

The HTA Programme and the authors would like to know your views about this report.

The Correspondence Page on the HTA website (http://www.hta.ac.uk) is a convenient way to publish your comments. If you prefer, you can send your comments to the address below, telling us whether you would like us to transfer them to the website.

We look forward to hearing from you.